General Information of Disease (ID: DISEAFTY)

Disease Name Ovarian neoplasm
Synonyms
ovary tumour; ovary tumor; ovarian neoplasm; tumour of ovary; tumor of ovary; tumour of the ovary; ovarian tumor; ovarian tumours; ovary neoplasm (disease); ovarian tumors; neoplasm of ovary; neoplasm of the ovary; ovary neoplasm; tumor of the ovary; ovarian tumour
Definition A benign, borderline, or malignant neoplasm involving the ovary.
Disease Hierarchy
DISTBY9Z: Tumour
DISHZX9D: Ovarian disorder
DISDVNRY: Female reproductive system neoplasm
DISEAFTY: Ovarian neoplasm
Disease Identifiers
MONDO ID
MONDO_0021068
MESH ID
D010051
UMLS CUI
C0919267
MedGen ID
181539
HPO ID
HP:0100615
SNOMED CT ID
123843001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 5 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Carboplatin DMG281S Approved Small molecular drug [1]
Doxorubicin DMVP5YE Approved Small molecular drug [2]
Gemcitabine DMSE3I7 Approved Small molecular drug [3]
Paclitaxel DMLB81S Approved Small molecular drug [4]
Vorinostat DMWMPD4 Approved Small molecular drug [5]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 1 Drugs in Phase 2 Trial
Drug Name Drug ID Highest Status Drug Type REF
Nintedanib DMMQ2OW Phase 2 Trial Small molecular drug [6]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 597 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
ALOX12B TTQ4QQH Limited Biomarker [7]
AURKA TTPS3C0 Limited Biomarker [8]
BUB1 TT78309 Limited Biomarker [9]
CAPN2 TTG5QB7 Limited Altered Expression [10]
CCR9 TTIPS8B Limited Biomarker [11]
CD47 TT28S46 Limited Biomarker [12]
CD55 TT5Z9WY Limited Altered Expression [13]
CDH1 TTLAWO6 Limited Altered Expression [14]
CDK2 TT7HF4W Limited Altered Expression [15]
CDK5R1 TTBYM6V Limited Altered Expression [16]
CDKN1A TT9GUW0 Limited Biomarker [17]
CEACAM5 TTY6DTE Limited Biomarker [18]
CLDN6 TTKSV48 Limited Biomarker [19]
COL18A1 TT63DI9 Limited Biomarker [20]
CSE1L TTTRULD Limited Altered Expression [21]
CYP3A5 TTHS0OK Limited Biomarker [22]
DCK TTJOCE4 Limited Biomarker [23]
ETS2 TT9AH0M Limited Biomarker [24]
FGF18 TT6ICRA Limited Biomarker [25]
FOXC2 TTLBAP1 Limited Biomarker [26]
FOXM1 TTD3KOX Limited Biomarker [27]
FST TTDNM9W Limited Genetic Variation [28]
GRIK2 TT0K5RG Limited Biomarker [29]
GSTA2 TTNLFBE Limited Genetic Variation [30]
GSTO1 TTWO3SH Limited Genetic Variation [30]
IGF2 TTE8WGO Limited Altered Expression [31]
IKBKB TTJ3E9X Limited Biomarker [32]
IL12A TTRTK6Y Limited Altered Expression [16]
IL16 TTW4R0B Limited Altered Expression [33]
IRAK1 TTXAJWN Limited Biomarker [9]
KLK6 TTLPF4X Limited Biomarker [34]
LHCGR TT2O4W9 Limited Altered Expression [35]
LTF TTSZDQU Limited Altered Expression [36]
MAGEA3 TTWSKHD Limited Altered Expression [37]
MAP3K8 TTGECUM Limited Altered Expression [38]
MKI67 TTB4UNG Limited Altered Expression [39]
MMP15 TTNSTO3 Limited Altered Expression [40]
MVD TTE5J6X Limited Altered Expression [41]
NEDD8 TTNDC4K Limited Biomarker [42]
NRP1 TTIPJCB Limited Altered Expression [43]
NUAK2 TTHVOTQ Limited Altered Expression [44]
PAK2 TT279WO Limited Posttranslational Modification [45]
PAK4 TT7Y3BZ Limited Biomarker [46]
POLB TTA0XPV Limited Genetic Variation [47]
PRMT5 TTR1D7X Limited Biomarker [48]
PROM1 TTXMZ81 Limited Biomarker [49]
PTGDR2 TTQDMX5 Limited Biomarker [50]
RENBP TTZCG0Q Limited Genetic Variation [51]
RHBDF2 TTH1ZOP Limited Biomarker [52]
ROBO1 TTND1YP Limited Altered Expression [53]
SERPINB3 TT6QLPX Limited Biomarker [54]
SLC22A3 TTG2UMS Limited Biomarker [55]
SLC5A6 TT61XTV Limited Biomarker [56]
SOD1 TTP9K3Q Limited Altered Expression [57]
SP1 TTZEP6S Limited Genetic Variation [58]
TLR4 TTISGCA Limited Biomarker [59]
BRD7 TT07ZS1 Disputed Biomarker [60]
CD248 TTYJWT7 Disputed Biomarker [61]
CS TTZA6B3 Disputed Altered Expression [62]
EGF TTED8JB Disputed Biomarker [63]
PTK2 TTON5IT Disputed Posttranslational Modification [64]
PTK7 TTXH2ZN Disputed Altered Expression [65]
SPRY1 TT0PSN6 Disputed Altered Expression [65]
TNFRSF21 TT8UA0T Disputed Genetic Variation [66]
BSG TT5UJWD moderate Biomarker [67]
CDC7 TTSMTDI moderate Altered Expression [68]
CHEK1 TTTU902 moderate Biomarker [69]
CNTN2 TT2Z1WB moderate Biomarker [70]
CRYZ TTP6UO8 moderate Altered Expression [71]
E2F3 TTWIJYH moderate Altered Expression [72]
EYA2 TTUY9C6 moderate Biomarker [73]
FGFR2 TTGJVQM moderate Biomarker [74]
HGFAC TTD96RW moderate Altered Expression [75]
HOXA11 TTEX4ZA moderate Biomarker [76]
HOXB13 TTZ6I58 moderate Biomarker [77]
HSPE1 TTWYMFE moderate Genetic Variation [78]
IL13RA2 TTMPZ7V moderate Biomarker [79]
MASP2 TTR01E9 moderate Altered Expression [80]
MSH2 TTCAWRT moderate Genetic Variation [81]
NQO2 TTJLP0R moderate Genetic Variation [71]
PTEN TTXJ3W7 moderate Altered Expression [82]
RNF43 TTD91BL moderate Genetic Variation [83]
SLIT2 TTDWK85 moderate Biomarker [53]
SRD5A2 TTT02K8 moderate Biomarker [84]
TMEM97 TT9NXW4 moderate Altered Expression [85]
ABCA4 TTLB52K Strong Altered Expression [86]
ABCC1 TTOI92F Strong Altered Expression [87]
ABCG2 TTIMJ02 Strong Altered Expression [88]
ACR TTAHE2N Strong Biomarker [89]
ADAM10 TTVXEGU Strong Biomarker [90]
ADAM17 TT6AZXG Strong Biomarker [91]
AGPAT2 TT9AYVR Strong Altered Expression [92]
AGR2 TT9K86S Strong Altered Expression [93]
AHSG TTKF4WV Strong Biomarker [94]
AKT2 TTH24WI Strong Biomarker [95]
ALCAM TT2AFT6 Strong Altered Expression [96]
ALDH5A1 TTJUWVB Strong Altered Expression [97]
ALOX5 TTSJ6Q4 Strong Biomarker [7]
AMHR2 TTZDCPK Strong Altered Expression [98]
ANGPTL3 TT59GO7 Strong Biomarker [99]
ANO1 TTOJI4S Strong Biomarker [100]
ANXA2 TT4YANI Strong Biomarker [101]
ANXA8 TTSW16P Strong Biomarker [102]
AOX1 TT3MOS2 Strong Altered Expression [103]
APC2 TTSMK36 Strong Biomarker [104]
APEX1 TTHGL48 Strong Biomarker [105]
APLNR TTJ8E43 Strong Biomarker [106]
AQP3 TTLDNMQ Strong Biomarker [107]
AREG TT76B3W Strong Biomarker [108]
ARRB1 TTMVD4A Strong Biomarker [109]
ASRGL1 TT4WT91 Strong Biomarker [110]
ATAD2 TT9A0HI Strong Biomarker [111]
ATF3 TTCE793 Strong Therapeutic [112]
ATG7 TTLVB9Z Strong Biomarker [113]
ATP7B TTOPO51 Strong Genetic Variation [114]
ATXN2 TTPQJ7P Strong Genetic Variation [115]
AXL TTZPY6J Strong Biomarker [116]
BACH1 TT2ME4S Strong Biomarker [117]
BAGE TTS5GLJ Strong Altered Expression [37]
BAP1 TT47RXJ Strong Biomarker [118]
BBC3 TT7JUKC Strong Biomarker [119]
BCAT1 TTES57P Strong Altered Expression [120]
BIRC2 TTQ5LRD Strong Altered Expression [121]
BIRC3 TTAIWZN Strong Biomarker [122]
BIRC5 TTTPU1G Strong Biomarker [123]
BMI1 TTIPNSR Strong Biomarker [124]
BMP10 TTTG6H1 Strong Altered Expression [125]
BMP4 TTD3BSX Strong Altered Expression [126]
BMP7 TTKOBRA Strong Altered Expression [127]
BPHL TTTZ3EU Strong Biomarker [128]
BRD1 TTT09OB Strong Biomarker [129]
BRS3 TTKYEPM Strong Biomarker [130]
BTG1 TTL7N2W Strong Biomarker [131]
C5AR1 TTHXFA1 Strong Biomarker [132]
CALCR TTLWS2O Strong Biomarker [133]
CAMKK2 TTV298Y Strong Altered Expression [134]
CAMP TTULOB6 Strong Biomarker [135]
CARM1 TTIZQFJ Strong Biomarker [136]
CASP9 TTB6T7O Strong Biomarker [137]
CAV1 TTXUBN2 Strong Altered Expression [138]
CBR1 TTVG0SN Strong Biomarker [139]
CBS TTVZJ7G Strong Biomarker [140]
CCL20 TT2XAZY Strong Biomarker [141]
CCL21 TTLZK1U Strong Biomarker [142]
CCL22 TTBTWI1 Strong Biomarker [143]
CCN1 TTPK79J Strong Biomarker [144]
CCNE1 TTCEJ4F Strong Altered Expression [145]
CD1A TTBGTFN Strong Altered Expression [146]
CD276 TT6CQUM Strong Biomarker [147]
CD44 TTWFBT7 Strong Biomarker [148]
CD46 TTMS7DF Strong Altered Expression [13]
CD59 TTBGTEJ Strong Altered Expression [13]
CDC123 TT3PRUG Strong Altered Expression [149]
CDC25A TTLZS4Q Strong Biomarker [150]
CDC25B TTR0SWN Strong Altered Expression [151]
CDH11 TTRGWZC Strong Biomarker [152]
CDH6 TT9QHUK Strong Altered Expression [153]
CDK19 TTNABU9 Strong Biomarker [154]
CDK7 TTQYF7G Strong Biomarker [155]
CEACAM1 TTA9CK4 Strong Altered Expression [156]
CEACAM3 TTPX7I5 Strong Biomarker [18]
CEACAM6 TTIGH2W Strong Altered Expression [157]
CFLAR TTJZQYH Strong Biomarker [158]
CGA TTFC29G Strong Biomarker [159]
CGB3 TTUH273 Strong Biomarker [159]
CHKA TT10AWB Strong Biomarker [160]
CLCA1 TT3AF4R Strong Biomarker [161]
CLDN4 TTMTS9H Strong Altered Expression [162]
CLIC1 TT8KZG6 Strong Biomarker [163]
CLN3 TTORF9W Strong Biomarker [164]
CLU TTRL76H Strong Biomarker [165]
CMA1 TT8VUE0 Strong Altered Expression [166]
CREB1 TTH4AN3 Strong Biomarker [167]
CSF1 TT0IQER Strong Biomarker [168]
CSK TTX6F0Q Strong Altered Expression [169]
CTCFL TTY0RZT Strong Biomarker [170]
CTSD TTPT2QI Strong Biomarker [171]
CTSL TT36ETB Strong Altered Expression [172]
CXCL11 TTWG0RE Strong Biomarker [173]
CXCL12 TT4UGTF Strong Biomarker [174]
CXCL8 TTCTE1G Strong Biomarker [175]
CXCR2 TT30C9G Strong Biomarker [176]
CXCR3 TT1UCIJ Strong Biomarker [177]
CXCR6 TT2BVUA Strong Biomarker [90]
CYP19A1 TTSZLWK Strong Biomarker [178]
CYP1B1 TTI84H7 Strong Altered Expression [179]
DDR2 TTU98HG Strong Biomarker [180]
DDX58 TTVB0O3 Strong Altered Expression [181]
DEPTOR TTLYP6D Strong Altered Expression [182]
DIABLO TTN74LE Strong Biomarker [183]
DICER1 TTTEOPU Strong Genetic Variation [184]
DKK3 TTY2ZV6 Strong Altered Expression [185]
DLK1 TTF4AVB Strong Biomarker [186]
DLL4 TTV23LH Strong Biomarker [187]
DNMT3A TTJUALD Strong Altered Expression [188]
DOT1L TTSZ8T1 Strong Altered Expression [189]
DUSP1 TTG8HIM Strong Biomarker [190]
DUSP3 TTIFAYS Strong Genetic Variation [191]
DYRK1B TTYGQ8A Strong Biomarker [192]
E2F1 TTASI04 Strong Altered Expression [193]
E2F2 TT5FYX0 Strong Biomarker [193]
EDNRA TTKRD0G Strong Biomarker [194]
EGFR TTGKNB4 Strong Biomarker [195]
EGLN1 TT9ISBX Strong Biomarker [196]
EIF4E TTZGCP6 Strong Biomarker [197]
EIF5A TTIVCNR Strong Biomarker [198]
EIF5A2 TTH53G9 Strong Altered Expression [199]
ENG TTB30LE Strong Biomarker [200]
ENPP2 TTSCIM2 Strong Biomarker [201]
ENTPD1 TTYM8DJ Strong Biomarker [202]
EPHA1 TTLFZVU Strong Biomarker [203]
EPHA2 TTRJB2G Strong Biomarker [204]
EPHA3 TTHS2LR Strong Biomarker [149]
EPHA5 TTV9KOD Strong Altered Expression [205]
EPHA7 TTAHTVG Strong Biomarker [206]
EPHB4 TTI4ZX2 Strong Altered Expression [207]
EPOR TTAUX24 Strong Biomarker [208]
EREG TTYSB89 Strong Altered Expression [209]
ERN1 TTKIAT3 Strong Biomarker [210]
ESRRA TTPNQAC Strong Biomarker [211]
ESRRB TTKF0XS Strong Altered Expression [212]
ETS1 TTTGPSD Strong Biomarker [213]
F2RL2 TTVSEBF Strong Altered Expression [214]
F2RL3 TTD0652 Strong Biomarker [215]
FABP4 TTHWMFZ Strong Altered Expression [216]
FAM83D TTFIW7J Strong Altered Expression [217]
FAP TTGPQ0F Strong Biomarker [218]
FASN TT7AOUD Strong Biomarker [219]
FBXW7 TT29KY7 Strong Genetic Variation [81]
FGF1 TTMY81X Strong Biomarker [220]
FGF7 TTFY134 Strong Biomarker [221]
FGF8 TTIUF3J Strong Biomarker [222]
FLT1 TT1VAUK Strong Altered Expression [223]
FLT4 TTDCBX5 Strong Biomarker [224]
FOSL1 TTY8LZG Strong Altered Expression [225]
FOSL2 TT689IR Strong Biomarker [226]
FOXP1 TT0MUCI Strong Altered Expression [227]
FOXQ1 TTEJZOL Strong Altered Expression [228]
FSCN1 TTTRS9B Strong Altered Expression [229]
FZD7 TTUQMO5 Strong Altered Expression [230]
GAS6 TT69QD2 Strong Biomarker [231]
GCLM TTNFESW Strong Altered Expression [232]
GDF2 TTAP4T1 Strong Biomarker [233]
GJB1 TTSJIRP Strong Altered Expression [234]
GLI1 TTJOMH6 Strong Genetic Variation [235]
GNRH1 TT0ID4A Strong Altered Expression [236]
GPC3 TTJTSX4 Strong Biomarker [237]
GPER1 TTDSB34 Strong Biomarker [238]
GPR137 TTATO6X Strong Biomarker [239]
GRB2 TTEYRJ9 Strong Biomarker [240]
GRHL2 TTUGH4C Strong Altered Expression [241]
GRN TT0LWE3 Strong Biomarker [242]
GSN TTUH7OM Strong Altered Expression [243]
GUSB TTHS7CM Strong Biomarker [244]
HBEGF TT15SL0 Strong Biomarker [245]
HDAC1 TT6R7JZ Strong Biomarker [246]
HDAC10 TTYHPU6 Strong Biomarker [247]
HDAC4 TTTQGH8 Strong Biomarker [248]
HDAC6 TT5ZKDI Strong Biomarker [249]
HDAC7 TTMUEK1 Strong Biomarker [250]
HK2 TTK02H8 Strong Biomarker [188]
HMGA1 TTBA219 Strong Biomarker [251]
HOXA5 TTXSVQP Strong Altered Expression [252]
HOXA7 TTMRE4Q Strong Biomarker [253]
HPN TT25MVL Strong Altered Expression [75]
HPSE TTR7GJO Strong Altered Expression [254]
HRC TTR4FKD Strong Genetic Variation [255]
HSD17B1 TTIWB6L Strong Genetic Variation [256]
HSD17B2 TT0PT1R Strong Genetic Variation [257]
HSF1 TTN6STZ Strong Biomarker [258]
HSPA9 TTMTPG3 Strong Biomarker [259]
HTRA1 TT8POQR Strong Altered Expression [260]
ID1 TTBXVDE Strong Altered Expression [261]
ID2 TTW8A5N Strong Genetic Variation [262]
IDE TT2EDHU Strong Altered Expression [263]
IDH1 TTV2A1R Strong Biomarker [264]
IGF2R TTPNE41 Strong Genetic Variation [265]
IGFBP1 TTCJTWF Strong Biomarker [266]
IGFBP2 TTU4QSN Strong Biomarker [267]
IGFBP3 TTZHNQA Strong Biomarker [268]
IGFBP5 TTDWEA8 Strong Altered Expression [269]
IL11RA TTZPLJS Strong Biomarker [270]
IL17D TTC5LTG Strong Genetic Variation [271]
IL21 TT9QEJ6 Strong Biomarker [272]
IL24 TT1EPXZ Strong Biomarker [273]
IL33 TT5MD4P Strong Biomarker [274]
IL7 TT8FRMO Strong Biomarker [275]
ILK TT7ALZG Strong Biomarker [276]
INHBA TTVB30D Strong Biomarker [277]
IRS1 TTAJSQ0 Strong Genetic Variation [278]
ISG15 TTVOH3T Strong Biomarker [279]
ITGA2 TTSJ542 Strong Biomarker [180]
ITGA5 TTHIZP9 Strong Biomarker [280]
ITGA6 TT165T3 Strong Biomarker [281]
ITGA8 TT1FW8B Strong Biomarker [282]
ITGB1 TTBVIQC Strong Biomarker [283]
ITGB8 TTIF29E Strong Altered Expression [284]
ITK TT3C80U Strong Biomarker [55]
KAT2B TTVK7SB Strong Biomarker [285]
KCNH1 TT9XKUC Strong Genetic Variation [115]
KCNMA1 TTE87WJ Strong Biomarker [286]
KCNN3 TT9JH25 Strong Biomarker [287]
KDM2A TT8XTY2 Strong Biomarker [288]
KDM3A TTKXS4A Strong Biomarker [289]
KDM5A TTIG67W Strong Biomarker [290]
KDM6B TTDIJUQ Strong Altered Expression [291]
KEAP1 TT3Z6Y9 Strong Altered Expression [292]
KHDRBS1 TTAT6C7 Strong Altered Expression [293]
KITLG TTDJ51N Strong Biomarker [294]
KLK1 TT5T3P6 Strong Genetic Variation [295]
KLK14 TTDA81R Strong Altered Expression [296]
KLK3 TTS78AZ Strong Genetic Variation [297]
KLK4 TT4319X Strong Altered Expression [298]
KLK5 TTULSEW Strong Altered Expression [299]
KLK7 TTE6GTB Strong Biomarker [300]
KLRK1 TTLRN4A Strong Biomarker [301]
KRT17 TTKV0EC Strong Biomarker [302]
KRT19 TT3JF9E Strong Biomarker [303]
L1CAM TTC9D3K Strong Biomarker [304]
L3MBTL3 TTQDMJN Strong Genetic Variation [305]
LAPTM4B TTEJQT0 Strong Altered Expression [306]
LARP1 TTSN1YP Strong Biomarker [307]
LATS2 TTML7FG Strong Altered Expression [308]
LCAT TTGZ91P Strong Biomarker [267]
LCK TT860QF Strong Biomarker [309]
LGALS1 TTO3NYT Strong Biomarker [310]
LGALS3 TTFPQV7 Strong Biomarker [311]
LGMN TTPTWV5 Strong Biomarker [312]
LGR5 TTTSGRH Strong Biomarker [313]
LIF TTGZ5WN Strong Biomarker [314]
LIMK1 TTWL9TY Strong Biomarker [315]
LIN28A TTO50LN Strong Altered Expression [316]
LNPEP TTY2KP7 Strong Biomarker [317]
LOX TTQHNAM Strong Altered Expression [318]
LPAR2 TTB7Y8I Strong Biomarker [319]
LPAR3 TTE2YJR Strong Biomarker [319]
LRP1 TTF2V7I Strong Biomarker [320]
LTB4R TTN53ZF Strong Altered Expression [321]
LTB4R2 TTVJX54 Strong Biomarker [322]
LY75 TTG180Q Strong Biomarker [323]
LYVE1 TTG8DNU Strong Genetic Variation [324]
MAGEA1 TT63M7Q Strong Altered Expression [37]
MAP2K1 TTIDAPM Strong Biomarker [325]
MAP2K2 TT8H9GB Strong Genetic Variation [326]
MAP2K7 TT6QY3J Strong Biomarker [327]
MAP3K1 TTW8TJI Strong Biomarker [328]
MAP3K5 TTOQCD8 Strong Biomarker [329]
MAP4 TT0VFPN Strong Altered Expression [330]
MAPK1 TT4TQBX Strong Biomarker [331]
MAPK3 TT1MG9E Strong Biomarker [332]
MARCKS TTHRM39 Strong Biomarker [333]
MBTPS1 TTNSM2I Strong Biomarker [334]
MCAM TTHRE05 Strong Biomarker [335]
MCL1 TTL53M6 Strong Biomarker [336]
MDK TTV8UE7 Strong Posttranslational Modification [337]
MDM4 TT9OUDQ Strong Altered Expression [87]
MELK TTBZOTY Strong Altered Expression [338]
MET TTNDSF4 Strong Biomarker [339]
MIA TT5HNVS Strong Biomarker [340]
MKNK1 TTEZAUX Strong Altered Expression [341]
MMP14 TTJ4QE7 Strong Biomarker [342]
MMP7 TTMTWOS Strong Biomarker [343]
MSI1 TTSM4BA Strong Altered Expression [344]
MSI2 TTTXQF6 Strong Biomarker [345]
MSMB TTYH1ZK Strong Biomarker [346]
MTA1 TTO4HUS Strong Altered Expression [347]
MTDH TTH6SA5 Strong Biomarker [174]
MTF1 TTTQDEO Strong Biomarker [348]
MTOR TTCJG29 Strong Biomarker [29]
MUC16 TTC1PS3 Strong Biomarker [349]
MYC TTNQ5ZP Strong Biomarker [350]
MYD88 TTB6Q2O Strong Biomarker [351]
NACC1 TT4AQ5F Strong Biomarker [352]
NAPRT TTVR1FW Strong Genetic Variation [353]
NCK1 TTMA3VF Strong Altered Expression [354]
NCOA3 TT124R0 Strong Biomarker [355]
NCOA4 TT8OY02 Strong Altered Expression [356]
NECTIN4 TTPO9EG Strong Altered Expression [357]
NEDD9 TT1UREA Strong Altered Expression [358]
NEK2 TT3VZ24 Strong Altered Expression [359]
NFKB1 TTUIZKC Strong Biomarker [360]
NISCH TT789FN Strong Biomarker [361]
NPEPPS TT371QC Strong Genetic Variation [297]
NR1D1 TTAD1O8 Strong Biomarker [362]
NR1H2 TTXA6PH Strong Altered Expression [363]
NR1I3 TTRANFM Strong Biomarker [364]
NTN1 TT0AH4L Strong Biomarker [365]
NTRK3 TTXABCW Strong Biomarker [366]
NTSR1 TTTUMEP Strong Biomarker [367]
OGFR TT6IEYX Strong Biomarker [368]
OLFM4 TTK1CX7 Strong Altered Expression [369]
OSCAR TT71Q5Y Strong Biomarker [370]
PADI4 TTQHAXM Strong Altered Expression [371]
PAK1 TTFN95D Strong Biomarker [372]
PARG TT39J16 Strong Biomarker [128]
PAWR TT3I4WV Strong Biomarker [215]
PBK TTMY6BZ Strong Biomarker [373]
PCSK6 TT75LN9 Strong Altered Expression [374]
PDCD1 TTNBFWK Strong Biomarker [375]
PDGFD TTSN0GA Strong Biomarker [376]
PDK1 TTCZOF2 Strong Biomarker [377]
PEBP1 TT1BGU8 Strong Altered Expression [378]
PF4 TTSG7Q5 Strong Biomarker [379]
PGF TT48I1Y Strong Altered Expression [380]
PGRMC1 TTY3LAZ Strong Biomarker [381]
PIN1 TTJNTSI Strong Altered Expression [382]
PKM TT4LOT8 Strong Altered Expression [383]
PLCG1 TT6T4JI Strong Biomarker [384]
PLG TTP86E2 Strong Genetic Variation [385]
PLK2 TT976FS Strong Biomarker [386]
PPM1D TTENJAB Strong Genetic Variation [387]
PRSS8 TTT4N0Q Strong Altered Expression [388]
PSEN2 TTWN3F4 Strong Altered Expression [389]
PSIP1 TTH9LDP Strong Altered Expression [390]
PSMB8 TTEAD9J Strong Biomarker [391]
PSMB9 TTOUSTQ Strong Genetic Variation [392]
PTAFR TTQL5VC Strong Altered Expression [393]
PTBP1 TTWMX0U Strong Altered Expression [384]
PTGER3 TTPNGDE Strong Biomarker [394]
PTGS1 TT8NGED Strong Biomarker [395]
PTH TT6F7GZ Strong Genetic Variation [396]
PTP4A3 TT7YM8D Strong Biomarker [397]
PTPN13 TT405FP Strong Biomarker [398]
PTPRC TTUS45N Strong Biomarker [399]
PTPRZ1 TT4SEA8 Strong Biomarker [400]
RAB22A TTAJ746 Strong Altered Expression [401]
RBP4 TT0C8BY Strong Biomarker [402]
RHOB TT6LPFO Strong Altered Expression [403]
ROCK1 TTZN7RP Strong Altered Expression [404]
ROCK2 TTGWKQJ Strong Altered Expression [316]
ROR1 TTDEJAU Strong Biomarker [405]
ROR2 TTUDPCI Strong Altered Expression [406]
RPE65 TTBOH16 Strong Genetic Variation [407]
RPS6KA1 TTIXKA4 Strong Biomarker [408]
RPS6KA6 TT3KYWB Strong Altered Expression [409]
RPS6KB1 TTG0U4H Strong Altered Expression [410]
RRM2 TT1S4LJ Strong Biomarker [411]
RSF1 TTMP86V Strong Altered Expression [412]
RSPO1 TTI9HL4 Strong Biomarker [413]
RUNX3 TTKCVO7 Strong Altered Expression [414]
SATB1 TTLFRIC Strong Biomarker [166]
SCGB1A1 TTONPVW Strong Altered Expression [415]
SCN1A TTANOZH Strong Biomarker [352]
SEMA3A TTVKD3S Strong Altered Expression [416]
SEMA4D TT5UT28 Strong Biomarker [417]
SERPINA6 TTJL8VG Strong Altered Expression [418]
SERPINC1 TT4QPUL Strong Biomarker [419]
SERPIND1 TT8XSKJ Strong Biomarker [420]
SERPINE1 TTTO43N Strong Biomarker [421]
SERPINF1 TTR59S1 Strong Biomarker [422]
SERPING1 TTVQ6R9 Strong Biomarker [421]
SFRP4 TTX8I1Y Strong Altered Expression [423]
SFTPD TTGLMU7 Strong Altered Expression [424]
SH2B3 TT36N7Z Strong Genetic Variation [115]
SIK2 TTCUGZR Strong Biomarker [425]
SIK3 TTW6L4V Strong Altered Expression [426]
SIRT2 TTLKF5M Strong Altered Expression [427]
SIRT3 TTVZLIJ Strong Biomarker [428]
SIRT5 TTH0IOD Strong Altered Expression [429]
SKP2 TT5B2EO Strong Altered Expression [430]
SLC11A2 TT2IS7P Strong Biomarker [431]
SLC13A5 TTFIMH7 Strong Biomarker [432]
SLC16A1 TTN1J82 Strong Altered Expression [166]
SLC2A1 TT79TKF Strong Altered Expression [433]
SLC6A1 TTPRKM0 Strong Biomarker [434]
SLC6A12 TTQBMPI Strong Posttranslational Modification [435]
SMAD7 TT0J32Z Strong Biomarker [436]
SMARCA4 TTVQEZS Strong Biomarker [437]
SMC2 TTS8D17 Strong Genetic Variation [305]
SMYD3 TTKLJYX Strong Biomarker [438]
SOD2 TT9O4C5 Strong Genetic Variation [439]
SPARC TTBQFM7 Strong Biomarker [440]
SPDEF TT2ZUPY Strong Altered Expression [441]
SPHK1 TTOHFIY Strong Altered Expression [442]
SQSTM1 TTOT2RY Strong Genetic Variation [443]
SRR TTZFUY6 Strong Biomarker [444]
SSTR4 TTAE1BR Strong Biomarker [130]
STAT3 TTHJT3X Strong Biomarker [314]
STC1 TTDLUER Strong Biomarker [445]
STC2 TT4EFTR Strong Biomarker [446]
STOML2 TTOI329 Strong Biomarker [447]
STS TTHM0R1 Strong Biomarker [448]
TACSTD2 TTP2HE5 Strong Biomarker [449]
TEK TT9VGXW Strong Biomarker [450]
TEP1 TTQGAVX Strong Genetic Variation [451]
TERT TTQY2EJ Strong Biomarker [452]
TFAP2A TTDY4BS Strong Biomarker [453]
TFF1 TTNOJIZ Strong Altered Expression [389]
TGFB3 TTWOMY8 Strong Biomarker [454]
TGFBR2 TTZE3P7 Strong Genetic Variation [455]
TGM2 TT2F4OL Strong Biomarker [456]
THPO TTCG5PE Strong Altered Expression [457]
THRA TTTSEPU Strong Genetic Variation [362]
TIE1 TTT4236 Strong Biomarker [458]
TIPARP TT2FRAN Strong Genetic Variation [459]
TK1 TTP3QRF Strong Biomarker [460]
TKT TT04R7I Strong Altered Expression [461]
TLR8 TT8CWFK Strong Biomarker [462]
TNFRSF10A TT5WLRX Strong Genetic Variation [463]
TNFRSF12A TTKPS7V Strong Genetic Variation [464]
TNFRSF14 TTWGTC1 Strong Biomarker [465]
TNFRSF4 TTL31H0 Strong Biomarker [466]
TNFSF10 TTA5MS9 Strong Biomarker [467]
TNFSF15 TTEST6I Strong Altered Expression [468]
TNKS TTVUSO7 Strong Biomarker [469]
TOP2A TTCGY2K Strong Biomarker [411]
TP53BP1 TTX4UE9 Strong Biomarker [29]
TPX2 TT0PHL4 Strong Biomarker [470]
TRIM27 TTTO3QN Strong Biomarker [471]
TRIM28 TTQ2BKV Strong Altered Expression [472]
TRIM59 TT613U4 Strong Biomarker [473]
TRPC1 TTA76X0 Strong Biomarker [474]
TRPC3 TTNVC34 Strong Altered Expression [475]
TRPM7 TTFPVZO Strong Biomarker [476]
TRPV6 TTBK14N Strong Altered Expression [477]
TSG101 TTHU7JA Strong Altered Expression [478]
TUSC2 TTJ8O14 Strong Biomarker [479]
TYMS TTP1UKZ Strong Biomarker [480]
UBC TTBP3XA Strong Biomarker [481]
UCHL3 TT23UD6 Strong Biomarker [482]
UCHL5 TTSX29Z Strong Biomarker [483]
UGT1A1 TT34ZAF Strong Genetic Variation [484]
ULK1 TT4D7MJ Strong Biomarker [485]
USP1 TTG9MT5 Strong Biomarker [486]
USP13 TTVJIO2 Strong Biomarker [487]
USP14 TTVSYP9 Strong Biomarker [488]
USP5 TTGYTMA Strong Biomarker [489]
UTRN TTNO1VA Strong Biomarker [425]
VCAM1 TTHCEF6 Strong Biomarker [200]
VEGFC TT0QUFV Strong Altered Expression [490]
VEGFD TTOM5H4 Strong Altered Expression [490]
VSIR TT51SK8 Strong Altered Expression [491]
VTCN1 TTCK85E Strong Altered Expression [492]
WEE1 TTJFOAL Strong Biomarker [493]
WNT7A TT8NARC Strong Biomarker [494]
WT1 TTZ8UT4 Strong Biomarker [495]
XPO1 TTCJUR4 Strong Biomarker [496]
YAP1 TT8UN2D Strong Altered Expression [497]
ZEB2 TTT2WK4 Strong Altered Expression [498]
ZNF217 TTY3BRA Strong Biomarker [499]
ZUP1 TTZC0KV Strong Altered Expression [500]
ABCB1 TT3OT40 Definitive Biomarker [141]
ABCB11 TTUXCAF Definitive Altered Expression [501]
ACVR1 TTJNBQA Definitive Altered Expression [502]
BCL2L1 TTRE6AX Definitive Biomarker [503]
BRD2 TTDP48B Definitive Biomarker [504]
CCR1 TTC24WT Definitive Biomarker [505]
CD24 TTCTYNP Definitive Altered Expression [506]
CHST15 TTFK7E1 Definitive Biomarker [507]
CRHR1 TT7EFHR Definitive Biomarker [508]
CTAG1A TTE5ITK Definitive Biomarker [509]
CTNNB1 TTRPKQG Definitive Altered Expression [510]
CTSB TTF2LRI Definitive Biomarker [511]
CYP1A2 TTS1DTU Definitive Genetic Variation [512]
DNM2 TTVRA5G Definitive Biomarker [513]
EPHB2 TTKPV6O Definitive Biomarker [331]
EZH2 TT9MZCQ Definitive Biomarker [514]
F3 TT38MDJ Definitive Biomarker [515]
FANCA TTV5HJS Definitive Genetic Variation [516]
G6PC TTBQMJ8 Definitive Altered Expression [517]
GNRHR TT8R70G Definitive Biomarker [518]
HMGA2 TTSTVM0 Definitive Biomarker [117]
HSD11B2 TT9H85R Definitive Altered Expression [519]
HSPA5 TTW26OG Definitive Biomarker [520]
IL1R1 TTWOTEA Definitive Biomarker [521]
IL1R2 TT51DEV Definitive Altered Expression [522]
ITGAE TTH0Z37 Definitive Biomarker [523]
KLK8 TTH5MRS Definitive Altered Expression [524]
MAP3K3 TTJZNIG Definitive Altered Expression [525]
MMP8 TTGA1IV Definitive Genetic Variation [526]
MRC1 TTKV8W5 Definitive Biomarker [527]
MST1R TTBQ3OC Definitive Altered Expression [528]
MUC1 TTBHFYQ Definitive Biomarker [529]
NOTCH3 TTVX7IA Definitive Biomarker [530]
NT5E TTK0O6Y Definitive Altered Expression [531]
NUAK1 TT65FL0 Definitive Altered Expression [532]
PGR TTUV8G9 Definitive Genetic Variation [533]
PIK3CB TT9H4P3 Definitive Biomarker [534]
PIM3 TTCGOIN Definitive Biomarker [535]
PLA2G4C TTBYG4O Definitive Altered Expression [536]
PNP TTMCF1Y Definitive Altered Expression [537]
PRDX5 TTLPJWH Definitive Biomarker [538]
PRKACA TT5U49F Definitive Posttranslational Modification [539]
PRKCA TTFJ8Q1 Definitive Biomarker [540]
PRKCI TTWJTHX Definitive Biomarker [541]
PTK6 TT6TH8V Definitive Biomarker [542]
QPCT TTJ7YTV Definitive Biomarker [543]
REG4 TTVZEHU Definitive Altered Expression [544]
RNASEL TT7V0K4 Definitive Genetic Variation [545]
SERPINB5 TT1KW50 Definitive Altered Expression [546]
SETD7 TTJ0FSU Definitive Altered Expression [547]
SPOCK1 TTF23RE Definitive Biomarker [548]
ST14 TTPRO7W Definitive Biomarker [549]
TWIST1 TTX1MY7 Definitive Biomarker [230]
TYMP TTO0IB8 Definitive Altered Expression [550]
WNT5A TTKG7F8 Definitive Biomarker [551]
WWP2 TT6TU05 Definitive Biomarker [552]
------------------------------------------------------------------------------------
⏷ Show the Full List of 597 DTT(s)
This Disease Is Related to 18 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC25A37 DTLBGTZ Limited Biomarker [553]
SLC2A3 DT9SQ3L Limited Altered Expression [554]
SLC31A1 DTP8L4F Limited Altered Expression [555]
SLC9A9 DT8LP62 Limited Genetic Variation [556]
ANXA11 DTGQ2CF moderate Biomarker [557]
ABCA7 DTDVSJA Strong Altered Expression [558]
ABCB9 DT68UV2 Strong Altered Expression [559]
ABCC10 DTPS120 Strong Altered Expression [560]
ATP7A DT0LT17 Strong Biomarker [561]
SLC13A2 DTUO05P Strong Biomarker [432]
SLC25A3 DTCRIWV Strong Biomarker [562]
SLC26A3 DTN1FMD Strong Genetic Variation [563]
SLC27A2 DTXK9WA Strong Biomarker [564]
SLC2A5 DTOR02F Strong Biomarker [565]
SLC30A1 DT1BO38 Strong Biomarker [566]
SLC35A2 DT0567K Strong Biomarker [567]
SLC39A4 DTEZCUM Strong Biomarker [568]
SLC4A11 DTH2J1G Strong Altered Expression [569]
------------------------------------------------------------------------------------
⏷ Show the Full List of 18 DTP(s)
This Disease Is Related to 29 DME Molecule(s)
Gene Name DME ID Evidence Level Mode of Inheritance REF
GPX6 DEOS3FD Limited Genetic Variation [570]
GSTZ1 DEQPEMB Limited Genetic Variation [30]
AKR1C1 DE7P2FB moderate Altered Expression [571]
CYP27B1 DE3FYEM moderate Altered Expression [572]
ABO DESIA7R Strong Biomarker [573]
ADH1B DEEN9RD Strong Biomarker [152]
ALDH1A2 DEKN1H4 Strong Biomarker [574]
ASNS DEXISVQ Strong Biomarker [575]
CRMP1 DE0EUXB Strong Biomarker [425]
EPHX1 DELB4KP Strong Genetic Variation [576]
GFPT2 DERQCJM Strong Altered Expression [577]
GGCT DEKW6PB Strong Altered Expression [578]
GSTO2 DEHMPZR Strong Genetic Variation [30]
HIF1AN DEY1CBW Strong Biomarker [579]
HSD17B12 DE915QP Strong Altered Expression [580]
HSD17B7 DEDMWFX Strong Genetic Variation [581]
IPMK DESA9EX Strong Biomarker [582]
PCYT1A DEQYXD4 Strong Biomarker [583]
PON2 DEHJU7E Strong Biomarker [584]
PSAT1 DEBS17P Strong Biomarker [585]
PTGDS DER3H9C Strong Altered Expression [586]
SULT1A1 DEYWLRK Strong Genetic Variation [587]
SULT1E1 DESTKG6 Strong Genetic Variation [262]
UBASH3B DE10BJ5 Strong Biomarker [588]
ALDH1A1 DE2JP1Y Definitive Biomarker [589]
CBR3 DEIVKZ8 Definitive Altered Expression [590]
CYP2C8 DES5XRU Definitive Genetic Variation [591]
PLPP1 DE6WXTH Definitive Biomarker [592]
SAT1 DEMWO83 Definitive Altered Expression [593]
------------------------------------------------------------------------------------
⏷ Show the Full List of 29 DME(s)
This Disease Is Related to 919 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ACOXL OTW680HT Limited Genetic Variation [570]
ACSL3 OT3MWER1 Limited Altered Expression [594]
ACTN3 OT9DZ7JQ Limited Genetic Variation [595]
ANKLE1 OTQ7WN9J Limited Genetic Variation [596]
ANXA3 OTDD8OI7 Limited Biomarker [597]
APC OTKV0TIK Limited Biomarker [598]
AQP5 OT77GBY8 Limited Altered Expression [599]
ASPM OTKXQMNA Limited Biomarker [600]
ATP11B OTQOXTH2 Limited Biomarker [601]
AXIN2 OTRMGQNU Limited Genetic Variation [602]
BAMBI OTCEJ8W5 Limited Biomarker [603]
BCAR1 OTKT2C2N Limited Altered Expression [604]
BCCIP OTFFKG79 Limited Altered Expression [605]
BMPR1B OTGFN0OD Limited Biomarker [606]
BOD1L1 OTTD5FJ8 Limited Genetic Variation [556]
BTN3A1 OTGZADIX Limited Biomarker [607]
CCL25 OTLWJ8CJ Limited Biomarker [11]
CCNH OTKDU3SR Limited Biomarker [29]
CD164 OTZ7FIU8 Limited Biomarker [608]
CDCA5 OTZLCQ5U Limited Altered Expression [16]
CGB1 OT7NFGXF Limited Biomarker [609]
CGB2 OTZJW4TH Limited Biomarker [609]
CHAC1 OTJGE772 Limited Altered Expression [610]
CIP2A OTVS2GXA Limited Altered Expression [611]
CLDN1 OT27KV99 Limited Altered Expression [612]
CNMD OTHND8EL Limited Biomarker [613]
CORO1A OTVAZOHC Limited Altered Expression [614]
COX5A OTP0961M Limited Altered Expression [615]
CTAG1B OTIQGW6U Limited Biomarker [509]
CTNND2 OTYKE30Y Limited Biomarker [616]
DLX5 OTEEFBEU Limited Altered Expression [617]
DOC2A OT5G9V94 Limited Biomarker [618]
DOK2 OTIJ38UF Limited Biomarker [619]
DVL1 OTD67RF1 Limited Posttranslational Modification [620]
EPB41L3 OTS6CHG2 Limited Biomarker [621]
EPS8 OTZ6ES6V Limited Biomarker [622]
FAM32A OTGU44V9 Limited Genetic Variation [623]
FCN3 OTPRENLS Limited Altered Expression [624]
FDCSP OT8KGE9M Limited Biomarker [625]
FRAS1 OTLPESF3 Limited Genetic Variation [556]
GADD45A OTDRV63V Limited Genetic Variation [626]
GATA5 OTO81B63 Limited Biomarker [627]
GCHFR OTEOT8GI Limited Altered Expression [16]
GNAI2 OTTLGRGH Limited Genetic Variation [628]
GPR4 OTIBF32I Limited Altered Expression [629]
HNF1B OTSYIC3T Limited Biomarker [241]
HOOK2 OTPO4NQV Limited Genetic Variation [595]
HUS1 OTY1XON9 Limited Genetic Variation [630]
IFFO1 OTQGJWI0 Limited Biomarker [631]
IMPA1 OTBUVW1Z Limited Biomarker [632]
INHA OT7HWCO3 Limited Biomarker [633]
JAG1 OT3LGT6K Limited Biomarker [634]
JAM3 OTX0F9QL Limited Biomarker [635]
KLK10 OTD573EL Limited Posttranslational Modification [636]
LDOC1 OTWZH4O9 Limited Biomarker [637]
LIG4 OT40DNXU Limited Genetic Variation [638]
LMX1B OTM8145D Limited Biomarker [639]
LRPPRC OTXSK5LP Limited Biomarker [640]
LRRC59 OT6BQJ5E Limited Biomarker [29]
MACIR OTPSW8Y8 Limited Biomarker [29]
MCPH1 OTYT3TT5 Limited Biomarker [600]
MED19 OTT9RT5N Limited Biomarker [641]
MEST OT8Q4U8Y Limited Biomarker [337]
MLLT10 OTURMDV7 Limited Genetic Variation [570]
MNAT1 OTXLOYCB Limited Altered Expression [16]
MSH6 OT46FP09 Limited Biomarker [642]
MTSS1 OT5DTDO2 Limited Altered Expression [643]
MXI1 OTUQ9E0D Limited Biomarker [553]
NDC80 OTS7D306 Limited Altered Expression [644]
NFATC1 OT4TMERS Limited Biomarker [645]
NKD1 OTY3MO97 Limited Posttranslational Modification [620]
NLK OT2LETFS Limited Biomarker [646]
NOB1 OTW0YNSL Limited Altered Expression [647]
NR2F2 OTJFS67N Limited Altered Expression [648]
P4HB OTTYNYPF Limited Biomarker [649]
PES1 OTMZK7XE Limited Biomarker [650]
PLEKHM1 OT1SLPGD Limited Genetic Variation [570]
PLXNB1 OTCA7JIT Limited Altered Expression [651]
PMS2 OTNLWTMI Limited Genetic Variation [652]
PNKD OT6G9UXN Limited Biomarker [653]
PPP1R13L OTNCPLWE Limited Biomarker [654]
PRKN OTJBN41W Limited Biomarker [122]
PROCR OTRHED17 Limited Biomarker [50]
PSMC3IP OT9UB5UO Limited Biomarker [655]
RAB5A OTFR2KM4 Limited Altered Expression [656]
RAI14 OT6USGBK Limited Altered Expression [648]
RBM38 OTPO8EXU Limited Altered Expression [657]
RPS7 OTIK25WI Limited Biomarker [658]
SEM1 OTASLBM1 Limited Genetic Variation [659]
SLC22A10 OTUVJI3H Limited Biomarker [29]
SNAI2 OT7Y8EJ2 Limited Biomarker [660]
SNCAIP OTH8VNOK Limited Genetic Variation [556]
SOX1 OTVI1RAR Limited Posttranslational Modification [661]
SRSF10 OTY6IJ11 Limited Biomarker [662]
TES OTL8PP6V Limited Posttranslational Modification [663]
THOC1 OTVABJ4Z Limited Altered Expression [664]
TMPRSS4 OTCCGY2K Limited Biomarker [665]
TNFRSF6B OTKAN9G7 Limited Altered Expression [666]
TRMT11 OTRK0IOR Limited Biomarker [29]
TTC28 OTFOOYC3 Limited Genetic Variation [570]
TTLL5 OTUKOVEM Limited Biomarker [667]
CELSR3 OT8P6QNJ Disputed Genetic Variation [65]
HOXA4 OTNVTQDT Disputed Altered Expression [668]
MTHFD1 OTMKHVWC Disputed Genetic Variation [669]
PCDHA1 OT65E2NU Disputed Genetic Variation [65]
PCDHB3 OTEDVXZY Disputed Altered Expression [65]
PFN2 OT5SSSA7 Disputed Genetic Variation [65]
PPP1R15A OTYG179K Disputed Biomarker [670]
PRICKLE4 OT19NLJR Disputed Altered Expression [65]
RBX1 OTYA1UIO Disputed Biomarker [671]
TARS1 OT0PWST5 Disputed Altered Expression [672]
TARS2 OTXQY23P Disputed Altered Expression [672]
TARS3 OTPMDV66 Disputed Altered Expression [672]
ADAMTSL4 OTBILJMW moderate Biomarker [673]
AFM OTPOR8IO moderate Biomarker [674]
ANGPTL2 OTB6JG41 moderate Posttranslational Modification [675]
ASS1 OT4ZMG0Q moderate Posttranslational Modification [676]
ATRIP OT78O9LF moderate Biomarker [677]
BDH2 OTDD7G8S moderate Altered Expression [678]
BEX4 OT3LXD15 moderate Biomarker [679]
CABLES1 OTMN4XSX moderate Altered Expression [680]
CACNB1 OTV42SIT moderate Biomarker [681]
CASP14 OTKY93H9 moderate Altered Expression [682]
CERT1 OTNUCNHX moderate Altered Expression [683]
CHP2 OT4UMKUR moderate Altered Expression [684]
CNTN4 OTULXVE0 moderate Biomarker [685]
DDB1 OTTR2L3Z moderate Altered Expression [686]
EEF1A1 OT00THXS moderate Biomarker [687]
FANCD2 OTVEB5LF moderate Biomarker [688]
FOXG1 OTAW57J4 moderate Altered Expression [689]
FRAT1 OT1PS84E moderate Altered Expression [690]
GALNT3 OT7M67WT moderate Biomarker [691]
GBE1 OTK2N05B moderate Biomarker [692]
HLA-DOA OTZE5Q7R moderate Biomarker [693]
HTRA2 OTC7616F moderate Altered Expression [260]
ING1 OTEZBRKW moderate Altered Expression [694]
IQGAP1 OTZRWTGA moderate Biomarker [695]
IRF2 OTAZRUW3 moderate Biomarker [696]
LGALS3BP OT9AGQKH moderate Altered Expression [697]
LRWD1 OTHRVJQC moderate Altered Expression [698]
LZTS1 OTXXL864 moderate Biomarker [699]
MFAP5 OT46VXSG moderate Biomarker [700]
MRPL23 OT7H7PM2 moderate Genetic Variation [701]
MTA3 OTIA6C79 moderate Biomarker [702]
NFKBIB OTY1ZJXH moderate Genetic Variation [703]
NMI OTYVG3NM moderate Genetic Variation [704]
NXPH2 OTHD8HPU moderate Genetic Variation [701]
PHF13 OT89FV4A moderate Altered Expression [705]
POLD1 OTWO4UCJ moderate Genetic Variation [706]
PRB2 OTAD4JZ0 moderate Biomarker [707]
PSD3 OTTN9B9O moderate Altered Expression [678]
PTBP2 OTF4S7NE moderate Altered Expression [708]
RAD52 OT0OTDHI moderate Biomarker [709]
SOHLH2 OTB9EM6C moderate Posttranslational Modification [710]
TOPBP1 OT6UPZPD moderate Biomarker [711]
TOX3 OTC9NR4W moderate Genetic Variation [701]
TPD52 OTPKSK43 moderate Biomarker [712]
TRIT1 OTCU9FS5 moderate Altered Expression [713]
ABHD2 OTCRUOCS Strong Altered Expression [714]
ABI1 OT5H4M62 Strong Biomarker [715]
ABRAXAS1 OT1K4J80 Strong Genetic Variation [716]
ACOT7 OT7C68YV Strong Genetic Variation [717]
ACTBL2 OTD6B81U Strong Genetic Variation [717]
ACTG2 OTRDWUO0 Strong Genetic Variation [717]
ACTL6A OT0EC5BQ Strong Biomarker [718]
ACTN4 OTCNZAJ5 Strong Biomarker [719]
ACVR1C OTOTYERF Strong Biomarker [720]
ADAM19 OTH88TXU Strong Biomarker [721]
ADAMTS16 OTTKUH99 Strong Genetic Variation [722]
ADARB2 OTDJKS39 Strong Genetic Variation [723]
ADGRE2 OTUYJVYG Strong Genetic Variation [724]
ADGRE5 OTTSB84Q Strong Genetic Variation [724]
ADIPOR1 OT65ZFZN Strong Biomarker [725]
ADIPOR2 OT2HDTL8 Strong Biomarker [725]
ADNP OTEGICWR Strong Biomarker [726]
ADRM1 OTOU4EY6 Strong Genetic Variation [727]
AGBL2 OTCX9987 Strong Altered Expression [728]
AGO2 OT4JY32Q Strong Biomarker [729]
AGR3 OTONJPDP Strong Altered Expression [93]
AKAP12 OTCVRDDX Strong Altered Expression [730]
AKAP3 OT42QOFG Strong Altered Expression [731]
AMBP OTLU8GU8 Strong Genetic Variation [255]
AMPD3 OT5SP1KJ Strong Biomarker [732]
ANAPC10 OTM03SME Strong Biomarker [733]
ANKRD11 OTV0V70M Strong Genetic Variation [734]
ANXA4 OTUCRYXL Strong Biomarker [735]
ANXA6 OT9KIQ0Y Strong Biomarker [588]
APBB1IP OTN02KUV Strong Altered Expression [736]
APELA OTYY0P69 Strong Biomarker [737]
APOBEC3B OTHLNI51 Strong Altered Expression [738]
ARHGAP10 OT84ATF5 Strong Biomarker [739]
ARHGEF28 OT3F32IU Strong Altered Expression [740]
ARID3B OTUP9MS4 Strong Biomarker [741]
ARL11 OTF6UDDB Strong Genetic Variation [742]
ARNT OTMSIEZY Strong Altered Expression [743]
ARR3 OTRZ00CH Strong Biomarker [364]
ATAD5 OTI8ABKF Strong Genetic Variation [570]
ATG5 OT4T5SMS Strong Altered Expression [744]
BABAM1 OTCFPER6 Strong Genetic Variation [570]
BACH2 OT17GS18 Strong Altered Expression [745]
BAD OT63ERYM Strong Posttranslational Modification [746]
BAG3 OTVXYUDQ Strong Biomarker [747]
BARX2 OT0R3QD3 Strong Altered Expression [153]
BCL10 OT47MCLI Strong Biomarker [398]
BCL3 OT1M5B95 Strong Altered Expression [748]
BCL7A OTYFUJTP Strong Biomarker [749]
BCL9 OTRBIPR4 Strong Altered Expression [430]
BIRC6 OTCQJAB0 Strong Biomarker [485]
BMS1 OTEGQ8ZO Strong Biomarker [750]
BNC2 OTU22H9Z Strong Biomarker [751]
BNIP3L OTJKOMXE Strong Biomarker [752]
BRMS1 OTV5A6LL Strong Biomarker [753]
BRMS1L OTJIW47U Strong Biomarker [754]
BTN3A2 OT3DIBU3 Strong Biomarker [755]
BUD31 OTN3HZYF Strong Altered Expression [756]
C12orf75 OTFVI3EY Strong Genetic Variation [757]
C19orf12 OTVSJ1AR Strong Biomarker [758]
C1GALT1 OT2ZSZ6P Strong Biomarker [759]
C20orf204 OT0GVQPP Strong Biomarker [760]
CACUL1 OT6P1ZVP Strong Biomarker [761]
CALB1 OTM7IXDG Strong Biomarker [762]
CALB2 OTSNMCG9 Strong Biomarker [133]
CAMKMT OTLJBRUW Strong Biomarker [304]
CAPNS1 OT95EBBD Strong Biomarker [763]
CARD10 OT2RPM4I Strong Biomarker [764]
CBFB OTIAC6W4 Strong Biomarker [765]
CBLL2 OTB4AD3V Strong Biomarker [122]
CBX2 OTOQ5WS4 Strong Biomarker [766]
CC2D1A OTVPU04K Strong Biomarker [767]
CCDC54 OTW5WCX9 Strong Biomarker [768]
CCL15 OTOGZ85M Strong Biomarker [142]
CCL18 OT7JYSK9 Strong Biomarker [769]
CCL8 OTCTWYN8 Strong Altered Expression [142]
CCNA1 OTX4HD45 Strong Biomarker [770]
CCND2 OTDULQF9 Strong Altered Expression [771]
CCNG1 OT17IA9L Strong Altered Expression [772]
CCNG2 OTII38K2 Strong Biomarker [773]
CCT4 OT5D452X Strong Biomarker [774]
CD151 OTF3UZS7 Strong Altered Expression [775]
CD63 OT2UGZA9 Strong Altered Expression [776]
CD82 OTH8MC64 Strong Biomarker [777]
CDC42 OT5QBC5M Strong Biomarker [778]
CDC6 OTX93FE7 Strong Biomarker [779]
CDCP1 OTD7RRWK Strong Biomarker [780]
CDH13 OTD2CYM5 Strong Biomarker [781]
CDK14 OT385ZH1 Strong Biomarker [782]
CDK2AP1 OTNFOHDJ Strong Biomarker [733]
CDKN2B OTAG24N1 Strong Posttranslational Modification [783]
CDKN2D OT2TTZPZ Strong Biomarker [784]
CDKN3 OTBE3H07 Strong Biomarker [785]
CDR2 OTD3ZJST Strong Biomarker [786]
CEACAM7 OTKFDTZY Strong Biomarker [18]
CEMIP OTK80FYN Strong Biomarker [787]
CHAF1A OTXSSY4H Strong Biomarker [285]
CHD2 OTRKL6YC Strong Biomarker [788]
CHD5 OTS5EVHH Strong Altered Expression [789]
CHFR OTRAD2TT Strong Biomarker [790]
CHGB OT7SAQT2 Strong Posttranslational Modification [791]
CHMP2B OTZA7RJB Strong Biomarker [431]
CHMP4C OT5X8A3O Strong Biomarker [792]
CHPT1 OT4FJ0K3 Strong Biomarker [793]
CHRD OTNM60Y1 Strong Biomarker [794]
CIB2 OT9ZJX1I Strong Biomarker [795]
CIC OTFXCHNZ Strong Biomarker [796]
CKAP2 OTCLTC0J Strong Altered Expression [797]
CKAP4 OTDUC9ME Strong Genetic Variation [407]
CKB OTUCKOTT Strong Biomarker [798]
CLDN10 OT2CVAKY Strong Biomarker [797]
CLDN11 OTNN6UTL Strong Biomarker [799]
CLDN3 OT71MN9S Strong Biomarker [800]
CLDN7 OTNE0XHQ Strong Altered Expression [801]
CLEC10A OTD8HQT6 Strong Biomarker [802]
CLEC11A OT9KBH7C Strong Altered Expression [803]
CLIC4 OT6KTPKD Strong Biomarker [804]
CMIP OTZN8Z4A Strong Genetic Variation [723]
CNDP2 OTJR9436 Strong Altered Expression [805]
CNOT2 OT98OJ42 Strong Genetic Variation [722]
COL11A1 OTB0DRMS Strong Biomarker [806]
COL5A1 OT24078H Strong Altered Expression [807]
COMMD1 OT7WUD5R Strong Altered Expression [808]
COX1 OTG3O9BN Strong Biomarker [395]
COX5B OTDP94F3 Strong Biomarker [809]
CPNE3 OTCR3WG2 Strong Biomarker [810]
CPOX OTIAY121 Strong Genetic Variation [255]
CREB3 OT9617UO Strong Genetic Variation [811]
CREB3L4 OTSGQGT2 Strong Biomarker [167]
CREBZF OTO3TOEU Strong Biomarker [248]
CRKL OTOYSD1R Strong Biomarker [812]
CSPP1 OTNX7GD4 Strong Altered Expression [813]
CSTB OT3U0JF8 Strong Biomarker [814]
CT45A1 OT80VTZO Strong Biomarker [815]
CTAG2 OT8HISP4 Strong Altered Expression [816]
CTBP1 OTVYH2DH Strong Altered Expression [817]
CTBP2 OTGZGT87 Strong Biomarker [818]
CTCF OT8ZB70U Strong Biomarker [819]
CTHRC1 OTV88X2G Strong Biomarker [820]
CTNNAL1 OTESJ6JD Strong Biomarker [821]
CTNNBIP1 OTX9SBJG Strong Biomarker [822]
CTNNBL1 OT6KLHPA Strong Biomarker [823]
CTNND1 OTUMPSHR Strong Altered Expression [824]
CUL4A OTTBV70J Strong Biomarker [825]
CXADR OT9ZP02A Strong Biomarker [364]
CXCL16 OTD49T9R Strong Biomarker [90]
CYGB OTX153DQ Strong Altered Expression [826]
CYP2A7 OTRJ3P2Z Strong Genetic Variation [827]
DAAM1 OT0VHIYZ Strong Altered Expression [828]
DACT1 OT19Z704 Strong Biomarker [829]
DAPK2 OTWODUQG Strong Biomarker [425]
DAXX OTX6O7PL Strong Biomarker [830]
DCTN4 OTM7C943 Strong Genetic Variation [443]
DCTN6 OTI8PIN9 Strong Biomarker [831]
DDA1 OTAZIAIH Strong Biomarker [832]
DDB2 OTO8HVVB Strong Biomarker [833]
DDX1 OT3U8FD0 Strong Biomarker [834]
DDX10 OTH48438 Strong Altered Expression [835]
DDX4 OTQOV093 Strong Biomarker [836]
DDX53 OTHK3EGZ Strong Biomarker [837]
DENR OTXP9HOY Strong Biomarker [425]
DESI2 OTHUOKOC Strong Therapeutic [838]
DGCR8 OT62LXE4 Strong Biomarker [839]
DHDDS OTVLYBUS Strong Biomarker [793]
DHRS2 OTFHWIY8 Strong Biomarker [840]
DIRAS3 OT3XHLQA Strong Altered Expression [841]
DLC1 OTP8LMCR Strong Therapeutic [112]
DLG2 OTQ3BD8U Strong Altered Expression [842]
DLX1 OT7BH057 Strong Biomarker [843]
DMP1 OTBWBWW7 Strong Altered Expression [844]
DMRT1 OT5PU9U1 Strong Biomarker [431]
DNAH8 OTGES2OU Strong Altered Expression [845]
DNER OT2GH2E5 Strong Biomarker [846]
DNM3 OTDMUGCR Strong Genetic Variation [722]
DOCK1 OTCFV3ON Strong Altered Expression [847]
DOK1 OTGVRLW6 Strong Therapeutic [848]
DPEP2 OTIKZDTG Strong Altered Expression [805]
DPH1 OT0QU3JY Strong Altered Expression [849]
DROSHA OTCE68KZ Strong Altered Expression [850]
DSC3 OTYG47F8 Strong Altered Expression [851]
DUSP6 OT4H6RKW Strong Biomarker [852]
DYNLT3 OT26QKCI Strong Biomarker [853]
E2F6 OT2PN28R Strong Altered Expression [854]
E2F7 OTWW358N Strong Altered Expression [855]
ECHDC1 OTMS00PY Strong Genetic Variation [856]
EFEMP2 OT0I2B4J Strong Biomarker [857]
EFNA1 OTU2NUA2 Strong Biomarker [203]
EHF OTY6TPWD Strong Altered Expression [858]
EIF1 OTB4GZ0V Strong Biomarker [444]
EIF3A OTFABY9G Strong Biomarker [859]
EIF5 OT79PQUN Strong Biomarker [198]
EIF5AL1 OTLA4ONW Strong Biomarker [198]
ELAVL2 OT6EJ8MQ Strong Biomarker [860]
ELF3 OTUTLEQO Strong Biomarker [861]
ELK1 OTH9MXD6 Strong Altered Expression [862]
ELOB OTZ3X84T Strong Altered Expression [863]
EN2 OT7EZCM2 Strong Biomarker [864]
EPSTI1 OT75I1UH Strong Biomarker [865]
ERAS OT528IZO Strong Biomarker [866]
ERCC5 OTQAKFJM Strong Posttranslational Modification [867]
ERV3-1 OT4CW64T Strong Biomarker [868]
ESRP1 OTNCS4SL Strong Biomarker [869]
ESRP2 OTVTKJ4I Strong Altered Expression [869]
ETFA OTXX61VZ Strong Genetic Variation [870]
ETV4 OT8C98UZ Strong Altered Expression [871]
ETV5 OTE2OBM4 Strong Altered Expression [872]
FAIM2 OT6QINVO Strong Biomarker [873]
FAM168A OTDXQCS5 Strong Biomarker [874]
FAM210B OT2QHEQ6 Strong Biomarker [875]
FAM53B OTVD7OU6 Strong Biomarker [876]
FANCG OT7MC8TZ Strong Genetic Variation [877]
FANCM OTNJG99Z Strong Genetic Variation [878]
FBLN5 OTLVNZ8U Strong Biomarker [879]
FBP1 OTQBANEP Strong Altered Expression [880]
FBXO5 OTTR957W Strong Altered Expression [881]
FCN2 OTTHJBKZ Strong Altered Expression [624]
FERMT3 OTFQOT3C Strong Biomarker [419]
FGF3 OT9PK2SI Strong Biomarker [882]
FGF9 OT2SKDGM Strong Biomarker [883]
FHL2 OT0OAYWT Strong Biomarker [884]
FHL5 OT6C00Z1 Strong Genetic Variation [717]
FILIP1L OTPY8IMS Strong Biomarker [885]
FLOT1 OT0JPPJZ Strong Altered Expression [886]
FMR1 OTWEV0T5 Strong Genetic Variation [887]
FNDC3A OTUX3S2I Strong Biomarker [888]
FOXA2 OTJOCVOY Strong Biomarker [889]
FOXK1 OTLZGS7J Strong Biomarker [890]
FOXL2 OTFRQUYL Strong Genetic Variation [28]
FRS2 OTDMD800 Strong Biomarker [891]
FRY OT74IAG2 Strong Genetic Variation [115]
FSD1 OT8P6PT3 Strong Altered Expression [892]
FSD1L OTBQ48RF Strong Altered Expression [892]
FSTL1 OT6KEZUD Strong Genetic Variation [757]
FUT1 OTODG57A Strong Altered Expression [893]
FXYD5 OT81DIOD Strong Biomarker [894]
FZD1 OTZATHVS Strong Biomarker [895]
GAB1 OTQKE6V4 Strong Biomarker [896]
GAB2 OTBFN705 Strong Biomarker [534]
GALNT14 OT9BSDDQ Strong Biomarker [897]
GALNT6 OTOQQVH1 Strong Altered Expression [898]
GCNT3 OTQ9ALTR Strong Biomarker [899]
GDE1 OTU6FSBF Strong Biomarker [900]
GEN1 OT1XFQXF Strong Altered Expression [901]
GGNBP2 OT7K9YZV Strong Biomarker [902]
GHRH OT94U6MO Strong Biomarker [903]
GIPC1 OTXLVCPJ Strong Biomarker [904]
GNA12 OT3IRZH3 Strong Altered Expression [86]
GOLGA6A OTHU9MRX Strong Biomarker [579]
GOLPH3 OTDLGYM3 Strong Biomarker [905]
GOLPH3L OTT2K3LQ Strong Biomarker [906]
GPR150 OTTA9DF6 Strong Biomarker [282]
GPR42 OTEB0ROY Strong Biomarker [130]
GRB7 OTF8Y9XY Strong Altered Expression [907]
GREB1 OTU6ZA26 Strong Biomarker [908]
GTF2H1 OTCRXC6B Strong Genetic Variation [443]
GULP1 OT1WMVDH Strong Genetic Variation [909]
H2AC11 OTN9P0BO Strong Biomarker [888]
H2BC12 OTQ8V0KG Strong Genetic Variation [888]
H2BC21 OT0FDCUC Strong Genetic Variation [888]
H3C1 OTGBGOZW Strong Biomarker [888]
H4C1 OTB71W46 Strong Biomarker [888]
HAPLN1 OTXWR9TJ Strong Biomarker [910]
HARS1 OTHOEOTS Strong Biomarker [786]
HAUS6 OT7ZVR57 Strong Biomarker [792]
HCFC1R1 OTGDPS5C Strong Biomarker [911]
HEATR6 OTD3MYS0 Strong Biomarker [355]
HECTD3 OTTGP4OK Strong Altered Expression [912]
HELQ OTL1STJT Strong Biomarker [913]
HIF3A OTPWAAMC Strong Altered Expression [914]
HLA-DMB OT17HGXJ Strong Altered Expression [915]
HLA-DRB3 OT5PM9N7 Strong Genetic Variation [916]
HLA-E OTX1CTFB Strong Altered Expression [917]
HLTF OTRX2OSF Strong Altered Expression [918]
HM13 OTGEO1LP Strong Biomarker [919]
HMBOX1 OTPKTBVI Strong Altered Expression [920]
HMCN1 OTLZAS0P Strong Biomarker [921]
HMGB3 OTCJ2EZY Strong Biomarker [922]
HMMR OT4M0JTZ Strong Biomarker [923]
HOXA1 OTMSOJ7D Strong Biomarker [924]
HOXA10 OTB6GQ09 Strong Biomarker [532]
HOXA9 OTKNK5H0 Strong Biomarker [925]
HOXB9 OTMVHQOU Strong Biomarker [926]
HOXD1 OTN4V9ZF Strong Genetic Variation [927]
HOXD11 OT9XGA4G Strong Biomarker [282]
HOXD3 OTBUZ35T Strong Genetic Variation [570]
HPR OTXSC9UB Strong Altered Expression [928]
HSDL2 OT4IN0MV Strong Altered Expression [929]
HSPA14 OTZCA5LK Strong Biomarker [930]
HSPA1A OTKGIE76 Strong Biomarker [931]
HSPA2 OTSDET7B Strong Biomarker [932]
HTRA3 OTXJ0H4X Strong Altered Expression [933]
HUWE1 OTFH6BJS Strong Biomarker [934]
ICMT OT8CNKBO Strong Altered Expression [935]
ID4 OTPMJ39I Strong Biomarker [936]
IFI27 OTI2XGIT Strong Biomarker [831]
IFT80 OTMH0MBI Strong Altered Expression [111]
IGF2BP1 OT9G360P Strong Biomarker [919]
IKBKE OT5VYOSM Strong Altered Expression [254]
IL17RB OT0KDNSF Strong Biomarker [122]
IL6ST OT1N9C70 Strong Biomarker [640]
IMMP1L OTA6LOLR Strong Biomarker [919]
INCENP OT9HFRYK Strong Genetic Variation [305]
ING4 OT0VVG4V Strong Biomarker [273]
ING5 OTRNNSFM Strong Altered Expression [937]
INPP4B OTLROA7G Strong Genetic Variation [938]
INSL3 OT7KUNTE Strong Altered Expression [939]
INTS2 OT2N5TCK Strong Biomarker [882]
IQGAP2 OTX2UA7P Strong Biomarker [940]
ITGB4 OT28UK84 Strong Biomarker [283]
ITGBL1 OTJDHE17 Strong Altered Expression [941]
ITIH2 OTG3WBBE Strong Biomarker [942]
ITM2A OT590V63 Strong Biomarker [943]
JARID2 OT14UM8H Strong Biomarker [944]
JAZF1 OTXTYSYD Strong Genetic Variation [723]
JMJD6 OTILR7E4 Strong Altered Expression [945]
JRK OTO8E77P Strong Altered Expression [946]
KANSL1 OTYNSNNZ Strong Biomarker [792]
KAT2A OTN0W2SW Strong Altered Expression [947]
KAT7 OTUN98IC Strong Altered Expression [948]
KAT8 OT5LPQTR Strong Altered Expression [949]
KATNA1 OTISKGMK Strong Biomarker [950]
KCNIP3 OTCQPEM4 Strong Biomarker [951]
KDM2B OTDMCVW7 Strong Biomarker [952]
KDM4B OT5P1UPY Strong Biomarker [953]
KIF14 OTXHT4JM Strong Biomarker [950]
KIF20A OTXOQHE0 Strong Altered Expression [954]
KIF23 OTY850JC Strong Altered Expression [955]
KIF2A OT2WQ6QD Strong Biomarker [956]
KIFC1 OTNQDS00 Strong Altered Expression [957]
KLF2 OTIP1UFX Strong Biomarker [958]
KLF6 OTQY9S7F Strong Altered Expression [959]
KLF8 OTUC5CDB Strong Altered Expression [960]
KLF9 OTBFEJRQ Strong Biomarker [961]
KLHL1 OTAX6SAD Strong Altered Expression [962]
KLK11 OT5PKX7Y Strong Altered Expression [963]
KLK13 OT8LOD2U Strong Altered Expression [296]
KLK15 OT7BVG17 Strong Genetic Variation [964]
KLK9 OTGJWBIF Strong Altered Expression [965]
KRIT1 OT58AP1I Strong Biomarker [304]
KRT5 OTVGI9HT Strong Altered Expression [966]
KRT6C OT9RXMPK Strong Altered Expression [966]
KRT8 OTTM4X11 Strong Genetic Variation [115]
KRT9 OTA10UCH Strong Genetic Variation [967]
LAMA3 OTFME7HT Strong Biomarker [968]
LAMP3 OTN0XL3W Strong Altered Expression [969]
LARP4 OTB10IJH Strong Biomarker [970]
LCP1 OTK61F2A Strong Biomarker [971]
LGR6 OTPZ1PWR Strong Biomarker [972]
LIMD2 OTSIFTD8 Strong Altered Expression [973]
LIN28B OTVWP0FN Strong Biomarker [974]
LIN7A OTFL3PUX Strong Altered Expression [975]
LMX1A OTEEYD5L Strong Biomarker [976]
LPP OT6TU8SE Strong Biomarker [977]
LRPAP1 OT6DVD2Q Strong Biomarker [978]
LRRC46 OTXU2A9W Strong Biomarker [792]
LSR OTR8Y32X Strong Biomarker [979]
LTBP1 OTR7Q75L Strong Biomarker [980]
LUM OTSRC874 Strong Biomarker [981]
LYPD4 OTYNO8BS Strong Biomarker [982]
MACC1 OTV3DLX0 Strong Biomarker [983]
MAGED4B OTO37U7W Strong Altered Expression [37]
MAGI2 OTXDDKZS Strong Biomarker [984]
MAK16 OTD546E5 Strong Altered Expression [384]
MAN1A1 OT6LIGJP Strong Biomarker [985]
MAP1LC3B OTUYHB84 Strong Biomarker [986]
MAP2K4 OTZPZX11 Strong Altered Expression [987]
MAP2K6 OTK13JKC Strong Biomarker [988]
MARCHF5 OTBK6BBM Strong Biomarker [989]
MARCHF7 OTG9SF10 Strong Biomarker [990]
MBD2 OTUQPP0R Strong Biomarker [288]
MCAT OTH07FIW Strong Altered Expression [166]
MCTS1 OT7SAOJP Strong Altered Expression [166]
MDC1 OTEUQH4J Strong Biomarker [991]
MECOM OTP983W8 Strong Biomarker [992]
MEF2A OTV2SF6E Strong Altered Expression [254]
MEF2D OT7CEIG0 Strong Biomarker [254]
MEGF8 OT5G38CH Strong Biomarker [993]
METTL3 OTSXP1M3 Strong Biomarker [994]
MGAT3 OTXI5X4T Strong Biomarker [995]
MICALL2 OT1IQM3K Strong Biomarker [996]
MICU1 OTS7N0LE Strong Biomarker [997]
MLLT11 OTG5RVHC Strong Altered Expression [998]
MMP19 OTLSTT2B Strong Altered Expression [999]
MOAP1 OTVF3LUG Strong Biomarker [1000]
MPP2 OTPH8CZY Strong Altered Expression [842]
MPZL1 OTJSUUHR Strong Altered Expression [1001]
MRPL28 OT4LUTZU Strong Posttranslational Modification [783]
MSC OTBRPZL5 Strong Biomarker [314]
MSH3 OTD3YPVL Strong Altered Expression [87]
MSN OTZJ4J6G Strong Biomarker [303]
MSX1 OT5U41ZP Strong Altered Expression [1002]
MTUS1 OTBPALMU Strong Biomarker [1003]
MTX1 OTLSDNZO Strong Genetic Variation [115]
MUC13 OTWKS9MF Strong Posttranslational Modification [1004]
MUL1 OT2JC9YR Strong Biomarker [122]
MUS81 OTVZ4E60 Strong Altered Expression [1005]
MYBL2 OTZ3JX8Q Strong Altered Expression [951]
MYH6 OT3YNCH1 Strong Biomarker [1006]
MYLK3 OTC58V2Q Strong Biomarker [1007]
MYO6 OTJQYRC7 Strong Biomarker [1006]
MYPN OTHTOFDU Strong Biomarker [1008]
N4BP1 OTN2TL6N Strong Biomarker [1009]
NAALADL2 OT2HOGPQ Strong Genetic Variation [827]
NANOG OTUEY1FM Strong Biomarker [1010]
NAV3 OT97M1TR Strong Biomarker [1011]
NBR1 OTVRL7J9 Strong Biomarker [1012]
NCALD OTJZ8UEL Strong Altered Expression [1013]
NCAM2 OT8LBJN8 Strong Genetic Variation [723]
NCK2 OTUYPF55 Strong Biomarker [283]
NCLN OTAYGGFL Strong Genetic Variation [723]
NDN OTYBYJ82 Strong Biomarker [1014]
NECTIN2 OTIE0W6O Strong Biomarker [1015]
NECTIN3 OTS8N7MK Strong Biomarker [1016]
NEK10 OTN0JAYL Strong Genetic Variation [115]
NEU3 OTQ5PQOW Strong Altered Expression [1017]
NFE2 OTLM94BI Strong Biomarker [1018]
NFIL3 OTQH9HM3 Strong Altered Expression [1019]
NIBAN1 OTYOLI12 Strong Biomarker [170]
NID1 OTKLBLS6 Strong Biomarker [1020]
NID2 OTHC33FF Strong Biomarker [1021]
NME2 OTCYGLHV Strong Therapeutic [112]
NME3 OT0CA0GF Strong Altered Expression [1022]
NPLOC4 OTC1WUVF Strong Altered Expression [1023]
NR2F6 OTNVO2B6 Strong Biomarker [832]
NR5A1 OTOULYR4 Strong Biomarker [1024]
NRSN2 OT4OS3M2 Strong Biomarker [1025]
NSD2 OTQ6SW4R Strong Altered Expression [1026]
NSF OTKRJ2ZT Strong Genetic Variation [1027]
NSUN2 OTZCNM33 Strong Biomarker [31]
NSUN4 OTY6O37Z Strong Genetic Variation [305]
NTS OTPGDNQS Strong Altered Expression [367]
NUCKS1 OTL4VJC5 Strong Altered Expression [1028]
NUDT1 OTZSES3W Strong Biomarker [1029]
NUP107 OTG4RDYS Strong Genetic Variation [1030]
NUP62 OTMN63DH Strong Genetic Variation [443]
NXF3 OTI0RW72 Strong Biomarker [1031]
NXT1 OT0VO6AY Strong Posttranslational Modification [783]
OCIAD1 OTJBY7PV Strong Altered Expression [1032]
OPCML OT93PQ6Y Strong Posttranslational Modification [1033]
OPN5 OTCYGHDA Strong Genetic Variation [1034]
OTUB1 OT8WWM9O Strong Biomarker [1035]
OTUD1 OTE6O5XB Strong Biomarker [1036]
OTUD6A OTBVBINP Strong Altered Expression [489]
OVGP1 OTL2W9M5 Strong Biomarker [797]
PAEP OTQA0NV4 Strong Biomarker [1037]
PAF1 OTDDGUBQ Strong Biomarker [1038]
PAK3 OT80M3BV Strong Biomarker [1039]
PAK5 OT32WQGL Strong Altered Expression [1040]
PALM2AKAP2 OTI618VF Strong Altered Expression [1041]
PAPPA OTTTG9PG Strong Biomarker [1042]
PARD3 OTH5BPLO Strong Altered Expression [214]
PAX1 OT0Y3MIM Strong Biomarker [1043]
PAX2 OTKP1N8F Strong Biomarker [1044]
PBOV1 OT67PERT Strong Biomarker [1045]
PBX1 OTORABGO Strong Altered Expression [1046]
PBXIP1 OTEAAUBY Strong Biomarker [1047]
PCDH8 OTDDOQM2 Strong Altered Expression [1048]
PCDH9 OTX3BFV4 Strong Biomarker [1049]
PCLAF OTMVIOUU Strong Altered Expression [1050]
PCM1 OTFM133C Strong Genetic Variation [1051]
PCNT OTW4Z65J Strong Biomarker [1052]
PDCD4 OTZ6NXUX Strong Biomarker [1053]
PDIA3 OTHPQ0Q3 Strong Biomarker [1054]
PDIA4 OTVFUJ13 Strong Biomarker [1055]
PDK4 OTCMHMBZ Strong Biomarker [1056]
PDLIM2 OTEURRPD Strong Biomarker [973]
PDLIM4 OT23LZYY Strong Altered Expression [1057]
PEA15 OTKCKTSX Strong Altered Expression [1058]
PEG3 OTHQW98S Strong Posttranslational Modification [1059]
PELP1 OTVXQNOT Strong Biomarker [1060]
PFN1 OTHTGA1H Strong Altered Expression [1061]
PHB2 OTCAX3AW Strong Altered Expression [428]
PHF19 OTF6RUCR Strong Altered Expression [1062]
PHF20 OTCBVH5P Strong Biomarker [1063]
PI3 OT47MTC3 Strong Biomarker [1064]
PIK3R3 OTXGJ8N1 Strong Altered Expression [1065]
PITX2 OTWMXAOY Strong Biomarker [1066]
PKP3 OTPL1HRB Strong Biomarker [332]
PLAA OTZ7NJGA Strong Biomarker [317]
PLAG1 OTT9AJQY Strong Genetic Variation [297]
PLAGL1 OTZAO900 Strong Genetic Variation [1067]
PLAGL2 OT6AP4V2 Strong Biomarker [780]
PLCZ1 OTJ2MEFA Strong Altered Expression [1068]
PLEC OTU4XDEG Strong Biomarker [1052]
PLEKHF1 OT9OL16U Strong Biomarker [758]
PLXNB2 OT56I2VD Strong Biomarker [1069]
PMAIP1 OTXEE550 Strong Biomarker [320]
PMEPA1 OTY8Z9UF Strong Altered Expression [1070]
PNO1 OT010GIS Strong Altered Expression [384]
PNPLA2 OTR3ERMR Strong Biomarker [1071]
POLE OTFM3MMU Strong Genetic Variation [734]
POLR2A OTHJQ1DZ Strong Biomarker [1072]
POP4 OTN0XJZJ Strong Biomarker [758]
POTED OTAUSTUK Strong Biomarker [1073]
POTEM OT7L2HGH Strong Genetic Variation [717]
POU4F3 OTILD0XS Strong Altered Expression [984]
PPA1 OTHZK1QB Strong Altered Expression [1074]
PPP1CC OTRZO26U Strong Biomarker [758]
PPP1R1A OTGTAGCV Strong Biomarker [1075]
PPP2R1A OTYA3GB4 Strong Genetic Variation [1076]
PPP2R2A OT9297OG Strong Biomarker [1077]
PPP2R2C OTXK0SDM Strong Biomarker [1078]
PPRC1 OT6GB3WR Strong Biomarker [1079]
PRC1 OTHD0XS0 Strong Biomarker [792]
PRDX1 OTZ3BEC4 Strong Altered Expression [1080]
PRKAA1 OT7TNF0L Strong Biomarker [1081]
PRKAA2 OTU1KZPV Strong Biomarker [1081]
PRKAB1 OT1OG4QZ Strong Biomarker [1081]
PRKRA OTUTVZZU Strong Biomarker [1082]
PROS1 OTXQWNOI Strong Genetic Variation [297]
PRPF31 OTSJ0Z1Y Strong Biomarker [1083]
PRR11 OT2JJ08Z Strong Altered Expression [1084]
PRSS21 OT8ZYC7G Strong Biomarker [1085]
PRSS3 OTN3S5YB Strong Altered Expression [1086]
PRTFDC1 OTKJ44KY Strong Biomarker [282]
PSG2 OT2EIXAI Strong Biomarker [18]
PSG5 OTHTU98X Strong Genetic Variation [827]
PSMD9 OT6Y5CC3 Strong Biomarker [831]
PSME1 OTDHLJWH Strong Biomarker [1087]
PTPRU OTHDO0QG Strong Biomarker [562]
PTTG1 OTIMYS4W Strong Biomarker [1088]
PUM1 OTTMWP8L Strong Biomarker [1089]
PXDN OTFGGM9R Strong Altered Expression [1090]
PXN OTVMMUOF Strong Biomarker [1091]
PYCARD OT67RON3 Strong Posttranslational Modification [1092]
QKI OTTAUGLB Strong Altered Expression [1093]
QRSL1 OTJDU2UG Strong Altered Expression [1094]
RAB23 OTBAKFBR Strong Altered Expression [1095]
RAD50 OTYMU9G1 Strong Biomarker [1096]
RAD51B OTCJVRMY Strong Biomarker [913]
RALY OT78NNWY Strong Genetic Variation [115]
RAP1B OTHEIIMM Strong Altered Expression [1097]
RASSF1 OTEZIPB7 Strong Genetic Variation [1098]
RASSF7 OT0V4EIZ Strong Genetic Variation [1099]
RB1CC1 OTZK8PFX Strong Biomarker [1100]
RBBP6 OTTVG4HU Strong Biomarker [1082]
RBFOX2 OTXY1WVH Strong Biomarker [1101]
RBL2 OTBQSOE6 Strong Therapeutic [1102]
RBM3 OTAJ7R31 Strong Altered Expression [1103]
RBMS3 OTFSC9MR Strong Altered Expression [384]
RBP1 OTRP1MFC Strong Altered Expression [1104]
RCBTB1 OTAYELI8 Strong Biomarker [579]
RCC2 OTUJVTLS Strong Biomarker [1105]
RCCD1 OT60N06L Strong Genetic Variation [305]
RECQL OTPCH3JH Strong Genetic Variation [878]
RELA OTUJP9CN Strong Altered Expression [1106]
REST OTLL92LQ Strong Biomarker [1107]
RGS10 OTQ8N1QH Strong Altered Expression [1108]
RGS5 OTUY0Q2I Strong Biomarker [1109]
RIF1 OTPE49OE Strong Altered Expression [1110]
RMI1 OT1ZVTFL Strong Biomarker [1111]
RNASE3 OTVE2XD1 Strong Altered Expression [1112]
RNASET2 OTWY64L7 Strong Biomarker [1113]
RNF146 OTE4CO7E Strong Biomarker [856]
RNF2 OTFPLOIN Strong Altered Expression [1114]
RNF20 OT9NK6ZT Strong Biomarker [1115]
RPH3AL OT9VFJEL Strong Biomarker [1116]
RPL22L1 OTNWGF5C Strong Altered Expression [1117]
RSAD2 OTCA9WCM Strong Altered Expression [1118]
RUNX1T1 OT30DED5 Strong Altered Expression [1119]
RUVBL1 OTWV19L7 Strong Genetic Variation [1120]
RYK OTZ3WWZH Strong Altered Expression [1121]
S100A1 OT1F2G4J Strong Biomarker [1122]
S100A10 OTI71243 Strong Biomarker [1123]
S100A11 OTI57KDN Strong Altered Expression [1124]
S100A7 OTJFVJRF Strong Biomarker [1125]
S100P OTJCXNJG Strong Altered Expression [1126]
SALL2 OTQWI68Q Strong Biomarker [1127]
SALL4 OTC08PR5 Strong Altered Expression [1128]
SCAF1 OT16TM3N Strong Biomarker [1129]
SCAI OTAK3TMO Strong Biomarker [1130]
SCGB2A1 OT9L87U9 Strong Biomarker [1131]
SCO2 OTJQQDRS Strong Altered Expression [550]
SEC14L1 OTA75FET Strong Biomarker [1132]
SELENBP1 OT3NZNTR Strong Biomarker [1133]
SEMG1 OT6Z4BPQ Strong Posttranslational Modification [791]
SEPTIN9 OT1VMRFQ Strong Altered Expression [1134]
SERBP1 OTZVSU0X Strong Biomarker [1135]
SERPINA3 OT9BP2S0 Strong Genetic Variation [717]
SERPINA5 OTTZXPGD Strong Biomarker [1136]
SERTAD1 OTBHKZQP Strong Altered Expression [1137]
SETDB1 OTWVUA1B Strong Altered Expression [1138]
SF1 OTLEDM2S Strong Biomarker [1139]
SFN OTLJCZ1U Strong Posttranslational Modification [1140]
SFRP1 OT0U9G41 Strong Altered Expression [1141]
SFRP2 OT8GZ0CA Strong Altered Expression [1142]
SFRP5 OTLCVVSH Strong Biomarker [1143]
SH2D4B OTM0KLPH Strong Genetic Variation [396]
SHARPIN OTU1J2KH Strong Altered Expression [1144]
SHBG OTPWU5IW Strong Biomarker [1145]
SHMT1 OTIINA3J Strong Biomarker [1146]
SIX1 OT70YYWM Strong Biomarker [467]
SKAP1 OTD4ZKAL Strong Genetic Variation [570]
SLC12A9 OTR7VRAK Strong Altered Expression [1147]
SLIT3 OTU8MKEU Strong Biomarker [1148]
SLPI OTUNFUU8 Strong Biomarker [1149]
SMARCE1 OTAX4ITH Strong Altered Expression [1150]
SMURF1 OT5UIZR8 Strong Biomarker [1151]
SNAP23 OTY2MYBX Strong Altered Expression [1152]
SNAP29 OTT30ZON Strong Biomarker [1153]
SNTN OTPNV1ZQ Strong Altered Expression [103]
SORBS2 OTJSX44Y Strong Biomarker [1154]
SOX11 OT4LG7LA Strong Altered Expression [1155]
SOX18 OTPUMHWA Strong Altered Expression [1156]
SOX3 OT1CRCOB Strong Altered Expression [1157]
SOX6 OTT0W0LE Strong Biomarker [365]
SOX9 OTVDJFGN Strong Altered Expression [1158]
SPA17 OT8J7T7U Strong Biomarker [768]
SPAG7 OTSDFA2D Strong Biomarker [821]
SPAG9 OT45AHMB Strong Biomarker [1159]
SPATA2 OTOA45GL Strong Altered Expression [1160]
SPDYA OTYKC1AJ Strong Altered Expression [1161]
SPECC1 OTPEML48 Strong Biomarker [1096]
SPG7 OT8OY9ST Strong Biomarker [364]
SPINK1 OTSUVAL2 Strong Biomarker [1162]
SPINK13 OTEU2OSU Strong Altered Expression [1163]
SPINT1 OT1CLR5L Strong Biomarker [549]
SPINT2 OTQV7BKQ Strong Altered Expression [75]
SPOCK2 OTXSVTSA Strong Biomarker [1164]
SPOP OTP0107S Strong Biomarker [1165]
SPRY4 OT2VK9N0 Strong Altered Expression [1166]
SPSB1 OTGY26U4 Strong Biomarker [1167]
SRA1 OTYOGMTG Strong Biomarker [1168]
SRPX OT5B9LXS Strong Biomarker [921]
SRRM2 OTSIMMC9 Strong Altered Expression [384]
SRSF3 OTOFT707 Strong Biomarker [1169]
SSH3 OT83V0ZK Strong Genetic Variation [1170]
ST3GAL1 OTFCO8QX Strong Biomarker [1171]
ST6GAL1 OT7US3NO Strong Biomarker [1172]
ST6GALNAC1 OT3JQD99 Strong Biomarker [1173]
STAG1 OT564IX4 Strong Altered Expression [1070]
STAG3 OTEV0AOD Strong Genetic Variation [1174]
STIL OT9799VN Strong Biomarker [1175]
STING1 OTDAP4G0 Strong Biomarker [1176]
STIP1 OT7TXLOX Strong Biomarker [1177]
STK11 OT1YZSP3 Strong Biomarker [1178]
STOML3 OTLQGALK Strong Biomarker [1179]
SUB1 OTK71JYU Strong Posttranslational Modification [783]
SULF1 OTJCNCO0 Strong Biomarker [986]
SUSD2 OTSJTAZP Strong Biomarker [1180]
SYCE1L OTXU44F3 Strong Altered Expression [962]
SYCP2 OTBH622S Strong Biomarker [1181]
SYTL2 OTUIOWKL Strong Biomarker [447]
TAB1 OTPM6F85 Strong Altered Expression [862]
TAB3 OT1ECMDL Strong Altered Expression [1182]
TBC1D8 OT2011SS Strong Biomarker [1183]
TBC1D9 OTSSCTB5 Strong Biomarker [1184]
TBX15 OTAZ9QDX Strong Biomarker [732]
TCEAL7 OTNPDZCN Strong Altered Expression [1185]
TCF12 OTZVONNU Strong Biomarker [1186]
TCF21 OT393IMA Strong Biomarker [1187]
TCHP OTVDMHSY Strong Altered Expression [142]
TEAD1 OTK6971C Strong Biomarker [1188]
TENM2 OTPLUYEF Strong Altered Expression [1189]
TENM4 OT91K3FC Strong Biomarker [1189]
TET1 OTZDHT1D Strong Biomarker [1190]
TET3 OT76U3YF Strong Altered Expression [1191]
TEX11 OTJDBGSS Strong Biomarker [568]
TEX19 OTY6MIZ9 Strong Altered Expression [1192]
TFAM OTXXV5V7 Strong Altered Expression [428]
TFPI2 OTZCRWOR Strong Biomarker [1188]
TGFBI OTR443C5 Strong Altered Expression [1193]
TGIF2 OTMKKE3W Strong Biomarker [1194]
THBS2 OTXET551 Strong Altered Expression [1195]
THEMIS2 OTI1OBLN Strong Genetic Variation [1196]
THSD7A OT7249HH Strong Genetic Variation [723]
THY1 OTVONVTB Strong Biomarker [1197]
TICAM2 OTK7GIJ5 Strong Biomarker [831]
TIMM8A OTDX9687 Strong Biomarker [354]
TLE3 OTR9PH95 Strong Biomarker [1198]
TM4SF1 OTY0ECQN Strong Biomarker [1199]
TMED2 OTBLO7RW Strong Biomarker [1200]
TMED7 OTONO8E6 Strong Biomarker [831]
TMEM14A OTANQA6G Strong Altered Expression [1201]
TMEM158 OT0KUBBI Strong Altered Expression [1202]
TMEM45A OT54KJG6 Strong Altered Expression [1203]
TMEM88 OTA96YEL Strong Biomarker [1170]
TMPRSS3 OT0GTO1Z Strong Altered Expression [1204]
TMSB10 OTLVZ13T Strong Altered Expression [1205]
TNFAIP8 OT1G9297 Strong Altered Expression [1206]
TNFRSF10C OTVHOL9B Strong Altered Expression [1207]
TOR2A OT1EGCDU Strong Biomarker [1208]
TPM4 OTN4YLYR Strong Biomarker [1209]
TRAF2 OT1MEZZN Strong Biomarker [482]
TRIAP1 OTEAUJXN Strong Biomarker [582]
TRIM13 OTQIUACB Strong Biomarker [364]
TRIM16 OTLRXYOZ Strong Biomarker [1210]
TRIM44 OT0B1T2B Strong Biomarker [1211]
TRIM50 OTXA2IXF Strong Biomarker [1212]
TRIM52 OTKTKCT1 Strong Biomarker [360]
TRIM56 OTFGU8E3 Strong Altered Expression [1213]
TRMT9B OTU3UPEE Strong Biomarker [1214]
TRO OTRZQMU8 Strong Altered Expression [1215]
TRRAP OT68OI2Y Strong Biomarker [1216]
TSGA10 OTIF1O1T Strong Altered Expression [1217]
TSPAN12 OTF9I3CX Strong Biomarker [1218]
TSPYL5 OT7QEI2X Strong Biomarker [1219]
TTF1 OT4K90WD Strong Altered Expression [1150]
ADAM15 OTZ7VLTP Definitive Biomarker [1220]
ARID1A OTRWDV3P Definitive Altered Expression [1221]
BHLHE22 OTZUQY5L Definitive Altered Expression [1222]
CAMK4 OT47RDGV Definitive Biomarker [1223]
CEACAM8 OTLL9WWO Definitive Altered Expression [1224]
CHST11 OTNJJ5Q1 Definitive Biomarker [507]
CLIP1 OTTGAEJE Definitive Biomarker [1225]
CLPTM1L OTDJWQXI Definitive Altered Expression [1226]
CNN1 OTVPG39Z Definitive Biomarker [1227]
COL11A2 OT3BQUBH Definitive Biomarker [1228]
COX2 OTTMVBJJ Definitive Biomarker [1229]
CRISP2 OT8HLTV5 Definitive Altered Expression [1230]
CTNNA1 OTFC725Z Definitive Genetic Variation [1231]
DLEC1 OTMKKBUW Definitive Posttranslational Modification [1232]
DLX4 OTLWVCN4 Definitive Altered Expression [1233]
DNAJC15 OTNDUKAA Definitive Altered Expression [1234]
DUSP4 OT6WAO12 Definitive Altered Expression [1235]
EBAG9 OTTQLQCP Definitive Biomarker [1236]
EEF1A2 OT9Z23K5 Definitive Biomarker [1237]
EIF6 OTEXMUED Definitive Biomarker [859]
ELMO1 OTY2ORXK Definitive Biomarker [847]
ERCC3 OTVAW3P1 Definitive Biomarker [1238]
FEN1 OT6QGG7O Definitive Biomarker [1239]
FGFRL1 OT8HZ3ZL Definitive Altered Expression [1240]
FOXO3 OTHXQG4P Definitive Altered Expression [119]
GBGT1 OTRB3JK7 Definitive Posttranslational Modification [1241]
GDI1 OTYM3928 Definitive Altered Expression [1242]
GPC1 OTQKRSSV Definitive Biomarker [1243]
GPLD1 OTUUQOVY Definitive Altered Expression [1244]
GRP OT8JDFNI Definitive Biomarker [1245]
GSTM2 OTG4WT05 Definitive Genetic Variation [1246]
HOXC6 OTBCRAZV Definitive Altered Expression [1247]
HOXD9 OTZ4GVR1 Definitive Biomarker [1248]
IFITM1 OTECO1G8 Definitive Biomarker [1249]
IGF2BP2 OT4ZSEEE Definitive Biomarker [919]
IGF2BP3 OTB97VIK Definitive Biomarker [974]
IMMP2L OT9WGAFD Definitive Biomarker [919]
KRT10 OTSVRD3Q Definitive Altered Expression [1250]
MEN1 OTN6U6V0 Definitive Biomarker [1251]
NEFH OTMSCW5I Definitive Genetic Variation [1252]
NEK11 OTMYENTC Definitive Biomarker [1253]
NEO1 OTGJ1997 Definitive Biomarker [1225]
NUDCD1 OT8DS3CX Definitive Biomarker [1254]
PEBP4 OTKDCVC6 Definitive Biomarker [1255]
PGK1 OT6V1ICH Definitive Altered Expression [1256]
PIAS2 OTJLSC3V Definitive Biomarker [1257]
POU5F1 OTDHHN7O Definitive Altered Expression [1158]
PPP2R5D OT43TTX0 Definitive Altered Expression [1258]
PRSS55 OTXXWI5Y Definitive Altered Expression [1230]
PSAP OTUOEKY7 Definitive Biomarker [171]
PYGO2 OTZHB2OI Definitive Altered Expression [1259]
RAB25 OTW0W6NP Definitive Biomarker [1260]
RASAL2 OTGMMX6W Definitive Biomarker [1261]
RASSF2 OT2JHDO4 Definitive Genetic Variation [1262]
REEP5 OTZU4TJI Definitive Biomarker [1263]
RNASE2 OT8Z4FNE Definitive Biomarker [1264]
S100A14 OTVFJJ91 Definitive Biomarker [1265]
SNAI1 OTDPYAMC Definitive Genetic Variation [1266]
SOX17 OT9H4WWE Definitive Biomarker [453]
SOX7 OTOZOFAG Definitive Altered Expression [1267]
SPPL3 OT2HLJF6 Definitive Biomarker [919]
SPZ1 OTQH8HJ5 Definitive Altered Expression [1230]
TBX3 OTM64N7K Definitive Altered Expression [1268]
TGFBR3 OTQOOUC4 Definitive Altered Expression [1269]
------------------------------------------------------------------------------------
⏷ Show the Full List of 919 DOT(s)

References

1 Carboplatin FDA Label
2 Doxorubicin FDA Label
3 Gemcitabine FDA Label
4 Paclitaxel FDA Label
5 Vorinostat FDA Label
6 Nintedanib FDA Label
7 Mitochondrial uncoupling reveals a novel therapeutic opportunity for p53-defective cancers. Nat Commun. 2018 Sep 26;9(1):3931.
8 Effect of AURKA Gene Expression Knockdown on Angiogenesis and Tumorigenesis of Human Ovarian Cancer Cell Lines.Target Oncol. 2016 Dec;11(6):771-781. doi: 10.1007/s11523-016-0436-7.
9 Identification of ovarian cancer associated genes using an integrated approach in a Boolean framework.BMC Syst Biol. 2013 Feb 6;7:12. doi: 10.1186/1752-0509-7-12.
10 Calpain-2 expression is associated with response to platinum based chemotherapy, progression-free and overall survival in ovarian cancer.J Cell Mol Med. 2012 Oct;16(10):2422-8. doi: 10.1111/j.1582-4934.2012.01559.x.
11 Expression and histopathological correlation of CCR9 and CCL25 in ovarian cancer.Int J Oncol. 2011 Aug;39(2):373-81. doi: 10.3892/ijo.2011.1059. Epub 2011 May 31.
12 CD47 promotes ovarian cancer progression by inhibiting macrophage phagocytosis.Oncotarget. 2017 Jun 13;8(24):39021-39032. doi: 10.18632/oncotarget.16547.
13 Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.Clin Exp Metastasis. 2011 Oct;28(7):689-700. doi: 10.1007/s10585-011-9401-0. Epub 2011 Jul 2.
14 E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness.PLoS One. 2017 Sep 21;12(9):e0184439. doi: 10.1371/journal.pone.0184439. eCollection 2017.
15 Hypo/unmethylated promoter status of Cdk2 gene correlates with its over-expression in ovarian cancer in north Indian population.Cell Mol Biol (Noisy-le-grand). 2016 Jan 22;62(1):67-72.
16 High IL-12 p35 and IL-23 p19 mRNA expression is associated with superior outcome in ovarian cancer.Gynecol Oncol. 2010 Sep;118(3):244-50. doi: 10.1016/j.ygyno.2010.05.024. Epub 2010 Jun 17.
17 MicroRNA-17 promotes normal ovarian cancer cells to cancer stem cells development via suppression of the LKB1-p53-p21/WAF1 pathway.Tumour Biol. 2015 Mar;36(3):1881-93. doi: 10.1007/s13277-014-2790-3. Epub 2014 Dec 16.
18 Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular-solid ovarian masses.Ultrasound Obstet Gynecol. 2019 Jan;53(1):116-123. doi: 10.1002/uog.19174.
19 Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma.Diagn Pathol. 2013 Nov 19;8:190. doi: 10.1186/1746-1596-8-190.
20 Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth.Oncogene. 2013 Feb 28;32(9):1082-90. doi: 10.1038/onc.2012.134. Epub 2012 May 7.
21 AKT activation drives the nuclear localization of CSE1L and a pro-oncogenic transcriptional activation in ovarian cancer cells.Exp Cell Res. 2013 Oct 15;319(17):2627-36. doi: 10.1016/j.yexcr.2013.07.030. Epub 2013 Aug 13.
22 Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.J Pharm Sci. 2011 Oct;100(10):4205-9. doi: 10.1002/jps.22680. Epub 2011 Jun 23.
23 Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.Biochem Pharmacol. 2004 Aug 15;68(4):601-9. doi: 10.1016/j.bcp.2004.05.007.
24 The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions.Clin Exp Metastasis. 2004;21(3):191-9. doi: 10.1023/b:clin.0000037703.37275.35.
25 FGF18 as a prognostic and therapeutic biomarker in ovarian cancer.J Clin Invest. 2013 Oct;123(10):4435-48. doi: 10.1172/JCI70625. Epub 2013 Sep 9.
26 Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo. Cell Physiol Biochem. 2016;39(1):242-52.
27 hsa_circ_0061140 Knockdown Reverses FOXM1-Mediated Cell Growth and Metastasis in Ovarian Cancer through miR-370 Sponge Activity.Mol Ther Nucleic Acids. 2018 Dec 7;13:55-63. doi: 10.1016/j.omtn.2018.08.010. Epub 2018 Aug 22.
28 Mutational analysis of FOXL2 p.C134W and expression of bone morphogenetic protein 2 in Japanese patients with granulosa cell tumor of ovary.J Obstet Gynaecol Res. 2014 May;40(5):1197-204. doi: 10.1111/jog.12324. Epub 2014 Apr 2.
29 Identification of recurrent fusion genes across multiple cancer types.Sci Rep. 2019 Jan 31;9(1):1074. doi: 10.1038/s41598-019-38550-6.
30 No evidence for glutathione S-transferases GSTA2, GSTM2, GSTO1, GSTO2, and GSTZ1 in breast cancer risk.Breast Cancer Res Treat. 2010 Jun;121(2):497-502. doi: 10.1007/s10549-009-0589-5. Epub 2009 Oct 27.
31 Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival.Future Oncol. 2017 Sep;13(22):1981-1990. doi: 10.2217/fon-2017-0084. Epub 2017 Aug 22.
32 Activation of TWIST1 by COL11A1 promotes chemoresistance and inhibits apoptosis in ovarian cancer cells by modulating NF-B-mediated IKK expression.Int J Cancer. 2017 Dec 1;141(11):2305-2317. doi: 10.1002/ijc.30932. Epub 2017 Aug 30.
33 Interleukin 16 expression changes in association with ovarian malignant transformation.Am J Obstet Gynecol. 2014 Mar;210(3):272.e1-10. doi: 10.1016/j.ajog.2013.12.041. Epub 2013 Dec 28.
34 Study of kallikrein-related peptidase 6 (KLK6) and its complex with 1-antitrypsin in biological fluids.Clin Chem Lab Med. 2017 Aug 28;55(9):1385-1396. doi: 10.1515/cclm-2017-0017.
35 The luteinizing hormone receptor: insights into structure-function relationships and hormone-receptor-mediated changes in gene expression in ovarian cancer cells.Mol Cell Endocrinol. 2010 Nov 25;329(1-2):47-55. doi: 10.1016/j.mce.2010.04.025. Epub 2010 May 2.
36 The relationship of haplotype in lactotransferrin and its expression levels in Chinese Han ovarian cancer.Acta Biochim Biophys Sin (Shanghai). 2011 Nov;43(11):884-90. doi: 10.1093/abbs/gmr089. Epub 2011 Sep 20.
37 Expression of tumor-specific antigen MAGE, GAGE and BAGE in ovarian cancer tissues and cell lines. BMC Cancer. 2010 Apr 27;10:163.
38 Identification, localization and characterization of the human gamma-synuclein gene.Hum Genet. 1998 Jul;103(1):106-12. doi: 10.1007/s004390050792.
39 Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.APMIS. 2013 Dec;121(12):1177-86. doi: 10.1111/apm.12071. Epub 2013 Apr 18.
40 Multiple steps of HLA-G in ovarian carcinoma metastasis: alter NK cytotoxicity and induce matrix metalloproteinase-15 (MMP-15) expression.Hum Immunol. 2013 Apr;74(4):439-46. doi: 10.1016/j.humimm.2012.11.021. Epub 2012 Dec 8.
41 Overexpression of EFEMP1 correlates with tumor progression and poor prognosis in human ovarian carcinoma.PLoS One. 2013 Nov 13;8(11):e78783. doi: 10.1371/journal.pone.0078783. eCollection 2013.
42 Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer.Clin Cancer Res. 2013 Jul 1;19(13):3577-90. doi: 10.1158/1078-0432.CCR-12-3212. Epub 2013 Apr 30.
43 Increased expression of neuropilin 1 is associated with epithelial ovarian carcinoma.Mol Med Rep. 2015 Aug;12(2):2114-20. doi: 10.3892/mmr.2015.3580. Epub 2015 Apr 1.
44 Comparison of expression profiles in ovarian epithelium in vivo and ovarian cancer identifies novel candidate genes involved in disease pathogenesis.PLoS One. 2011 Mar 15;6(3):e17617. doi: 10.1371/journal.pone.0017617.
45 Differential expression and phosphorylation of Pak1 and Pak2 in ovarian cancer: effects on prognosis and cell invasion.Int J Cancer. 2010 Jul 1;127(1):21-31. doi: 10.1002/ijc.25005.
46 p21-activated kinase 4 regulates ovarian cancer cell proliferation, migration, and invasion and contributes to poor prognosis in patients.Proc Natl Acad Sci U S A. 2010 Oct 26;107(43):18622-7. doi: 10.1073/pnas.0907481107. Epub 2010 Oct 6.
47 Association between newly identified variant form of DNA polymerase beta ( 208-304) and ovarian cancer.Cancer Biomark. 2012;11(4):155-60. doi: 10.3233/CBM-2012-00275.
48 Overexpression of PRMT5 promotes tumor cell growth and is associated with poor disease prognosis in epithelial ovarian cancer.J Histochem Cytochem. 2013 Mar;61(3):206-17. doi: 10.1369/0022155413475452. Epub 2013 Jan 4.
49 Clinicopathological and Prognostic Significance of Cancer Stem Cell Markers in Ovarian Cancer Patients: Evidence from 52 Studies.Cell Physiol Biochem. 2018;46(4):1716-1726. doi: 10.1159/000489586. Epub 2018 Apr 28.
50 Plasma endothelial protein C receptor influences innate immune response in ovarian cancer by decreasing the population of natural killer and TH17 helper cells.Int J Oncol. 2013 Oct;43(4):1011-8. doi: 10.3892/ijo.2013.2021. Epub 2013 Jul 18.
51 Modern trends into the epidemiology and screening of ovarian cancer. Genetic substrate of the sporadic form.Pathol Oncol Res. 2012 Apr;18(2):135-48. doi: 10.1007/s12253-011-9482-8. Epub 2011 Dec 9.
52 Chromosome 17q25 genes, RHBDF2 and CYGB, in ovarian cancer.Int J Oncol. 2012 Jun;40(6):1865-80. doi: 10.3892/ijo.2012.1371. Epub 2012 Feb 14.
53 ROBO1 Expression in Metastasizing Breast and Ovarian Cancer: SLIT2-induced Chemotaxis Requires Heparan Sulfates (Heparin).Anticancer Res. 2019 Mar;39(3):1267-1273. doi: 10.21873/anticanres.13237.
54 SERPINB3 in the chicken model of ovarian cancer: a prognostic factor for platinum resistance and survival in patients with epithelial ovarian cancer.PLoS One. 2012;7(11):e49869. doi: 10.1371/journal.pone.0049869. Epub 2012 Nov 21.
55 Annexin A2 inhibition suppresses ovarian cancer progression via regulating -catenin/EMT. Oncol Rep. 2017 Jun;37(6):3643-3650.
56 Biotinylated PAMAM dendrimers for intracellular delivery of cisplatin to ovarian cancer: role of SMVT.Anticancer Res. 2011 Mar;31(3):897-906.
57 Knock-down of superoxide dismutase 1 sensitizes cisplatin-resistant human ovarian cancer cells.Anticancer Res. 2010 Jul;30(7):2577-81.
58 The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.Cancer Cell. 2011 Feb 15;19(2):273-82. doi: 10.1016/j.ccr.2010.12.019.
59 TLR4 activates NF-B in human ovarian granulosa tumor cells.Biochem Biophys Res Commun. 2011 Jun 17;409(4):675-80. doi: 10.1016/j.bbrc.2011.05.063. Epub 2011 May 17.
60 Tumor suppressive effects of bromodomain-containing protein 7 (BRD7) in epithelial ovarian carcinoma.Clin Cancer Res. 2014 Feb 1;20(3):565-75. doi: 10.1158/1078-0432.CCR-13-1271. Epub 2013 Nov 6.
61 Rapid isolation of high-affinity human antibodies against the tumor vascular marker Endosialin/TEM1, using a paired yeast-display/secretory scFv library platform.J Immunol Methods. 2011 Jan 5;363(2):221-32. doi: 10.1016/j.jim.2010.09.001. Epub 2010 Sep 15.
62 Citrate synthase expression affects tumor phenotype and drug resistance in human ovarian carcinoma.PLoS One. 2014 Dec 29;9(12):e115708. doi: 10.1371/journal.pone.0115708. eCollection 2014.
63 M2-like tumor-associated macrophages-secreted EGF promotes epithelial ovarian cancer metastasis via activating EGFR-ERK signaling and suppressing lncRNA LIMT expression.Cancer Biol Ther. 2019;20(7):956-966. doi: 10.1080/15384047.2018.1564567. Epub 2019 May 7.
64 FAK activity sustains intrinsic and acquired ovarian cancer resistance to platinum chemotherapy.Elife. 2019 Sep 3;8:e47327. doi: 10.7554/eLife.47327.
65 FZD7 drives in vitro aggressiveness in Stem-A subtype of ovarian cancer via regulation of non-canonical Wnt/PCP pathway.Cell Death Dis. 2014 Jul 17;5(7):e1346. doi: 10.1038/cddis.2014.302.
66 Vascular marker expression during the development of various types of gynaecological malignancy.Tumour Biol. 2014 Nov;35(11):11229-35. doi: 10.1007/s13277-014-2447-2. Epub 2014 Aug 12.
67 Hepatitis B X-interacting protein promotes cisplatin resistance and regulates CD147 via Sp1 in ovarian cancer.Exp Biol Med (Maywood). 2017 Mar;242(5):497-504. doi: 10.1177/1535370216685007. Epub 2017 Jan 5.
68 Cdc7 kinase is a predictor of survival and a novel therapeutic target in epithelial ovarian carcinoma.Clin Cancer Res. 2009 Apr 1;15(7):2417-25. doi: 10.1158/1078-0432.CCR-08-1276. Epub 2009 Mar 24.
69 Directing the use of DDR kinase inhibitors in cancer treatment.Expert Opin Investig Drugs. 2017 Dec;26(12):1341-1355. doi: 10.1080/13543784.2017.1389895. Epub 2017 Oct 14.
70 Gene directed enzyme prodrug therapy for ovarian cancer: could GDEPT become a promising treatment against ovarian cancer?.Anticancer Agents Med Chem. 2008 Feb;8(2):232-9. doi: 10.2174/187152008783497000.
71 NAD(P)H:quinone oxidoreductase 1 and nrh:quinone oxidoreductase 2 activity and expression in bladder and ovarian cancer and lower NRH:quinone oxidoreductase 2 activity associated with an NQO2 exon 3 single-nucleotide polymorphism.Clin Cancer Res. 2007 Mar 1;13(5):1584-90. doi: 10.1158/1078-0432.CCR-06-1416.
72 Identification of Aurora-A as a direct target of E2F3 during G2/M cell cycle progression.J Biol Chem. 2008 Nov 7;283(45):31012-20. doi: 10.1074/jbc.M803547200. Epub 2008 Sep 7.
73 Transcriptional coactivator Drosophila eyes absent homologue 2 is up-regulated in epithelial ovarian cancer and promotes tumor growth.Cancer Res. 2005 Feb 1;65(3):925-32.
74 Alofanib, an allosteric FGFR2 inhibitor, has potent effects on ovarian cancer growth in preclinical studies.Invest New Drugs. 2017 Apr;35(2):127-133. doi: 10.1007/s10637-016-0404-1. Epub 2016 Nov 3.
75 Expression of hepatocyte growth factor activator inhibitors (HAI-1 and HAI-2) in ovarian cancer.Int J Oncol. 2009 Feb;34(2):345-53.
76 HOXA11 DNA methylation--a novel prognostic biomarker in ovarian cancer.Int J Cancer. 2008 Aug 1;123(3):725-9. doi: 10.1002/ijc.23563.
77 HOXB13 promotes ovarian cancer progression.Proc Natl Acad Sci U S A. 2007 Oct 23;104(43):17093-8. doi: 10.1073/pnas.0707938104. Epub 2007 Oct 17.
78 Heparanase gene haplotype (CGC) is associated with stage of disease in patients with ovarian carcinoma.Cancer Sci. 2007 Jun;98(6):844-9. doi: 10.1111/j.1349-7006.2007.00461.x. Epub 2007 Apr 5.
79 Interleukin-13 receptor alpha2 chain: a potential biomarker and molecular target for ovarian cancer therapy.Cancer. 2006 Sep 15;107(6):1407-18. doi: 10.1002/cncr.22134.
80 Mannan-binding lectin (MBL) in women with tumours of the reproductive system.Cancer Immunol Immunother. 2007 Jul;56(7):959-71. doi: 10.1007/s00262-006-0250-7. Epub 2006 Nov 28.
81 Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883).J Med Genet. 2019 Sep;56(9):574-580. doi: 10.1136/jmedgenet-2018-105930. Epub 2019 Apr 12.
82 L-Tetrahydropalmatine enhances the sensitivity of human ovarian cancer cells to cisplatin via microRNA-93/PTEN/Akt cascade.J BUON. 2019 Mar-Apr;24(2):701-708.
83 RNF43 is a tumour suppressor gene mutated in mucinous tumours of the ovary.J Pathol. 2013 Feb;229(3):469-76. doi: 10.1002/path.4134.
84 Association between single-nucleotide polymorphisms in hormone metabolism and DNA repair genes and epithelial ovarian cancer: results from two Australian studies and an additional validation set.Cancer Epidemiol Biomarkers Prev. 2007 Dec;16(12):2557-65. doi: 10.1158/1055-9965.EPI-07-0542.
85 Coordinate up-regulation of TMEM97 and cholesterol biosynthesis genes in normal ovarian surface epithelial cells treated with progesterone: implications for pathogenesis of ovarian cancer. BMC Cancer. 2007 Dec 11;7:223.
86 The Expression of MicroRNA-598 Inhibits Ovarian Cancer Cell Proliferation and Metastasis by Targeting URI.Mol Ther Oncolytics. 2018 Dec 8;12:9-15. doi: 10.1016/j.omto.2018.12.002. eCollection 2019 Mar 29.
87 Expression levels of MRP1, GST-, and GSK3 in ovarian cancer and the relationship with drug resistance and prognosis of patients.Oncol Lett. 2019 Jul;18(1):22-28. doi: 10.3892/ol.2019.10315. Epub 2019 May 6.
88 Hypoxia-inducible factor-2 directly promotes BCRP expression and mediates the resistance of ovarian cancer stem cells to adriamycin.Mol Oncol. 2019 Feb;13(2):403-421. doi: 10.1002/1878-0261.12419. Epub 2019 Jan 14.
89 ACR Appropriateness Criteria() StagingandFollow-Up of Ovarian Cancer.J Am Coll Radiol. 2018 May;15(5S):S198-S207. doi: 10.1016/j.jacr.2018.03.015.
90 Higher CXCL16 exodomain is associated with aggressive ovarian cancer and promotes the disease by CXCR6 activation and MMP modulation.Sci Rep. 2019 Feb 21;9(1):2527. doi: 10.1038/s41598-019-38766-6.
91 ADAM17 inhibition enhances platinum efficiency in ovarian cancer.Oncotarget. 2018 Mar 23;9(22):16043-16058. doi: 10.18632/oncotarget.24682. eCollection 2018 Mar 23.
92 Expression of lysophosphatidic acid acyltransferase beta (LPAAT-beta) in ovarian carcinoma: correlation with tumour grading and prognosis.Br J Cancer. 2005 May 9;92(9):1729-36. doi: 10.1038/sj.bjc.6602528.
93 Anterior Gradient-3: a novel biomarker for ovarian cancer that mediates cisplatin resistance in xenograft models.J Immunol Methods. 2012 Apr 30;378(1-2):20-32. doi: 10.1016/j.jim.2012.01.013. Epub 2012 Feb 15.
94 Using a panel of multiple tumor-associated antigens to enhance the autoantibody detection in the immunodiagnosis of ovarian cancer.J Cell Biochem. 2019 Mar;120(3):3091-3100. doi: 10.1002/jcb.27497. Epub 2018 Nov 28.
95 AKT2 contributes to increase ovarian cancer cell migration and invasion through the AKT2-PKM2-STAT3/NF-B axis.Cell Signal. 2018 May;45:122-131. doi: 10.1016/j.cellsig.2018.01.021. Epub 2018 Jan 31.
96 Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.Clin Cancer Res. 2008 Mar 15;14(6):1726-33. doi: 10.1158/1078-0432.CCR-07-0428.
97 Decreased expression of ALDH5A1 predicts prognosis in patients with ovarian cancer.Cancer Biol Ther. 2017 Apr 3;18(4):245-251. doi: 10.1080/15384047.2017.1295175. Epub 2017 Mar 27.
98 The anti-tumor efficacy of 3C23K, a glyco-engineered humanized anti-MISRII antibody, in an ovarian cancer model is mainly mediated by engagement of immune effector cells.Oncotarget. 2017 Jun 6;8(23):37061-37079. doi: 10.18632/oncotarget.15715.
99 Profiling of selected angiogenesis-related genes in serous ovarian cancer patients.Adv Med Sci. 2017 Mar;62(1):116-120. doi: 10.1016/j.advms.2016.11.005. Epub 2017 Feb 21.
100 Inhibition of Ca(2+) -activated chloride channel ANO1 suppresses ovarian cancer through inactivating PI3K/Akt signaling.Int J Cancer. 2019 May 1;144(9):2215-2226. doi: 10.1002/ijc.31887. Epub 2019 Feb 12.
101 Anti-tumour effects of all-trans retinoid acid on serous ovarian cancer.J Exp Clin Cancer Res. 2019 Jan 8;38(1):10. doi: 10.1186/s13046-018-1017-7.
102 Annexin A8 can serve as potential prognostic biomarker and therapeutic target for ovarian cancer: based on the comprehensive analysis of Annexins.J Transl Med. 2019 Sep 2;17(1):275. doi: 10.1186/s12967-019-2023-z.
103 Intraoperative Diagnosis Support Tool for Serous Ovarian Tumors Based on Microarray Data Using Multicategory Machine Learning.Int J Gynecol Cancer. 2016 Jan;26(1):104-13. doi: 10.1097/IGC.0000000000000566.
104 Human APC2 localization and allelic imbalance.Cancer Res. 2001 Nov 1;61(21):7978-84.
105 Silencing of Apurinic/Apyrimidinic Endonuclease 1 Inhibits the Growth and Migration in Ovarian Cancer Cell via Activator-Protein-1 Signaling.Gynecol Obstet Invest. 2017;82(2):188-199. doi: 10.1159/000447261. Epub 2016 Aug 24.
106 Multifunctional APJ Pathway Promotes Ovarian Cancer Progression and Metastasis.Mol Cancer Res. 2019 Jun;17(6):1378-1390. doi: 10.1158/1541-7786.MCR-18-0989. Epub 2019 Mar 11.
107 Curcumin attenuates EGF-induced AQP3 up-regulation and cell migration in human ovarian cancer cells. Cancer Chemother Pharmacol. 2008 Oct;62(5):857-65. doi: 10.1007/s00280-007-0674-6. Epub 2008 Jan 23.
108 miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway.Oncogenesis. 2017 May 1;6(5):e326. doi: 10.1038/oncsis.2017.25.
109 Targeting Endothelin-1 Receptor/-Arrestin-1 Axis in Ovarian Cancer: From Basic Research to a Therapeutic Approach.Front Endocrinol (Lausanne). 2019 Sep 4;10:609. doi: 10.3389/fendo.2019.00609. eCollection 2019.
110 L-asparaginase inhibits invasive and angiogenic activity and induces autophagy in ovarian cancer.J Cell Mol Med. 2012 Oct;16(10):2369-78. doi: 10.1111/j.1582-4934.2012.01547.x.
111 ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation.Int J Oncol. 2020 Jan;56(1):219-231. doi: 10.3892/ijo.2019.4913. Epub 2019 Nov 14.
112 Identification of ATF-3, caveolin-1, DLC-1, and NM23-H2 as putative antitumorigenic, progesterone-regulated genes for ovarian cancer cells by gene profiling. Oncogene. 2005 Mar 3;24(10):1774-87. doi: 10.1038/sj.onc.1207991.
113 Knockdown of long non-coding RNA HOTAIR increases cisplatin sensitivity in ovarian cancer by inhibiting cisplatin-induced autophagy.J BUON. 2018 Sep-Oct;23(5):1396-1401.
114 Genetic polymorphisms and gene-dosage effect in ovarian cancer risk and response to paclitaxel/cisplatin chemotherapy.J Exp Clin Cancer Res. 2015 Jan 16;34(1):2. doi: 10.1186/s13046-015-0124-y.
115 Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations.Cancer Res. 2016 Sep 1;76(17):5103-14. doi: 10.1158/0008-5472.CAN-15-2980. Epub 2016 Apr 20.
116 Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.Mol Cancer Ther. 2019 Feb;18(2):389-398. doi: 10.1158/1535-7163.MCT-18-0537. Epub 2018 Nov 26.
117 BTB and CNC homology 1 (Bach1) promotes human ovarian cancer cell metastasis by HMGA2-mediated epithelial-mesenchymal transition.Cancer Lett. 2019 Mar 31;445:45-56. doi: 10.1016/j.canlet.2019.01.003. Epub 2019 Jan 14.
118 Inference on germline BAP1 mutations and asbestos exposure from the analysis of familial and sporadic mesothelioma in a high-risk area.Genes Chromosomes Cancer. 2015 Jan;54(1):51-62. doi: 10.1002/gcc.22218. Epub 2014 Sep 18.
119 Resensitization of cisplatin resistance ovarian cancer cells to cisplatin through pretreatment with low-dose fraction radiation.Cancer Med. 2019 May;8(5):2442-2448. doi: 10.1002/cam4.2116. Epub 2019 Apr 2.
120 BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.Oncotarget. 2015 Oct 13;6(31):31522-43. doi: 10.18632/oncotarget.5159.
121 Inhibition of the inflammatory cytokine TNF- increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.Mol Ther. 2011 Mar;19(3):490-9. doi: 10.1038/mt.2010.247. Epub 2010 Nov 16.
122 Cul4 E3 ubiquitin ligase regulates ovarian cancer drug resistance by targeting the antiapoptotic protein BIRC3.Cell Death Dis. 2019 Feb 4;10(2):104. doi: 10.1038/s41419-018-1200-y.
123 Identification of Key Genes and Pathway for Ovarian Neoplasms Using the OVDM1 Cell Line Based on Bioinformatics Analysis.Med Sci Monit. 2019 Jun 9;25:4305-4313. doi: 10.12659/MSM.915422.
124 Evaluating the Mechanism and Therapeutic Potential of PTC-028, a Novel Inhibitor of BMI-1 Function in Ovarian Cancer.Mol Cancer Ther. 2018 Jan;17(1):39-49. doi: 10.1158/1535-7163.MCT-17-0574. Epub 2017 Nov 20.
125 Loss of BMP-10 is correlated with poor survival in ovarian cancer.Pathol Res Pract. 2019 Jan;215(1):121-126. doi: 10.1016/j.prp.2018.10.025. Epub 2018 Oct 28.
126 Human carcinoma-associated mesenchymal stem cells promote ovarian cancer chemotherapy resistance via a BMP4/HH signaling loop.Oncotarget. 2016 Feb 9;7(6):6916-32. doi: 10.18632/oncotarget.6870.
127 Expression Of BMP7 In Ovarian Cancer And Biological Effect Of BMP7 Knockdown On Ovarian Cancer Cells.Onco Targets Ther. 2019 Sep 26;12:7897-7909. doi: 10.2147/OTT.S217975. eCollection 2019.
128 DNA Replication Vulnerabilities Render Ovarian Cancer Cells Sensitive to Poly(ADP-Ribose) Glycohydrolase Inhibitors.Cancer Cell. 2019 Mar 18;35(3):519-533.e8. doi: 10.1016/j.ccell.2019.02.004.
129 Altered uterine contractility in response to -adrenoceptor agonists in ovarian cancer.J Physiol Sci. 2017 Nov;67(6):711-722. doi: 10.1007/s12576-016-0500-1. Epub 2016 Nov 12.
130 Luteinizing hormone-induced up-regulation of ErbB-2 is insufficient stimulant of growth and invasion in ovarian cancer cells.Mol Cancer Res. 2008 Nov;6(11):1775-85. doi: 10.1158/1541-7786.MCR-08-0214.
131 microRNA-27a-3p Down-regulation Inhibits Malignant Biological Behaviors of Ovarian Cancer by Targeting BTG1.Open Med (Wars). 2019 Jul 31;14:577-585. doi: 10.1515/med-2019-0065. eCollection 2019.
132 Genetic and pharmacologic inhibition of complement impairs endothelial cell function and ablates ovarian cancer neovascularization.Neoplasia. 2012 Nov;14(11):994-1004. doi: 10.1593/neo.121262.
133 Serum calretinin as an independent predictor for platinum resistance and prognosis in ovarian cancer.Int J Cancer. 2020 May 1;146(9):2608-2618. doi: 10.1002/ijc.32676. Epub 2019 Nov 6.
134 Akt activation by Ca(2+)/calmodulin-dependent protein kinase kinase 2 (CaMKK2) in ovarian cancer cells. J Biol Chem. 2017 Aug 25;292(34):14188-14204. doi: 10.1074/jbc.M117.778464. Epub 2017 Jun 20.
135 Antimicrobial peptide LL-37 promotes the viability and invasion of skin squamous cell carcinoma by upregulating YB-1.Exp Ther Med. 2017 Jul;14(1):499-506. doi: 10.3892/etm.2017.4546. Epub 2017 Jun 6.
136 CARM1-expressing ovarian cancer depends on the histone methyltransferase EZH2 activity.Nat Commun. 2018 Feb 12;9(1):631. doi: 10.1038/s41467-018-03031-3.
137 Costunolide Inhibits the Growth of OAW42-A Multidrug-Resistant Human Ovarian Cancer Cells by Activating Apoptotic and Autophagic Pathways, Production of Reactive Oxygen Species (ROS), Cleaved Caspase-3 and Cleaved Caspase-9.Med Sci Monit. 2019 May 2;25:3231-3237. doi: 10.12659/MSM.914029.
138 miR-96-5p promotes the proliferation and migration of ovarian cancer cells by suppressing Caveolae1.J Ovarian Res. 2019 Jun 22;12(1):57. doi: 10.1186/s13048-019-0533-1.
139 Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model.Mol Biol Rep. 2019 Oct;46(5):4685-4697. doi: 10.1007/s11033-019-04788-6. Epub 2019 Apr 25.
140 Targeting Glutathione and Cystathionine -Synthase in Ovarian Cancer Treatment by Selenium-Chrysin Polyurea Dendrimer Nanoformulation.Nutrients. 2019 Oct 19;11(10):2523. doi: 10.3390/nu11102523.
141 CCL20 Promotes Ovarian Cancer Chemotherapy Resistance by Regulating ABCB1 Expression.Cell Struct Funct. 2019;44(1):21-28. doi: 10.1247/csf.18029.
142 Chemokine Network and Overall Survival in TP53 Wild-Type and Mutant Ovarian Cancer.Immune Netw. 2018 Aug 13;18(4):e29. doi: 10.4110/in.2018.18.e29. eCollection 2018 Aug.
143 Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients.Tumour Biol. 2015 Jun;36(6):4811-7. doi: 10.1007/s13277-015-3133-8. Epub 2015 Feb 3.
144 CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.BMC Cancer. 2019 Nov 25;19(1):1140. doi: 10.1186/s12885-019-6321-x.
145 MicroRNA-107 induces cell cycle arrests by directly targeting cyclin E1 in ovarian cancer.Biochem Biophys Res Commun. 2019 Apr 30;512(2):331-337. doi: 10.1016/j.bbrc.2019.03.009. Epub 2019 Mar 16.
146 Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells.Clin Transl Oncol. 2017 Dec;19(12):1489-1497. doi: 10.1007/s12094-017-1686-2. Epub 2017 Jun 6.
147 B7-H3-targeted (212)Pb radioimmunotherapy of ovarian cancer in preclinical models.Nucl Med Biol. 2017 Apr;47:23-30. doi: 10.1016/j.nucmedbio.2017.01.003. Epub 2017 Jan 10.
148 CD44 Expression Predicts Prognosis of Ovarian Cancer Patients Through Promoting Epithelial-Mesenchymal Transition (EMT) by Regulating Snail, ZEB1, and Caveolin-1.Front Oncol. 2019 Aug 21;9:802. doi: 10.3389/fonc.2019.00802. eCollection 2019.
149 Synthesis and antiproliferative activities of doxorubicin thiol conjugates and doxorubicin-SS-cyclic peptide.Eur J Med Chem. 2019 Jan 1;161:594-606. doi: 10.1016/j.ejmech.2018.10.042. Epub 2018 Oct 23.
150 CDC25A Facilitates Chemo-resistance in Ovarian Cancer Multicellular Spheroids by Promoting E-cadherin Expression and Arresting Cell Cycles.J Cancer. 2019 Jun 2;10(13):2874-2884. doi: 10.7150/jca.31329. eCollection 2019.
151 Inhibition of CDC25B With WG-391D Impedes the Tumorigenesis of Ovarian Cancer.Front Oncol. 2019 Apr 8;9:236. doi: 10.3389/fonc.2019.00236. eCollection 2019.
152 Identification of modules and hub genes associated with platinum-based chemotherapy resistance and treatment response in ovarian cancer by weighted gene co-expression network analysis.Medicine (Baltimore). 2019 Nov;98(44):e17803. doi: 10.1097/MD.0000000000017803.
153 BARX2 induces cadherin 6 expression and is a functional suppressor of ovarian cancer progression.Cancer Res. 2001 Oct 1;61(19):6977-81.
154 Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.Mol Cancer Ther. 2016 Jul;15(7):1691-701. doi: 10.1158/1535-7163.MCT-16-0032. Epub 2016 May 20.
155 Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.Elife. 2018 Nov 13;7:e39030. doi: 10.7554/eLife.39030.
156 Prognostic Impact of CEACAM1 in Node-Negative Ovarian Cancer Patients.Dis Markers. 2018 Jun 28;2018:6714287. doi: 10.1155/2018/6714287. eCollection 2018.
157 Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms.Gynecol Oncol. 2008 May;109(2):234-9. doi: 10.1016/j.ygyno.2008.01.031. Epub 2008 Mar 10.
158 The role of c-FLIP(L) in ovarian cancer: chaperoning tumor cells from immunosurveillance and increasing their invasive potential.Gynecol Oncol. 2010 Jun;117(3):451-9. doi: 10.1016/j.ygyno.2010.02.024. Epub 2010 Mar 15.
159 Chemiluminescence noncompetitive immunoassay based on microchip electrophoresis for the determination of -subunit of human chorionic gonadotropin.J Chromatogr B Analyt Technol Biomed Life Sci. 2017 May 15;1053:42-47. doi: 10.1016/j.jchromb.2017.03.031. Epub 2017 Mar 29.
160 Choline kinase-alpha by regulating cell aggressiveness and drug sensitivity is a potential druggable target for ovarian cancer.Br J Cancer. 2014 Jan 21;110(2):330-40. doi: 10.1038/bjc.2013.729. Epub 2013 Nov 26.
161 The Emerging Role of Calcium-activated Chloride Channel Regulator 1 in Cancer.Anticancer Res. 2019 Apr;39(4):1661-1666. doi: 10.21873/anticanres.13271.
162 Ovarian Tumor Cell Expression of Claudin-4 Reduces Apoptotic Response to Paclitaxel.Mol Cancer Res. 2019 Mar;17(3):741-750. doi: 10.1158/1541-7786.MCR-18-0451. Epub 2019 Jan 3.
163 Expression and prognostic value of CLIC1 in epithelial ovarian cancer.Exp Ther Med. 2018 Jun;15(6):4943-4949. doi: 10.3892/etm.2018.6000. Epub 2018 Mar 28.
164 RNAi-mediated knockdown of the CLN3 gene inhibits proliferation and promotes apoptosis in drug-resistant ovarian cancer cells.Mol Med Rep. 2015 Nov;12(5):6635-41. doi: 10.3892/mmr.2015.4238. Epub 2015 Aug 21.
165 Heat Shock Proteins and Ovarian Cancer: Important Roles and Therapeutic Opportunities.Cancers (Basel). 2019 Sep 18;11(9):1389. doi: 10.3390/cancers11091389.
166 Lactate dehydrogenase is correlated with clinical stage and grade and is downregulated by siSAB1 in ovarian cancer.Oncol Rep. 2018 Nov;40(5):2788-2797. doi: 10.3892/or.2018.6658. Epub 2018 Aug 17.
167 Long noncoding RNA DQ786243 interacts with miR-506 and promotes progression of ovarian cancer through targeting cAMP responsive element binding protein 1.J Cell Biochem. 2018 Dec;119(12):9764-9780. doi: 10.1002/jcb.27295. Epub 2018 Aug 13.
168 Epigenetic silencing of miR-130b in ovarian cancer promotes the development of multidrug resistance by targeting colony-stimulating factor 1.Gynecol Oncol. 2012 Feb;124(2):325-34. doi: 10.1016/j.ygyno.2011.10.013. Epub 2011 Oct 15.
169 Genome-wide methylation profiling of ovarian cancer patient-derived xenografts treated with the demethylating agent decitabine identifies novel epigenetically regulated genes and pathways.Genome Med. 2016 Oct 20;8(1):107. doi: 10.1186/s13073-016-0361-5.
170 The epigenetic factor BORIS (CTCFL) controls the androgen receptor regulatory network in ovarian cancer.Oncogenesis. 2019 Aug 12;8(8):41. doi: 10.1038/s41389-019-0150-2.
171 Procathepsin D interacts with prosaposin in cancer cells but its internalization is not mediated by LDL receptor-related protein.Exp Cell Res. 2002 Jul 15;277(2):210-9. doi: 10.1006/excr.2002.5556.
172 Overexpression of Cathepsin L is associated with chemoresistance and invasion of epithelial ovarian cancer.Oncotarget. 2016 Jul 19;7(29):45995-46001. doi: 10.18632/oncotarget.10276.
173 A 2-Protein Signature Predicting Clinical Outcome in High-Grade Serous Ovarian Cancer.Int J Gynecol Cancer. 2018 Jan;28(1):51-58. doi: 10.1097/IGC.0000000000001141.
174 Significance of BRCA1 expression in breast and ovarian cancer patients with brain metastasis - A multicentre study.Adv Med Sci. 2019 Sep;64(2):235-240. doi: 10.1016/j.advms.2018.12.007. Epub 2019 Feb 26.
175 IL-8 promotes cell migration through regulating EMT by activating the Wnt/-catenin pathway in ovarian cancer.J Cell Mol Med. 2020 Jan;24(2):1588-1598. doi: 10.1111/jcmm.14848. Epub 2019 Dec 2.
176 CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer.Oncotarget. 2018 Jan 15;9(11):9751-9765. doi: 10.18632/oncotarget.24231. eCollection 2018 Feb 9.
177 Feedback control of the CXCR7/CXCL11 chemokine axis by estrogen receptor in ovarian cancer.Mol Oncol. 2018 Oct;12(10):1689-1705. doi: 10.1002/1878-0261.12362. Epub 2018 Aug 23.
178 Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.Medicine (Baltimore). 2019 Mar;98(13):e15052. doi: 10.1097/MD.0000000000015052.
179 CYP1B1 enhances the resistance of epithelial ovarian cancer cells to paclitaxel in vivo and in vitro.Int J Mol Med. 2015 Feb;35(2):340-8. doi: 10.3892/ijmm.2014.2041. Epub 2014 Dec 16.
180 TWIST1 induces expression of discoidin domain receptor 2 to promote ovarian cancer metastasis.Oncogene. 2018 Mar;37(13):1714-1729. doi: 10.1038/s41388-017-0043-9. Epub 2018 Jan 19.
181 High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.Int J Cancer. 2020 Apr 1;146(7):2007-2018. doi: 10.1002/ijc.32818. Epub 2019 Dec 19.
182 Differential expression of mTOR components in endometriosis and ovarian cancer: Effects of rapalogues and dual kinase inhibitors on mTORC1 and mTORC2 stoichiometry.Int J Mol Med. 2019 Jan;43(1):47-56. doi: 10.3892/ijmm.2018.3967. Epub 2018 Oct 31.
183 Prognostic significance of pretreatment VEGF, survivin, and Smac/DIABLO serum levels in patients with serous ovarian carcinoma.Tumour Biol. 2015 Jun;36(6):4157-65. doi: 10.1007/s13277-015-3050-x. Epub 2015 Jan 12.
184 Novel DICER1 mutation as cause of multinodular goiter in children.Head Neck. 2013 Dec;35(12):E369-71. doi: 10.1002/hed.23250. Epub 2013 Jun 1.
185 Folate-receptor 1 (FOLR1) protein is elevated in the serum of ovarian cancer patients.Clin Biochem. 2013 Oct;46(15):1462-8. doi: 10.1016/j.clinbiochem.2013.03.010. Epub 2013 Mar 23.
186 Delta-like 1 homologue promotes tumorigenesis and epithelial-mesenchymal transition of ovarian high-grade serous carcinoma through activation of Notch signaling.Oncogene. 2019 Apr;38(17):3201-3215. doi: 10.1038/s41388-018-0658-5. Epub 2019 Jan 9.
187 Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.Cancer Res. 2015 Oct 1;75(19):4086-96. doi: 10.1158/0008-5472.CAN-14-3773. Epub 2015 Sep 16.
188 miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells.Arch Biochem Biophys. 2019 Jan;661:1-9. doi: 10.1016/j.abb.2018.10.014. Epub 2018 Oct 23.
189 Depletion of H3K79 methyltransferase Dot1L promotes cell invasion and cancer stem-like cell property in ovarian cancer.Am J Transl Res. 2019 Feb 15;11(2):1145-1153. eCollection 2019.
190 Adrenergic Stimulation of DUSP1 Impairs Chemotherapy Response in Ovarian Cancer.Clin Cancer Res. 2016 Apr 1;22(7):1713-24. doi: 10.1158/1078-0432.CCR-15-1275. Epub 2015 Nov 18.
191 Localization of the VHR phosphatase gene and its analysis as a candidate for BRCA1.Genomics. 1994 Sep 1;23(1):163-7. doi: 10.1006/geno.1994.1473.
192 The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.Int J Oncol. 2012 Apr;40(4):1203-9. doi: 10.3892/ijo.2011.1293. Epub 2011 Dec 12.
193 E2F2/5/8 Serve as Potential Prognostic Biomarkers and Targets for Human Ovarian Cancer.Front Oncol. 2019 Mar 22;9:161. doi: 10.3389/fonc.2019.00161. eCollection 2019.
194 Targeting endothelin-1 receptor/-arrestin1 network for the treatment of ovarian cancer.Expert Opin Ther Targets. 2017 Oct;21(10):925-932. doi: 10.1080/14728222.2017.1361930. Epub 2017 Sep 5.
195 Anti-EpCAM-conjugated adeno-associated virus serotype 2 for systemic delivery of EGFR shRNA: Its retargeting and antitumor effects on OVCAR3 ovarian cancer in vivo.Acta Biomater. 2019 Jun;91:258-269. doi: 10.1016/j.actbio.2019.04.044. Epub 2019 Apr 23.
196 ERK Regulates HIF1-Mediated Platinum Resistance by Directly Targeting PHD2 in Ovarian Cancer.Clin Cancer Res. 2019 Oct 1;25(19):5947-5960. doi: 10.1158/1078-0432.CCR-18-4145. Epub 2019 Jul 8.
197 Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer.Biochem Biophys Res Commun. 2019 Mar 19;510(4):580-586. doi: 10.1016/j.bbrc.2019.01.117. Epub 2019 Feb 7.
198 Isolation of a novel candidate oncogene within a frequently amplified region at 3q26 in ovarian cancer.Cancer Res. 2001 May 1;61(9):3806-9.
199 Oncogenic role of eIF-5A2 in the development of ovarian cancer.Cancer Res. 2004 Jun 15;64(12):4197-200. doi: 10.1158/0008-5472.CAN-03-3747.
200 Human epithelial ovarian cancer cells expressing CD105, CD44 and CD106 surface markers exhibit increased invasive capacity and drug resistance.Oncol Lett. 2019 Jun;17(6):5351-5360. doi: 10.3892/ol.2019.10221. Epub 2019 Apr 5.
201 Positive feedback between vascular endothelial growth factor-A and autotaxin in ovarian cancer cells.Mol Cancer Res. 2008 Mar;6(3):352-63. doi: 10.1158/1541-7786.MCR-07-0143.
202 Metformin-Induced Reduction of CD39 and CD73 Blocks Myeloid-Derived Suppressor Cell Activity in Patients with Ovarian Cancer.Cancer Res. 2018 Apr 1;78(7):1779-1791. doi: 10.1158/0008-5472.CAN-17-2460. Epub 2018 Jan 26.
203 Knockdown of EPHA1 Using CRISPR/CAS9 Suppresses Aggressive Properties of Ovarian Cancer Cells.Anticancer Res. 2017 Aug;37(8):4415-4424. doi: 10.21873/anticanres.11836.
204 The role of miR-200a in vasculogenic mimicry and its clinical significance in ovarian cancer.Gynecol Oncol. 2014 Mar;132(3):730-8. doi: 10.1016/j.ygyno.2014.01.047. Epub 2014 Feb 4.
205 EphA5 protein, a potential marker for distinguishing histological grade and prognosis in ovarian serous carcinoma.J Ovarian Res. 2016 Nov 25;9(1):83. doi: 10.1186/s13048-016-0292-1.
206 Analysis of microarray-identified genes and microRNAs associated with drug resistance in ovarian cancer.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6847-58. eCollection 2015.
207 The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome.Br J Cancer. 2007 Apr 10;96(7):1083-91. doi: 10.1038/sj.bjc.6603642. Epub 2007 Mar 13.
208 Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells.Int J Cancer. 2008 Jan 15;122(2):274-80. doi: 10.1002/ijc.23068.
209 Epiregulin as a marker for the initial steps of ovarian cancer development.Int J Oncol. 2011 Nov;39(5):1165-72. doi: 10.3892/ijo.2011.1123. Epub 2011 Jul 14.
210 IRE1-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.Nature. 2018 Oct;562(7727):423-428. doi: 10.1038/s41586-018-0597-x. Epub 2018 Oct 10.
211 Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells.Mol Ther. 2014 Apr;22(4):743-51. doi: 10.1038/mt.2014.1. Epub 2014 Jan 14.
212 High expression of orphan nuclear receptor NR4A1 in a subset of ovarian tumors with worse outcome.Gynecol Oncol. 2016 May;141(2):348-356. doi: 10.1016/j.ygyno.2016.02.030. Epub 2016 Mar 11.
213 ETS1 induction by the microenvironment promotes ovarian cancer metastasis through focal adhesion kinase.Cancer Lett. 2018 Feb 1;414:190-204. doi: 10.1016/j.canlet.2017.11.012. Epub 2017 Nov 22.
214 Expression of Par3 polarity protein correlates with poor prognosis in ovarian cancer.BMC Cancer. 2016 Nov 17;16(1):897. doi: 10.1186/s12885-016-2929-2.
215 Role of PAR-4 in ovarian cancer.Oncotarget. 2015 Sep 8;6(26):22641-52. doi: 10.18632/oncotarget.4010.
216 IL-17A promotes fatty acid uptake through the IL-17A/IL-17RA/p-STAT3/FABP4 axis to fuel ovarian cancer growth in an adipocyte-rich microenvironment.Cancer Immunol Immunother. 2020 Jan;69(1):115-126. doi: 10.1007/s00262-019-02445-2. Epub 2019 Dec 4.
217 FAM83D inhibits autophagy and promotes proliferation and invasion of ovarian cancer cells via PI3K/AKT/mTOR pathway.Acta Biochim Biophys Sin (Shanghai). 2019 May 23;51(5):509-516. doi: 10.1093/abbs/gmz028.
218 Role of Alpha-Smooth Muscle Actin and Fibroblast Activation Protein Alpha in Ovarian Neoplasms.Gynecol Obstet Invest. 2018;83(4):381-387. doi: 10.1159/000488088. Epub 2018 Apr 5.
219 The effect of FASN inhibition on the growth and metabolism of a cisplatin-resistant ovarian carcinoma model.Int J Cancer. 2018 Aug 15;143(4):992-1002. doi: 10.1002/ijc.31392. Epub 2018 Apr 1.
220 Cancer-associated fibroblasts secrete FGF-1 to promote ovarian proliferation, migration, and invasion through the activation of FGF-1/FGFR4 signaling.Tumour Biol. 2017 Jul;39(7):1010428317712592. doi: 10.1177/1010428317712592.
221 Keratinocyte growth factor binding to fibroblast growth factor receptor 2-IIIb promotes epithelial ovarian cancer cell proliferation and invasion.J Cancer Res Ther. 2018 Jun;14(Supplement):S347-S353. doi: 10.4103/0973-1482.235353.
222 Role of fibroblast growth factor 8 in growth and progression of hormonal cancer.Cytokine Growth Factor Rev. 2007 Jun-Aug;18(3-4):257-66. doi: 10.1016/j.cytogfr.2007.04.010. Epub 2007 May 23.
223 Expression profiles of VEGF-A, VEGF-D and VEGFR1 are higher in distant metastases than in matched primary high grade epithelial ovarian cancer.BMC Cancer. 2019 Jun 14;19(1):584. doi: 10.1186/s12885-019-5757-3.
224 VEGFR3 inhibition chemosensitizes ovarian cancer stemlike cells through down-regulation of BRCA1 and BRCA2.Neoplasia. 2014 Apr;16(4):343-53.e1-2. doi: 10.1016/j.neo.2014.04.003.
225 C-Fos expression is a molecular predictor of progression and survival in epithelial ovarian carcinoma.Br J Cancer. 2008 Oct 21;99(8):1269-75. doi: 10.1038/sj.bjc.6604650.
226 lncRNA UCA1 Mediates Resistance to Cisplatin by Regulating the miR-143/FOSL2-Signaling Pathway in Ovarian Cancer.Mol Ther Nucleic Acids. 2019 Sep 6;17:92-101. doi: 10.1016/j.omtn.2019.05.007. Epub 2019 May 24.
227 MicroRNA-152 inhibits ovarian cancer cell proliferation and migration and may infer improved outcomes in ovarian cancer through targeting FOXP1.Exp Ther Med. 2018 Feb;15(2):1672-1679. doi: 10.3892/etm.2017.5529. Epub 2017 Nov 17.
228 Forkhead box Q1: A key player in the pathogenesis of tumors (Review).Int J Oncol. 2016 Jul;49(1):51-8. doi: 10.3892/ijo.2016.3517. Epub 2016 May 12.
229 Inhibition of fascin in cancer and stromal cells blocks ovarian cancer metastasis.Gynecol Oncol. 2019 May;153(2):405-415. doi: 10.1016/j.ygyno.2019.01.020. Epub 2019 Feb 20.
230 The FZD7-TWIST1 axis is responsible for anoikis resistance and tumorigenesis in ovarian carcinoma.Mol Oncol. 2019 Apr;13(4):757-780. doi: 10.1002/1878-0261.12425. Epub 2019 Jan 19.
231 The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer.Sci Signal. 2016 Oct 4;9(448):ra97. doi: 10.1126/scisignal.aaf8175.
232 Evidence for altered regulation of gamma-glutamylcysteine synthetase gene expression among cisplatin-sensitive and cisplatin-resistant human ovarian cancer cell lines.Cancer Res. 1995 Oct 1;55(19):4367-74.
233 Epithelialmesenchymal transition induced by bone morphogenetic protein 9 hinders cisplatin efficacy in ovarian cancer cells.Mol Med Rep. 2019 Mar;19(3):1501-1508. doi: 10.3892/mmr.2019.9814. Epub 2019 Jan 3.
234 Cx32 mediates cisplatin resistance in human ovarian cancer cells by affecting drug efflux transporter expression and activating the EGFRAkt pathway.Mol Med Rep. 2019 Mar;19(3):2287-2296. doi: 10.3892/mmr.2019.9876. Epub 2019 Jan 17.
235 Regulation of Survivin Isoform Expression by GLI Proteins in Ovarian Cancer.Cells. 2019 Feb 6;8(2):128. doi: 10.3390/cells8020128.
236 Targeted Microbubbles for Ultrasound Mediated Short Hairpin RNA Plasmid Transfection to Inhibit Survivin Gene Expression and Induce Apoptosis of Ovarian Cancer A2780/DDP Cells.Mol Pharm. 2015 Sep 8;12(9):3137-45. doi: 10.1021/mp500835z. Epub 2015 Aug 3.
237 Glypican-3 gene silencing for ovarian cancer using siRNA-PLGA hybrid micelles in a murine peritoneal dissemination model.J Pharmacol Sci. 2019 Mar;139(3):231-239. doi: 10.1016/j.jphs.2019.01.009. Epub 2019 Feb 10.
238 Nuclear G protein-coupled oestrogen receptor (GPR30) predicts poor survival in patients with ovarian cancer.J Int Med Res. 2018 Feb;46(2):723-731. doi: 10.1177/0300060517717625. Epub 2017 Sep 12.
239 GRP137 promotes cell proliferation and metastasis through regulation of the PI3K/AKT pathway in human ovarian cancer.Tumori. 2018 Oct;104(5):330-337. doi: 10.5301/tj.5000703. Epub 2018 May 9.
240 Grb2 depletion under non-stimulated conditions inhibits PTEN, promotes Akt-induced tumor formation and contributes to poor prognosis in ovarian cancer.Oncogene. 2016 Apr 28;35(17):2186-96. doi: 10.1038/onc.2015.279. Epub 2015 Jul 27.
241 Suppression of the grainyhead transcription factor 2 gene (GRHL2) inhibits the proliferation, migration, invasion and mediates cell cycle arrest of ovarian cancer cells.Cell Cycle. 2017 Apr 3;16(7):693-706. doi: 10.1080/15384101.2017.1295181. Epub 2017 Feb 22.
242 GEP oncogene promotes cell proliferation through YAP activation in ovarian cancer.Oncogene. 2016 Aug 25;35(34):4471-80. doi: 10.1038/onc.2015.505. Epub 2016 Jan 25.
243 The exosome-mediated autocrine and paracrine actions of plasma gelsolin in ovarian cancer chemoresistance.Oncogene. 2020 Feb;39(7):1600-1616. doi: 10.1038/s41388-019-1087-9. Epub 2019 Nov 7.
244 Selection of suitable reference genes for gene expression studies in normal human ovarian tissues, borderline ovarian tumours and ovarian cancer.Mol Med Rep. 2016 Dec;14(6):5725-5731. doi: 10.3892/mmr.2016.5933. Epub 2016 Nov 8.
245 Contribution of transcription factor, SP1, to the promotion of HB-EGF expression in defense mechanism against the treatment of irinotecan in ovarian clear cell carcinoma.Cancer Med. 2014 Oct;3(5):1159-69. doi: 10.1002/cam4.301. Epub 2014 Jul 24.
246 HDAC1 Silencing in Ovarian Cancer Enhances the Chemotherapy Response.Cell Physiol Biochem. 2018;48(4):1505-1518. doi: 10.1159/000492260. Epub 2018 Aug 2.
247 HDAC10 as a potential therapeutic target in ovarian cancer.Gynecol Oncol. 2017 Mar;144(3):613-620. doi: 10.1016/j.ygyno.2017.01.009. Epub 2017 Jan 7.
248 Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1-mediated regulation of apoptosis and autophagy.Theranostics. 2019 Jan 30;9(4):1096-1114. doi: 10.7150/thno.29673. eCollection 2019.
249 HDAC6 Inhibition Synergizes with Anti-PD-L1 Therapy in ARID1A-Inactivated Ovarian Cancer.Cancer Res. 2019 Nov 1;79(21):5482-5489. doi: 10.1158/0008-5472.CAN-19-1302. Epub 2019 Jul 16.
250 Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer.Oncogene. 2017 Mar 23;36(12):1707-1720. doi: 10.1038/onc.2016.337. Epub 2016 Oct 3.
251 MicroRNA let?d?p rescues ovarian cancer cell apoptosis and restores chemosensitivity by regulating the p53 signaling pathway via HMGA1.Int J Oncol. 2019 May;54(5):1771-1784. doi: 10.3892/ijo.2019.4731. Epub 2019 Feb 27.
252 Lowly-expressed lncRNA GAS5 facilitates progression of ovarian cancer through targeting miR-196-5p and thereby regulating HOXA5.Gynecol Oncol. 2018 Nov;151(2):345-355. doi: 10.1016/j.ygyno.2018.08.032. Epub 2018 Sep 7.
253 The effect of lncRNA HOTAIR on chemoresistance of ovarian cancer through regulation of HOXA7.Biol Chem. 2018 Apr 25;399(5):485-497. doi: 10.1515/hsz-2017-0274.
254 Overexpression of MEF2D contributes to oncogenic malignancy and chemotherapeutic resistance in ovarian carcinoma.Am J Cancer Res. 2019 May 1;9(5):887-905. eCollection 2019.
255 A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.BMC Cancer. 2018 Mar 5;18(1):254. doi: 10.1186/s12885-018-4153-8.
256 Characterization of HSD17B1 sequence variants in breast cancer cases from French Canadian families with high risk of breast and ovarian cancer.J Steroid Biochem Mol Biol. 2008 Mar;109(1-2):115-28. doi: 10.1016/j.jsbmb.2007.10.004. Epub 2007 Nov 17.
257 Very frequent loss of heterozygosity throughout chromosome 17 in sporadic ovarian carcinoma.Int J Cancer. 1993 May 8;54(2):220-5. doi: 10.1002/ijc.2910540210.
258 The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model.PLoS One. 2016 Dec 20;11(12):e0168389. doi: 10.1371/journal.pone.0168389. eCollection 2016.
259 NF-B p65 promotes ovarian cancer cell proliferation and migration via regulating mortalin.J Cell Mol Med. 2019 Jun;23(6):4338-4348. doi: 10.1111/jcmm.14325. Epub 2019 Apr 14.
260 Changes in mRNA and protein levels of human HtrA1, HtrA2 and HtrA3 in ovarian cancer.Clin Biochem. 2008 May;41(7-8):561-9. doi: 10.1016/j.clinbiochem.2008.01.004. Epub 2008 Jan 16.
261 Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors.Clin Cancer Res. 2003 Feb;9(2):779-85.
262 SULT1E1 and ID2 genes as candidates for inherited predisposition to breast and ovarian cancer in Jewish women.Fam Cancer. 2009;8(2):135-44. doi: 10.1007/s10689-008-9218-4. Epub 2008 Sep 27.
263 Expression of metalloprotease insulin-degrading enzyme insulysin in normal and malignant human tissues.Int J Mol Med. 2008 Oct;22(4):421-31.
264 Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.Mol Cancer Res. 2019 Aug;17(8):1710-1720. doi: 10.1158/1541-7786.MCR-18-1233. Epub 2019 May 20.
265 LOH at 6q and 10q in fractionated circulating DNA of ovarian cancer patients is predictive for tumor cell spread and overall survival.BMC Cancer. 2012 Jul 31;12:325. doi: 10.1186/1471-2407-12-325.
266 IGFBP-1 is expressed specifically in ovarian clear cell adenocarcinoma.Histopathology. 2011 Apr;58(5):729-38. doi: 10.1111/j.1365-2559.2011.03817.x. Epub 2011 Apr 4.
267 A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.Br J Cancer. 2017 Aug 22;117(5):666-674. doi: 10.1038/bjc.2017.199. Epub 2017 Jun 29.
268 The NF-B-modulated miR-19a-3p enhances malignancy of human ovarian cancer cells through inhibition of IGFBP-3 expression.Mol Carcinog. 2019 Dec;58(12):2254-2265. doi: 10.1002/mc.23113. Epub 2019 Sep 12.
269 The C-terminus of IGFBP-5 suppresses tumor growth by inhibiting angiogenesis.Sci Rep. 2016 Dec 23;6:39334. doi: 10.1038/srep39334.
270 Interleukin-11 receptor expression in primary ovarian carcinomas.Gynecol Oncol. 2001 Feb;80(2):121-7. doi: 10.1006/gyno.2000.6064.
271 Common Polymorphisms in IL-27 Genes May Contribute to Risk of Various Human Diseases in Asian Populations: A Meta-Analysis.Med Sci Monit. 2016 Mar 7;22:766-75. doi: 10.12659/msm.895558.
272 Gene therapy of ovarian cancer using IL-21-secreting human umbilical cord mesenchymal stem cells in nude mice.J Ovarian Res. 2014 Jan 20;7:8. doi: 10.1186/1757-2215-7-8.
273 Combinatorial strategies based on CRAd-IL24 and CRAd-ING4 virotherapy with anti-angiogenesis treatment for ovarian cancer.J Ovarian Res. 2016 Jun 27;9(1):38. doi: 10.1186/s13048-016-0248-5.
274 Dual-specificity phosphatase 5 suppresses ovarian cancer progression by inhibiting IL-33 signaling.Am J Transl Res. 2019 Feb 15;11(2):844-854. eCollection 2019.
275 Improving cancer detection through combinations of cancer and immune biomarkers: a modelling approach.J Transl Med. 2018 Mar 20;16(1):73. doi: 10.1186/s12967-018-1432-8.
276 Effect of integrinlinked kinase gene silencing on microRNA expression in ovarian cancer.Mol Med Rep. 2017 Nov;16(5):7267-7276. doi: 10.3892/mmr.2017.7523. Epub 2017 Sep 19.
277 Targeting INHBA in Ovarian Cancer Cells Suppresses Cancer Xenograft Growth by Attenuating Stromal Fibroblast Activation.Dis Markers. 2019 Nov 11;2019:7275289. doi: 10.1155/2019/7275289. eCollection 2019.
278 A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers.Cancer Epidemiol Biomarkers Prev. 2012 Aug;21(8):1362-70. doi: 10.1158/1055-9965.EPI-12-0229. Epub 2012 Jun 22.
279 Crimean-Congo Hemorrhagic Fever Virus Suppresses Innate Immune Responses via a Ubiquitin and ISG15 Specific Protease.Cell Rep. 2017 Sep 5;20(10):2396-2407. doi: 10.1016/j.celrep.2017.08.040.
280 miR-92a inhibits peritoneal dissemination of ovarian cancer cells by inhibiting integrin 5 expression.Am J Pathol. 2013 May;182(5):1876-89. doi: 10.1016/j.ajpath.2013.01.039. Epub 2013 Mar 15.
281 Expression of integrin -6 is associated with multi drug resistance and prognosis in ovarian cancer.Oncol Lett. 2019 Apr;17(4):3974-3980. doi: 10.3892/ol.2019.10056. Epub 2019 Feb 20.
282 Identification of PRTFDC1 silencing and aberrant promoter methylation of GPR150, ITGA8 and HOXD11 in ovarian cancers.Life Sci. 2007 Mar 27;80(16):1458-65. doi: 10.1016/j.lfs.2007.01.015. Epub 2007 Jan 20.
283 Non-catalytic region of tyrosine kinase adaptor protein 2 (NCK2) pathways as factor promoting aggressiveness in ovarian cancer.Int J Biol Markers. 2018 Jan;33(1):124-131. doi: 10.5301/ijbm.5000264.
284 Integrin Subunit beta 8 (ITGB8) Upregulation Is an Independent Predictor of Unfavorable Survival of High-Grade Serous Ovarian Carcinoma Patients.Med Sci Monit. 2018 Dec 10;24:8933-8940. doi: 10.12659/MSM.911518.
285 Reprogramming of stromal fibroblasts by SNAI2 contributes to tumor desmoplasia and ovarian cancer progression.Mol Cancer. 2017 Oct 17;16(1):163. doi: 10.1186/s12943-017-0732-6.
286 Calcium-activated potassium channels as potential early markers of human cervical cancer.Oncol Lett. 2018 May;15(5):7249-7254. doi: 10.3892/ol.2018.8187. Epub 2018 Mar 7.
287 Low expression of KCNN3 may affect drug resistance in ovarian cancer.Mol Med Rep. 2018 Aug;18(2):1377-1386. doi: 10.3892/mmr.2018.9107. Epub 2018 May 31.
288 Lysine demethylase2A promotes the progression of ovarian cancer by regulating the PI3K pathway and reversing epithelialmesenchymal transition.Oncol Rep. 2019 Feb;41(2):917-927. doi: 10.3892/or.2018.6888. Epub 2018 Nov 27.
289 Lysine-specific demethylase KDM3A regulates ovarian cancer stemness and chemoresistance.Oncogene. 2017 Mar;36(11):1537-1545. doi: 10.1038/onc.2016.320. Epub 2016 Oct 3.
290 KDM5A promotes proliferation and EMT in ovarian cancer and closely correlates with PTX resistance.Mol Med Rep. 2017 Sep;16(3):3573-3580. doi: 10.3892/mmr.2017.6960. Epub 2017 Jul 12.
291 Targeting estrogen receptor beta (ER) for treatment of ovarian cancer: importance of KDM6B and SIRT1 for ER expression and functionality.Oncogenesis. 2018 Feb 9;7(2):15. doi: 10.1038/s41389-018-0027-9.
292 Expression Patterns of Nrf2 and Keap1 in Ovarian Cancer Cells and their Prognostic Role in Disease Recurrence and Patient Survival.Int J Gynecol Cancer. 2017 Mar;27(3):412-419. doi: 10.1097/IGC.0000000000000908.
293 A comprehensive study on genome-wide coexpression network of KHDRBS1/Sam68 reveals its cancer and patient-specific association.Sci Rep. 2019 Jul 31;9(1):11083. doi: 10.1038/s41598-019-47558-x.
294 Human KIT ligand promoter is positively regulated by HMGA1 in breast and ovarian cancer cells.Oncogene. 2004 Nov 4;23(52):8557-62. doi: 10.1038/sj.onc.1207926.
295 Genomic instability and copy-number heterogeneity of chromosome 19q, including the kallikrein locus, in ovarian carcinomas.Mol Oncol. 2011 Feb;5(1):48-60. doi: 10.1016/j.molonc.2010.08.002. Epub 2010 Aug 11.
296 Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis.J Cancer Res Clin Oncol. 2018 Jun;144(6):1109-1118. doi: 10.1007/s00432-018-2623-7. Epub 2018 Mar 15.
297 Kallikrein-related peptidase 3 (KLK3/PSA) single nucleotide polymorphisms and ovarian cancer survival.Twin Res Hum Genet. 2011 Aug;14(4):323-7. doi: 10.1375/twin.14.4.323.
298 Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients.PLoS One. 2019 Feb 27;14(2):e0212968. doi: 10.1371/journal.pone.0212968. eCollection 2019.
299 Quantitative assessment and clinical relevance of kallikrein-related peptidase 5 mRNA expression in advanced high-grade serous ovarian cancer.BMC Cancer. 2019 Jul 15;19(1):696. doi: 10.1186/s12885-019-5901-0.
300 Kallikrein family proteases KLK6 and KLK7 are potential early detection and diagnostic biomarkers for serous and papillary serous ovarian cancer subtypes.J Ovarian Res. 2014 Dec 5;7:109. doi: 10.1186/s13048-014-0109-z.
301 Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation.Oncoimmunology. 2017 Aug 21;6(9):e1339854. doi: 10.1080/2162402X.2017.1339854. eCollection 2017.
302 Basal cytokeratins in breast tumours among BRCA1, BRCA2 and mutation-negative breast cancer families.Breast Cancer Res. 2008;10(1):R17. doi: 10.1186/bcr1863. Epub 2008 Feb 14.
303 Kallikrein-related peptidases 4, 5, 6 and 7 regulate tumour-associated factors in serous ovarian cancer.Br J Cancer. 2018 Oct;119(7):1-9. doi: 10.1038/s41416-018-0260-1. Epub 2018 Oct 5.
304 L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.PLoS One. 2016 Jan 13;11(1):e0146885. doi: 10.1371/journal.pone.0146885. eCollection 2016.
305 Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types.Cancer Discov. 2016 Sep;6(9):1052-67. doi: 10.1158/2159-8290.CD-15-1227. Epub 2016 Jul 17.
306 Lentivirus-mediated RNA Interference Targeting LAPTM4B Inhibits Human Ovarian Cancer Cell Invasion In Vitro.Chem Biol Drug Des. 2016 Jan;87(1):121-30. doi: 10.1111/cbdd.12632. Epub 2015 Aug 31.
307 The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer.Nucleic Acids Res. 2016 Feb 18;44(3):1227-46. doi: 10.1093/nar/gkv1515. Epub 2015 Dec 29.
308 Outcome in serous ovarian cancer is not associated with LATS expression.J Cancer Res Clin Oncol. 2019 Nov;145(11):2737-2749. doi: 10.1007/s00432-019-03037-4. Epub 2019 Oct 4.
309 Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature.Cancer Immunol Immunother. 2019 Sep;68(9):1515-1526. doi: 10.1007/s00262-019-02385-x. Epub 2019 Sep 12.
310 Galectin-1 induces metastasis and epithelial-mesenchymal transition (EMT) in human ovarian cancer cells via activation of the MAPK JNK/p38 signalling pathway.Am J Transl Res. 2019 Jun 15;11(6):3862-3878. eCollection 2019.
311 Galectins-1, -3, and -7 Are Prognostic Markers for Survival of Ovarian Cancer Patients.Int J Mol Sci. 2017 Jun 8;18(6):1230. doi: 10.3390/ijms18061230.
312 Legumain: a biomarker for diagnosis and prognosis of human ovarian cancer.J Cell Biochem. 2012 Aug;113(8):2679-86. doi: 10.1002/jcb.24143.
313 LGR5 and LGR6 in stem cell biology and ovarian cancer.Oncotarget. 2017 Aug 11;9(1):1346-1355. doi: 10.18632/oncotarget.20178. eCollection 2018 Jan 2.
314 Leukemia inhibitory factor functions in parallel with interleukin-6 to promote ovarian cancer growth.Oncogene. 2019 Feb;38(9):1576-1584. doi: 10.1038/s41388-018-0523-6. Epub 2018 Oct 10.
315 Upregulation of Limk1 caused by microRNA-138 loss aggravates the metastasis of ovarian cancer by activation of Limk1/cofilin signaling.Oncol Rep. 2014 Nov;32(5):2070-6. doi: 10.3892/or.2014.3461. Epub 2014 Sep 2.
316 The interaction of Lin28A/Rho associated coiled-coil containing protein kinase2 accelerates the malignancy of ovarian cancer.Oncogene. 2019 Feb;38(9):1381-1397. doi: 10.1038/s41388-018-0512-9. Epub 2018 Sep 28.
317 Clinical and biological significance of an isozyme tumor marker--PLAP.Clin Biochem. 1987 Dec;20(6):387-92. doi: 10.1016/0009-9120(87)90003-8.
318 Uncovering the role of nuclear Lysyl oxidase (LOX) in advanced high grade serous ovarian cancer.Gynecol Oncol. 2017 Jul;146(1):170-178. doi: 10.1016/j.ygyno.2017.05.001. Epub 2017 May 9.
319 LPA receptor 1 mediates LPA-induced ovarian cancer metastasis: an in vitro and in vivo study.BMC Cancer. 2016 Nov 4;16(1):846. doi: 10.1186/s12885-016-2865-1.
320 Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.
321 Lipoxygenase pathway receptor expression in ovarian cancer.Reprod Sci. 2008 Apr;15(3):321-6. doi: 10.1177/1933719108316390.
322 Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.Biochim Biophys Acta. 2016 Feb;1863(2):236-43. doi: 10.1016/j.bbamcr.2015.11.011. Epub 2015 Nov 17.
323 Interleukin-6 receptor enhances early colonization of the murine omentum by upregulation of a mannose family receptor, LY75, in ovarian tumor cells.Clin Exp Metastasis. 2011 Dec;28(8):887-97. doi: 10.1007/s10585-011-9420-x. Epub 2011 Sep 2.
324 Androgen receptor gene mutations do not occur in ovarian cancer.Anticancer Res. 2000 Mar-Apr;20(2A):815-9.
325 MEK1 is associated with carboplatin resistance and is a prognostic biomarker in epithelial ovarian cancer.BMC Cancer. 2014 Nov 18;14:837. doi: 10.1186/1471-2407-14-837.
326 Mutation analysis of BRAF, MEK1 and MEK2 in 15 ovarian cancer cell lines: implications for therapy.PLoS One. 2007 Dec 5;2(12):e1279. doi: 10.1371/journal.pone.0001279.
327 Novel Small Molecule MEK Inhibitor URML-3881 Enhances Cisplatin Sensitivity in Clear Cell Ovarian Cancer.Transl Oncol. 2019 Jul;12(7):917-924. doi: 10.1016/j.tranon.2019.04.009. Epub 2019 May 10.
328 Lysophosphatidic Acid Stimulates Ovarian Cancer Cell Migration via a Ras-MEK Kinase 1 Pathway.Cancer Res. 2004 Jun 15;64(12):4209-17. doi: 10.1158/0008-5472.CAN-04-0060.
329 ASK1-dependent endothelial cell activation is critical in ovarian cancer growth and metastasis.JCI Insight. 2017 Sep 21;2(18):e91828. doi: 10.1172/jci.insight.91828. eCollection 2017 Sep 21.
330 Expression of Syk and MAP4 proteins in ovarian cancer.J Cancer Res Clin Oncol. 2019 Apr;145(4):909-919. doi: 10.1007/s00432-019-02856-9. Epub 2019 Feb 8.
331 Combined MEK and BCL-2/X(L) Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.Mol Cancer Ther. 2019 Mar;18(3):642-655. doi: 10.1158/1535-7163.MCT-18-0413. Epub 2019 Jan 24.
332 PKP3 interactions with MAPK-JNK-ERK1/2-mTOR pathway regulates autophagy and invasion in ovarian cancer.Biochem Biophys Res Commun. 2019 Jan 8;508(2):646-653. doi: 10.1016/j.bbrc.2018.11.163. Epub 2018 Dec 4.
333 MARCKS contributes to stromal cancer-associated fibroblast activation and facilitates ovarian cancer metastasis.Oncotarget. 2016 Jun 21;7(25):37649-37663. doi: 10.18632/oncotarget.8726.
334 Sphingosine kinase 1/sphingosine-1-phosphate (S1P)/S1P receptor axis is involved in ovarian cancer angiogenesis.Oncotarget. 2017 Aug 24;8(43):74947-74961. doi: 10.18632/oncotarget.20471. eCollection 2017 Sep 26.
335 METCAM/MUC18 Decreases the Malignant Propensity of Human Ovarian Carcinoma Cells.Int J Mol Sci. 2018 Sep 29;19(10):2976. doi: 10.3390/ijms19102976.
336 MGMT-activated DUB3 stabilizes MCL1 and drives chemoresistance in ovarian cancer.Proc Natl Acad Sci U S A. 2019 Feb 19;116(8):2961-2966. doi: 10.1073/pnas.1814742116. Epub 2019 Feb 4.
337 Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.Oncogene. 2012 Oct 18;31(42):4567-76. doi: 10.1038/onc.2011.611. Epub 2012 Jan 16.
338 Integrated Analysis To Identify Molecular Biomarkers Of High-Grade Serous Ovarian Cancer.Onco Targets Ther. 2019 Nov 21;12:10057-10075. doi: 10.2147/OTT.S228678. eCollection 2019.
339 Regulation of HGF and c-MET Interaction in Normal Ovary and Ovarian Cancer.Reprod Sci. 2017 Apr;24(4):494-501. doi: 10.1177/1933719116648212. Epub 2016 Sep 27.
340 The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers.Transl Res. 2019 Apr;206:71-90. doi: 10.1016/j.trsl.2018.11.001. Epub 2018 Nov 20.
341 Inhibiting ERK/Mnk/eIF4E broadly sensitizes ovarian cancer response to chemotherapy.Clin Transl Oncol. 2018 Mar;20(3):374-381. doi: 10.1007/s12094-017-1724-0. Epub 2017 Aug 1.
342 Primary Ovarian Tumors With Lymphogenic and Hematogenic Metastasis Express High MMP-14, Which Colocalizes With Highly Sulfated Chondroitin Sulfate in the Stroma.Int J Gynecol Pathol. 2020 Mar;39(2):184-192. doi: 10.1097/PGP.0000000000000587.
343 Aberrant Activation Of Hedgehog Signalling Promotes Cell Migration And Invasion Via Matrix Metalloproteinase-7 In Ovarian Cancer Cells.J Cancer. 2019 Jan 29;10(4):990-1003. doi: 10.7150/jca.26478. eCollection 2019.
344 miR-761 inhibits tumor progression by targeting MSI1 in ovarian carcinoma.Tumour Biol. 2016 Apr;37(4):5437-43. doi: 10.1007/s13277-015-4377-z. Epub 2015 Nov 12.
345 Musashi-2 is a novel regulator of paclitaxel sensitivity in ovarian cancer cells.Int J Oncol. 2016 Nov;49(5):1945-1952. doi: 10.3892/ijo.2016.3683. Epub 2016 Sep 6.
346 PSP94, an upstream signaling mediator of prostasin found highly elevated in ovarian cancer.Cell Death Dis. 2014 Sep 4;5(9):e1407. doi: 10.1038/cddis.2014.374.
347 MicroRNA-30c inhibits metastasis of ovarian cancer by targeting metastasis-associated gene 1.J Cancer Res Ther. 2017;13(4):676-682. doi: 10.4103/jcrt.JCRT_132_17.
348 Knockout of MTF1 Inhibits the Epithelial to Mesenchymal Transition in Ovarian Cancer Cells. J Cancer. 2018 Nov 11;9(24):4578-4585.
349 A biosensor for determination of the circulating biomarker CA125/MUC16 by Surface Plasmon Resonance Imaging.Talanta. 2020 Jan 1;206:120187. doi: 10.1016/j.talanta.2019.120187. Epub 2019 Jul 29.
350 MYC status as a determinant of synergistic response to Olaparib and Palbociclib in ovarian cancer.EBioMedicine. 2019 May;43:225-237. doi: 10.1016/j.ebiom.2019.03.027. Epub 2019 Mar 18.
351 P-MAPA immunotherapy potentiates the effect of cisplatin on serous ovarian carcinoma through targeting TLR4 signaling.J Ovarian Res. 2018 Jan 17;11(1):8. doi: 10.1186/s13048-018-0380-5.
352 Nucleus accumbens-1/GADD45GIP1 axis mediates cisplatin resistance through cellular senescence in ovarian cancer.Oncol Lett. 2017 Jun;13(6):4713-4719. doi: 10.3892/ol.2017.6099. Epub 2017 Apr 26.
353 Nicotinic Acid Phosphoribosyltransferase Regulates Cancer Cell Metabolism, Susceptibility to NAMPT Inhibitors, and DNA Repair.Cancer Res. 2017 Jul 15;77(14):3857-3869. doi: 10.1158/0008-5472.CAN-16-3079. Epub 2017 May 15.
354 NCK1-AS1 promotes NCK1 expression to facilitate tumorigenesis and chemo-resistance in ovarian cancer.Biochem Biophys Res Commun. 2020 Feb 5;522(2):292-299. doi: 10.1016/j.bbrc.2019.11.014. Epub 2019 Nov 21.
355 AIB1 regulates the ovarian cancer cell cycle through TUG1.Eur Rev Med Pharmacol Sci. 2017 Dec;21(24):5610-5617. doi: 10.26355/eurrev_201712_14002.
356 Activation of androgen receptor-associated protein 70 (ARA70) mRNA expression in ovarian cancer.Gynecol Oncol. 2001 Feb;80(2):132-8. doi: 10.1006/gyno.2000.6068.
357 Ectodomain shedding of the cell adhesion molecule Nectin-4 in ovarian cancer is mediated by ADAM10 and ADAM17.J Biol Chem. 2017 Apr 14;292(15):6339-6351. doi: 10.1074/jbc.M116.746859. Epub 2017 Feb 23.
358 NEDD9 overexpression is associated with the progression of and an unfavorable prognosis in epithelial ovarian cancer.Hum Pathol. 2014 Feb;45(2):401-8. doi: 10.1016/j.humpath.2013.10.005. Epub 2013 Oct 19.
359 PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2.Eur Rev Med Pharmacol Sci. 2019 Oct;23(19):8239-8248. doi: 10.26355/eurrev_201910_19133.
360 TRIM52 plays an oncogenic role in ovarian cancer associated with NF-kB pathway.Cell Death Dis. 2018 Sep 5;9(9):908. doi: 10.1038/s41419-018-0881-6.
361 Frequent Loss of NISCH Promotes Tumor Proliferation and Invasion in Ovarian Cancer via Inhibiting the FAK Signal Pathway.Mol Cancer Ther. 2015 May;14(5):1202-12. doi: 10.1158/1535-7163.MCT-14-0911. Epub 2015 Feb 27.
362 THRA1 and D17S183 flank an interval of < 4 cM for the breast-ovarian cancer gene (BRCA1) on chromosome 17q21.Am J Hum Genet. 1993 Apr;52(4):718-22.
363 Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells.Mol Cancer. 2011 Mar 8;10:24. doi: 10.1186/1476-4598-10-24.
364 Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.Onco Targets Ther. 2019 Sep 30;12:8015-8022. doi: 10.2147/OTT.S203550. eCollection 2019.
365 The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis.Tumour Biol. 2017 May;39(5):1010428317705508. doi: 10.1177/1010428317705508.
366 Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer.Medicine (Baltimore). 2017 Jul;96(30):e7621. doi: 10.1097/MD.0000000000007621.
367 Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.J Pathol. 2019 Jul;248(3):352-362. doi: 10.1002/path.5264. Epub 2019 May 14.
368 Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis.Am J Physiol Regul Integr Comp Physiol. 2009 Jun;296(6):R1716-25. doi: 10.1152/ajpregu.00075.2009. Epub 2009 Mar 18.
369 Estrogen receptor-mediated miR-486-5p regulation of OLFM4 expression in ovarian cancer.Oncotarget. 2016 Mar 1;7(9):10594-605. doi: 10.18632/oncotarget.7236.
370 Role of front-line bevacizumab in advanced ovarian cancer: the OSCAR study.Int J Gynecol Cancer. 2020 Feb;30(2):213-220. doi: 10.1136/ijgc-2019-000512. Epub 2019 Nov 27.
371 The role of peptidylarginine deiminase 4 in ovarian cancer cell tumorigenesis and invasion.Tumour Biol. 2016 Apr;37(4):5375-83. doi: 10.1007/s13277-015-4363-5. Epub 2015 Nov 12.
372 Effects of p21-activated kinase 1 inhibition on 11q13-amplified ovarian cancer cells.Oncogene. 2016 Apr 28;35(17):2178-85. doi: 10.1038/onc.2015.278. Epub 2015 Aug 10.
373 PBK, targeted by EVI1, promotes metastasis and confers cisplatin resistance through inducing autophagy in high-grade serous ovarian carcinoma.Cell Death Dis. 2019 Feb 18;10(3):166. doi: 10.1038/s41419-019-1415-6.
374 Analysis of epigenetic alterations to proprotein convertase genes in disease.Methods Mol Biol. 2011;768:231-45. doi: 10.1007/978-1-61779-204-5_12.
375 Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.FASEB J. 2019 May;33(5):6596-6608. doi: 10.1096/fj.201802067RR. Epub 2019 Feb 25.
376 Platelet-derived growth factor-D promotes ovarian cancer invasion by regulating matrix metalloproteinases 2 and 9.Asian Pac J Cancer Prev. 2011;12(12):3367-70.
377 Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation.J Cell Physiol. 2019 May;234(5):6361-6370. doi: 10.1002/jcp.27369. Epub 2018 Sep 19.
378 Effects of raf kinase inhibitor protein expression on metastasis and progression of human epithelial ovarian cancer.Mol Cancer Res. 2008 Jun;6(6):917-28. doi: 10.1158/1541-7786.MCR-08-0093.
379 Therapeutic effects of viral vector-mediated antiangiogenic gene transfer in malignant ascites.Hum Gene Ther. 2001 Sep 20;12(14):1713-29. doi: 10.1089/104303401750476221.
380 Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.Tohoku J Exp Med. 2018 Apr;244(4):291-296. doi: 10.1620/tjem.244.291.
381 Progesterone receptor membrane component-1 regulates the development and Cisplatin sensitivity of human ovarian tumors in athymic nude mice.Endocrinology. 2009 Nov;150(11):4846-54. doi: 10.1210/en.2009-0730. Epub 2009 Oct 1.
382 Virtual screening identifies a PIN1 inhibitor with possible antiovarian cancer effects.J Cell Physiol. 2019 Sep;234(9):15708-15716. doi: 10.1002/jcp.28224. Epub 2019 Jan 29.
383 Ginsenoside 20(S)-Rg3 Inhibits the Warburg Effect Via Modulating DNMT3A/ MiR-532-3p/HK2 Pathway in Ovarian Cancer Cells.Cell Physiol Biochem. 2018;45(6):2548-2559. doi: 10.1159/000488273. Epub 2018 Mar 16.
384 Identification of clinical trait-related lncRNA and mRNA biomarkers with weighted gene co-expression network analysis as useful tool for personalized medicine in ovarian cancer.EPMA J. 2019 Jul 19;10(3):273-290. doi: 10.1007/s13167-019-00175-0. eCollection 2019 Sep.
385 Plasminogen Activator Inhibitor Type 1 in Blood at Onset of Chemotherapy Unfavorably Affects Survival in Primary Ovarian Cancer.Adv Exp Med Biol. 2019;1153:47-54. doi: 10.1007/5584_2019_353.
386 Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.Oncotarget. 2012 Jan;3(1):78-83. doi: 10.18632/oncotarget.332.
387 Somatic mosaic truncating mutations of PPM1D in blood can result from expansion of a mutant clone under selective pressure of chemotherapy.PLoS One. 2019 Jun 26;14(6):e0217521. doi: 10.1371/journal.pone.0217521. eCollection 2019.
388 The serine protease prostasin (PRSS8) is a potential biomarker for early detection of ovarian cancer.J Ovarian Res. 2016 Mar 31;9:20. doi: 10.1186/s13048-016-0228-9.
389 Relationship of c-myc and erbB oncogene family gene aberrations and other selected factors to ex vivo chemosensitivity of ovarian cancer in the modified ATP-chemosensitivity assay.Acta Biochim Pol. 2000;47(1):157-64.
390 Gonadotropin-regulated lymphangiogenesis in ovarian cancer is mediated by LEDGF-induced expression of VEGF-C.Cancer Res. 2009 Dec 15;69(24):9306-14. doi: 10.1158/0008-5472.CAN-09-1213.
391 Distinct methylation profile of mucinous ovarian carcinoma reveals susceptibility to proteasome inhibitors.Int J Cancer. 2018 Jul 15;143(2):355-367. doi: 10.1002/ijc.31324. Epub 2018 Mar 8.
392 Association between LMP2/LMP7 genetic variability and the metastasis risk of ovarian cancer in Chinese women in Beijing.Hum Immunol. 2014 Mar;75(3):239-44. doi: 10.1016/j.humimm.2013.12.006. Epub 2013 Dec 27.
393 Human mesenchymal stem cells in the tumour microenvironment promote ovarian cancer progression: the role of platelet-activating factor.BMC Cancer. 2018 Oct 19;18(1):999. doi: 10.1186/s12885-018-4918-0.
394 EP3 receptor is a prognostic factor in TA-MUC1-negative ovarian cancer.J Cancer Res Clin Oncol. 2019 Oct;145(10):2519-2527. doi: 10.1007/s00432-019-03017-8. Epub 2019 Sep 4.
395 Discovery of Furanone-Based Radiopharmaceuticals for Diagnostic Targeting of COX-1 in Ovarian Cancer.ACS Omega. 2019 May 31;4(5):9251-9261. doi: 10.1021/acsomega.9b01093. Epub 2019 May 24.
396 Genome-wide association study evaluating single-nucleotide polymorphisms and outcomes in patients with advanced stage serous ovarian or primary peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.Gynecol Oncol. 2017 Nov;147(2):396-401. doi: 10.1016/j.ygyno.2017.08.024. Epub 2017 Sep 19.
397 PRL-3 suppresses c-Fos and integrin 2 expression in ovarian cancer cells.BMC Cancer. 2013 Feb 18;13:80. doi: 10.1186/1471-2407-13-80.
398 Differential expression of Fas family members and Bcl-2 family members in benign versus malignant epithelial ovarian cancer (EOC) in North Indian population.Mol Cell Biochem. 2012 Sep;368(1-2):119-26. doi: 10.1007/s11010-012-1350-7. Epub 2012 Jun 12.
399 Diagnostic value of HE4+ circulating tumor cells in patients with suspicious ovarian cancer.Oncotarget. 2018 Jan 4;9(7):7522-7533. doi: 10.18632/oncotarget.23943. eCollection 2018 Jan 26.
400 PTN signaling: Components and mechanistic insights in human ovarian cancer.Mol Carcinog. 2015 Dec;54(12):1772-85. doi: 10.1002/mc.22249. Epub 2014 Nov 21.
401 LncRNA HOTAIR controls the expression of Rab22a by sponging miR-373 in ovarian cancer.Mol Med Rep. 2016 Sep;14(3):2465-72. doi: 10.3892/mmr.2016.5572. Epub 2016 Jul 28.
402 Adipokine RBP4 drives ovarian cancer cell migration.J Ovarian Res. 2018 Apr 11;11(1):29. doi: 10.1186/s13048-018-0397-9.
403 Expression loss and revivification of RhoB gene in ovary carcinoma carcinogenesis and development.PLoS One. 2013 Nov 1;8(11):e78417. doi: 10.1371/journal.pone.0078417. eCollection 2013.
404 RhoC expression level is correlated with the clinicopathological characteristics of ovarian cancer and the expression levels of ROCK-I, VEGF, and MMP9.Gynecol Oncol. 2010 Mar;116(3):563-71. doi: 10.1016/j.ygyno.2009.11.015.
405 Ovarian Cancer Stem Cells with High ROR1 Expression Serve as a New Prophylactic Vaccine for Ovarian Cancer.J Immunol Res. 2019 Mar 17;2019:9394615. doi: 10.1155/2019/9394615. eCollection 2019.
406 Distinct Patterns of Stromal and Tumor Expression of ROR1 and ROR2 in Histological Subtypes of Epithelial Ovarian Cancer.Transl Oncol. 2017 Jun;10(3):346-356. doi: 10.1016/j.tranon.2017.01.014. Epub 2017 Mar 23.
407 Polymorphisms in the p63 and p73 genes are associated with ovarian cancer risk and clinicopathological variables.J Exp Clin Cancer Res. 2012 Oct 24;31(1):89. doi: 10.1186/1756-9966-31-89.
408 Peritoneal and hematogenous metastases of ovarian cancer cells are both controlled by the p90RSK through a self-reinforcing cell autonomous mechanism.Oncotarget. 2016 Jan 5;7(1):712-28. doi: 10.18632/oncotarget.6412.
409 Ribosomal S6 kinase 4 (RSK4) expression in ovarian tumors and its regulation by antineoplastic drugs in ovarian cancer cell lines.Med Oncol. 2016 Feb;33(2):11. doi: 10.1007/s12032-015-0724-6. Epub 2016 Jan 5.
410 MiR-145 is downregulated in human ovarian cancer and modulates cell growth and invasion by targeting p70S6K1 and MUC1.Biochem Biophys Res Commun. 2013 Nov 29;441(4):693-700. doi: 10.1016/j.bbrc.2013.10.053. Epub 2013 Oct 21.
411 Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis.J Ovarian Res. 2019 Nov 15;12(1):110. doi: 10.1186/s13048-019-0578-1.
412 RSF1 is a positive regulator of NF-B-induced gene expression required for ovarian cancer chemoresistance.Cancer Res. 2014 Apr 15;74(8):2258-69. doi: 10.1158/0008-5472.CAN-13-2459. Epub 2014 Feb 24.
413 The role of R-spondin 1 through activating Wnt/-catenin in the growth, survival and migration of ovarian cancer cells.Gene. 2019 Mar 20;689:124-130. doi: 10.1016/j.gene.2018.11.098. Epub 2018 Dec 17.
414 Effect of histone deacetylase inhibitors on cell apoptosis and expression of the tumor suppressor genes RUNX3 and ARHI in ovarian tumors.Mol Med Rep. 2013 May;7(5):1705-9. doi: 10.3892/mmr.2013.1371. Epub 2013 Mar 14.
415 Mammaglobin B expression in human endometrial cancer.Int J Gynecol Cancer. 2008 Sep-Oct;18(5):1090-6. doi: 10.1111/j.1525-1438.2007.01137.x. Epub 2007 Nov 16.
416 Decreased semaphorin 3A expression is associated with a poor prognosis in patients with epithelial ovarian carcinoma.Int J Mol Med. 2015 May;35(5):1374-80. doi: 10.3892/ijmm.2015.2142. Epub 2015 Mar 17.
417 VEGF and SEMA4D have synergistic effects on the promotion of angiogenesis in epithelial ovarian cancer.Cell Mol Biol Lett. 2018 Jan 3;23:2. doi: 10.1186/s11658-017-0058-9. eCollection 2018.
418 Levels of corticosteroid-binding globulin mRNA in human ovarian cancers.Tumour Biol. 1999 Sep-Oct;20(5):263-9. doi: 10.1159/000030073.
419 Discovery of serum biomarkers implicated in the onset and progression of serous ovarian cancer in a rat model using iTRAQ technique.Eur J Obstet Gynecol Reprod Biol. 2012 Nov;165(1):96-103. doi: 10.1016/j.ejogrb.2012.06.031. Epub 2012 Jul 18.
420 SERPIND1 Affects the Malignant Biological Behavior of Epithelial Ovarian Cancer via the PI3K/AKT Pathway: A Mechanistic Study.Front Oncol. 2019 Oct 4;9:954. doi: 10.3389/fonc.2019.00954. eCollection 2019.
421 The core genes involved in the promotion of depression in patients with ovarian cancer.Oncol Lett. 2019 Dec;18(6):5995-6007. doi: 10.3892/ol.2019.10934. Epub 2019 Sep 30.
422 Malignant ascites: a source of therapeutic protein against ovarian cancer?.Oncotarget. 2019 Oct 15;10(57):5894-5905. doi: 10.18632/oncotarget.27185. eCollection 2019 Oct 15.
423 Loss of secreted frizzled-related protein 4 correlates with an aggressive phenotype and predicts poor outcome in ovarian cancer patients.PLoS One. 2012;7(2):e31885. doi: 10.1371/journal.pone.0031885. Epub 2012 Feb 21.
424 Surfactant Protein D as a Potential Biomarker and Therapeutic Target in Ovarian Cancer.Front Oncol. 2019 Jul 9;9:542. doi: 10.3389/fonc.2019.00542. eCollection 2019.
425 SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1 pathway and Drp1-mediated mitochondrial fission in ovarian cancer.Cancer Lett. 2020 Jan 28;469:89-101. doi: 10.1016/j.canlet.2019.10.029. Epub 2019 Oct 19.
426 Downregulated Salt-inducible Kinase 3 Expression Promotes Chemoresistance in Serous Ovarian Cancer via the ATP-binding Cassette Protein ABCG2.J Cancer. 2019 Oct 15;10(24):6025-6036. doi: 10.7150/jca.34886. eCollection 2019.
427 Reduced expression of SIRT2 in serous ovarian carcinoma promotes cell proliferation through disinhibition of CDK4 expression.Mol Med Rep. 2017 Apr;15(4):1638-1646. doi: 10.3892/mmr.2017.6183. Epub 2017 Feb 8.
428 Human Ovarian Cancer Tissue Exhibits Increase of Mitochondrial Biogenesis and Cristae Remodeling.Cancers (Basel). 2019 Sep 12;11(9):1350. doi: 10.3390/cancers11091350.
429 Comprehensive Analysis of Expression and Prognostic Value of Sirtuins in Ovarian Cancer.Front Genet. 2019 Sep 13;10:879. doi: 10.3389/fgene.2019.00879. eCollection 2019.
430 Mechanism of Low Expression of miR-30a-5p on Epithelial-Mesenchymal Transition and Metastasis in Ovarian Cancer.DNA Cell Biol. 2019 Apr;38(4):341-351. doi: 10.1089/dna.2018.4396. Epub 2019 Mar 6.
431 The iron chelator desferrioxamine synergizes with chemotherapy for cancer treatment.J Trace Elem Med Biol. 2019 Dec;56:131-138. doi: 10.1016/j.jtemb.2019.07.008. Epub 2019 Aug 19.
432 The role of neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer: a systematic review and meta-analysis of randomized controlled trials and observational studies.Oncotarget. 2017 Dec 27;9(9):8614-8628. doi: 10.18632/oncotarget.23808. eCollection 2018 Feb 2.
433 GLUT 1 receptor expression and circulating levels of fasting glucose in high grade serous ovarian cancer.J Cell Physiol. 2018 Feb;233(2):1396-1401. doi: 10.1002/jcp.26023. Epub 2017 Jul 14.
434 SLC6A1-miR133a-CDX2 loop regulates SK-OV-3 ovarian cancer cell proliferation, migration and invasion.Oncol Lett. 2018 Oct;16(4):4977-4983. doi: 10.3892/ol.2018.9273. Epub 2018 Aug 7.
435 Aberrant Hypomethylation of Solute Carrier Family 6 Member 12 Promoter Induces Metastasis of Ovarian Cancer. Yonsei Med J. 2017 Jan;58(1):27-34.
436 Circular RNA circ-SMAD7 promoted ovarian cancer cell proliferation and metastasis by suppressing KLF6.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5603-5610. doi: 10.26355/eurrev_201907_18294.
437 Clinical utility of SMARCA4 testing by immunohistochemistry in rare ovarian tumours.Br J Cancer. 2020 Feb;122(4):564-568. doi: 10.1038/s41416-019-0687-z. Epub 2019 Dec 17.
438 SMYD3 promotes implant metastasis of ovarian cancer via H3K4 trimethylation of integrin promoters.Int J Cancer. 2020 Mar 15;146(6):1553-1567. doi: 10.1002/ijc.32673. Epub 2019 Oct 30.
439 Manganese superoxide dismutase gene polymorphism, MnSOD plasma levels and risk of epithelial ovarian cancer.J Obstet Gynaecol Res. 2008 Oct;34(5):878-84. doi: 10.1111/j.1447-0756.2008.00851.x.
440 Regulation of the bi-directional cross-talk between ovarian cancer cells and adipocytes by SPARC.Oncogene. 2019 May;38(22):4366-4383. doi: 10.1038/s41388-019-0728-3. Epub 2019 Feb 14.
441 Prostate-derived Ets transcription factor as a favorable prognostic marker in ovarian cancer patients. Int J Cancer. 2008 Sep 15;123(6):1376-84. doi: 10.1002/ijc.23667.
442 SPHK1 Is a Novel Target of Metformin in Ovarian Cancer. Mol Cancer Res. 2019 Apr;17(4):870-881.
443 Expression and role of autophagy-associated p62 (SQSTM1) in multidrug resistant ovarian cancer.Gynecol Oncol. 2018 Jul;150(1):143-150. doi: 10.1016/j.ygyno.2018.04.557. Epub 2018 Apr 24.
444 Pre-operative Circulating Plasma Gelsolin Predicts Residual Disease and Detects Early Stage Ovarian Cancer.Sci Rep. 2019 Sep 26;9(1):13924. doi: 10.1038/s41598-019-50436-1.
445 Stanniocalcin 1 in tumor microenvironment promotes metastasis of ovarian cancer.Onco Targets Ther. 2019 Apr 11;12:2789-2798. doi: 10.2147/OTT.S196150. eCollection 2019.
446 STC2 overexpression mediated by HMGA2 is a biomarker for aggressiveness of high-grade serous ovarian cancer.Oncol Rep. 2015 Sep;34(3):1494-502. doi: 10.3892/or.2015.4120. Epub 2015 Jul 9.
447 Expression and clinical significance of SLP-2 in ovarian tumors.Oncol Lett. 2019 May;17(5):4626-4632. doi: 10.3892/ol.2019.10116. Epub 2019 Mar 5.
448 Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours.Eur J Cancer. 2019 Oct;120:132-139. doi: 10.1016/j.ejca.2019.07.024. Epub 2019 Sep 12.
449 Overexpression of TROP2 promotes proliferation and invasion of ovarian cancer cells.Exp Ther Med. 2017 Sep;14(3):1947-1952. doi: 10.3892/etm.2017.4788. Epub 2017 Jul 12.
450 Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.Lancet Oncol. 2019 Jun;20(6):862-876. doi: 10.1016/S1470-2045(19)30178-0. Epub 2019 May 7.
451 Genetic variants in telomere-maintenance genes are associated with ovarian cancer risk and outcome.J Cell Mol Med. 2017 Mar;21(3):510-518. doi: 10.1111/jcmm.12995. Epub 2016 Nov 7.
452 MicroRNA-532 and microRNA-3064 inhibit cell proliferation and invasion by acting as direct regulators of human telomerase reverse transcriptase in ovarian cancer.PLoS One. 2017 Mar 14;12(3):e0173912. doi: 10.1371/journal.pone.0173912. eCollection 2017.
453 Screening the molecular targets of ovarian cancer based on bioinformatics analysis.Tumori. 2015 Jul-Aug;101(4):384-9. doi: 10.5301/tj.5000319. Epub 2015 Jul 2.
454 Transforming growth factor-beta isoform expression in human ovarian tumours.Eur J Cancer. 1997 Dec;33(14):2397-403. doi: 10.1016/s0959-8049(97)00304-3.
455 Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer.Oncotarget. 2016 Oct 25;7(43):69097-69110. doi: 10.18632/oncotarget.10215.
456 Extracellular tissue transglutaminase activates noncanonical NF-B signaling and promotes metastasis in ovarian cancer.Neoplasia. 2013 Jun;15(6):609-19. doi: 10.1593/neo.121878.
457 Preoperative serum thrombopoietin levels are higher in patients with ovarian cancer than with benign cysts.Eur J Obstet Gynecol Reprod Biol. 2008 Sep;140(1):67-70. doi: 10.1016/j.ejogrb.2005.10.037. Epub 2005 Dec 15.
458 Tyrosine kinase receptor TIE-1 mediates platinum resistance by promoting nucleotide excision repair in ovarian cancer.Sci Rep. 2018 Sep 4;8(1):13207. doi: 10.1038/s41598-018-31069-2.
459 GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer.Nat Genet. 2013 Apr;45(4):362-70, 370e1-2. doi: 10.1038/ng.2564.
460 Research on application value of combined detection of serum CA125, HE4 and TK1 in the diagnosis of ovarian cancer.Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4536-4541.
461 Prognostic values of transketolase family genes in ovarian cancer.Oncol Lett. 2019 Nov;18(5):4845-4857. doi: 10.3892/ol.2019.10818. Epub 2019 Sep 6.
462 Integrative Development of a TLR8 Agonist for Ovarian Cancer Chemoimmunotherapy.Clin Cancer Res. 2017 Apr 15;23(8):1955-1966. doi: 10.1158/1078-0432.CCR-16-1453. Epub 2016 Oct 4.
463 Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers.Int J Cancer. 2012 Mar 15;130(6):1314-8. doi: 10.1002/ijc.26134. Epub 2011 May 30.
464 Fn14 overcomes cisplatin resistance of high-grade serous ovarian cancer by promoting Mdm2-mediated p53-R248Q ubiquitination and degradation.J Exp Clin Cancer Res. 2019 Apr 25;38(1):176. doi: 10.1186/s13046-019-1171-6.
465 Knockdown of HVEM, a Lymphocyte Regulator Gene, in Ovarian Cancer Cells Increases Sensitivity to Activated T Cells.Oncol Res. 2016;24(3):189-96. doi: 10.3727/096504016X14641336229602.
466 Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.PLoS One. 2017 Oct 18;12(10):e0186965. doi: 10.1371/journal.pone.0186965. eCollection 2017.
467 Pro-survival effects by NF-B, Akt and ERK(1/2) and anti-apoptosis actions by Six1 disrupt apoptotic functions of TRAIL-Dr4/5 pathway in ovarian cancer.Biomed Pharmacother. 2016 Dec;84:1078-1087. doi: 10.1016/j.biopha.2016.10.028. Epub 2016 Oct 22.
468 Interferon- produced by tumor-infiltrating NK cells and CD4+ T cells downregulates TNFSF15 expression in vascular endothelial cells.Angiogenesis. 2014 Jul;17(3):529-40. doi: 10.1007/s10456-013-9397-y. Epub 2013 Oct 20.
469 Tankyrase Promotes Aerobic Glycolysis and Proliferation of Ovarian Cancer through Activation of Wnt/-Catenin Signaling.Biomed Res Int. 2019 Feb 20;2019:2686340. doi: 10.1155/2019/2686340. eCollection 2019.
470 TPX2 gene silencing inhibits cell proliferation and promotes apoptosis through negative regulation of AKT signaling pathway in ovarian cancer.J Cell Biochem. 2018 Sep;119(9):7540-7555. doi: 10.1002/jcb.27065. Epub 2018 Jun 15.
471 Up-regulation of miR-383-5p suppresses proliferation and enhances chemosensitivity in ovarian cancer cells by targeting TRIM27.Biomed Pharmacother. 2019 Jan;109:595-601. doi: 10.1016/j.biopha.2018.10.148. Epub 2018 Nov 3.
472 High levels of KAP1 expression are associated with aggressive clinical features in ovarian cancer.Int J Mol Sci. 2014 Dec 26;16(1):363-77. doi: 10.3390/ijms16010363.
473 TRIM59 Is a Novel Marker of Poor Prognosis and Promotes Malignant Progression of Ovarian Cancer by Inducing Annexin A2 Expression.Int J Biol Sci. 2018 Nov 3;14(14):2073-2082. doi: 10.7150/ijbs.28757. eCollection 2018.
474 Downregulation of transient receptor potential cation channel, subfamily C, member 1 contributes to drug resistance and high histological grade in ovarian cancer.Int J Oncol. 2016 Jan;48(1):243-52. doi: 10.3892/ijo.2015.3254. Epub 2015 Nov 19.
475 FSH enhances the proliferation of ovarian cancer cells by activating transient receptor potential channel C3.Endocr Relat Cancer. 2013 May 30;20(3):415-29. doi: 10.1530/ERC-12-0005. Print 2013 Jun.
476 TRPM7 promotes the epithelial-mesenchymal transition in ovarian cancer through the calcium-related PI3K / AKT oncogenic signaling.J Exp Clin Cancer Res. 2019 Feb 28;38(1):106. doi: 10.1186/s13046-019-1061-y.
477 Inhibition of Transient Receptor Potential Vanilloid 6 channel, elevated in human ovarian cancers, reduces tumour growth in a xenograft model.J Cancer. 2018 Aug 6;9(17):3196-3207. doi: 10.7150/jca.20639. eCollection 2018.
478 Up-regulation of tumor susceptibility gene 101 protein in ovarian carcinomas revealed by proteomics analyses.Mol Cell Proteomics. 2007 Feb;6(2):294-304. doi: 10.1074/mcp.M600305-MCP200. Epub 2006 Nov 16.
479 MicroRNA-663 facilitates the growth, migration and invasion of ovarian cancer cell by inhibiting TUSC2.Biol Res. 2019 Apr 3;52(1):18. doi: 10.1186/s40659-019-0219-6.
480 Protein-protein interface-binding peptides inhibit the cancer therapy target human thymidylate synthase.Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):E542-9. doi: 10.1073/pnas.1104829108. Epub 2011 Jul 27.
481 Recurrent ubiquitin B silencing in gynecological cancers establishes dependence on ubiquitin C.J Clin Invest. 2017 Dec 1;127(12):4554-4568. doi: 10.1172/JCI92914. Epub 2017 Nov 13.
482 UCHL3 promotes ovarian cancer progression by stabilizing TRAF2 to activate the NF-B pathway.Oncogene. 2020 Jan;39(2):322-333. doi: 10.1038/s41388-019-0987-z. Epub 2019 Sep 2.
483 The proteasome deubiquitinase inhibitor bAP15 downregulates TGF-/Smad signaling and induces apoptosis via UCHL5 inhibition in ovarian cancer. Oncotarget. 2019 Oct 15;10(57):5932-5948.
484 Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.Genet Mol Res. 2015 Jun 29;14(2):7241-7. doi: 10.4238/2015.June.29.17.
485 Loss of BRUCE reduces cellular energy level and induces autophagy by driving activation of the AMPK-ULK1 autophagic initiating axis.PLoS One. 2019 May 15;14(5):e0216553. doi: 10.1371/journal.pone.0216553. eCollection 2019.
486 USP1 links platinum resistance to cancer cell dissemination by regulating Snail stability.Sci Adv. 2019 May 8;5(5):eaav3235. doi: 10.1126/sciadv.aav3235. eCollection 2019 May.
487 Amplification of USP13 drives ovarian cancer metabolism.Nat Commun. 2016 Nov 28;7:13525. doi: 10.1038/ncomms13525.
488 Inhibition of ubiquitinspecific protease14 promotes connexin32 internalization and counteracts cisplatin cytotoxicity in human ovarian cancer cells.Oncol Rep. 2019 Sep;42(3):1237-1247. doi: 10.3892/or.2019.7232. Epub 2019 Jul 15.
489 Ubiquitin-specific peptidase 5 and ovarian tumor deubiquitinase6A are differentially expressed in p53+/+ and p53-/- HCT116 cells.Int J Oncol. 2018 May;52(5):1705-1714. doi: 10.3892/ijo.2018.4302. Epub 2018 Mar 5.
490 SPARC suppresses lymph node metastasis by regulating the expression of VEGFs in ovarian carcinoma.Int J Oncol. 2017 Dec;51(6):1920-1928. doi: 10.3892/ijo.2017.4168. Epub 2017 Oct 19.
491 VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.Cancer Immunol Immunother. 2020 Jan;69(1):33-42. doi: 10.1007/s00262-019-02434-5. Epub 2019 Nov 28.
492 Tumor cell expression of B7-H4 correlates with higher frequencies of tumor-infiltrating APCs and higher CXCL17 expression in human epithelial ovarian cancer.Oncoimmunology. 2019 Sep 30;8(12):e1665460. doi: 10.1080/2162402X.2019.1665460. eCollection 2019.
493 Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.Cancer Treat Rev. 2018 Dec;71:1-7. doi: 10.1016/j.ctrv.2018.09.003. Epub 2018 Sep 11.
494 An integrated analysis identifies STAT4 as a key regulator of ovarian cancer metastasis.Oncogene. 2017 Jun 15;36(24):3384-3396. doi: 10.1038/onc.2016.487. Epub 2017 Jan 23.
495 Molecular changes in endometriosis-associated ovarian clear cell carcinoma.Eur J Cancer. 2015 Sep;51(13):1831-42. doi: 10.1016/j.ejca.2015.05.011. Epub 2015 Jun 6.
496 Inhibition of the Nuclear Export Receptor XPO1 as a Therapeutic Target for Platinum-Resistant Ovarian Cancer.Clin Cancer Res. 2017 Mar 15;23(6):1552-1563. doi: 10.1158/1078-0432.CCR-16-1333. Epub 2016 Sep 20.
497 Expression of Yes-associated protein1 and its clinical significance in ovarian serous cystadenocarcinoma.Oncol Rep. 2017 May;37(5):2620-2632. doi: 10.3892/or.2017.5517. Epub 2017 Mar 21.
498 Placental Growth Factor Promotes Ovarian Cancer Cell Invasion via ZEB2.Cell Physiol Biochem. 2016;38(1):351-8. doi: 10.1159/000438635. Epub 2016 Jan 29.
499 ZNF217 is associated with poor prognosis and enhances proliferation and metastasis in ovarian cancer.Int J Clin Exp Pathol. 2014 May 15;7(6):3038-47. eCollection 2014.
500 A mobile loop near the active site acts as a switch between the dual activities of a viral protease/deubiquitinase.PLoS Pathog. 2017 Nov 8;13(11):e1006714. doi: 10.1371/journal.ppat.1006714. eCollection 2017 Nov.
501 [Value of P-glycoprotein and glutathione S-transferase-pi as chemo-resistant indicators in ovarian cancers].Zhonghua Zhong Liu Za Zhi. 2001 Jul;23(4):313-6.
502 Imbalanced expression of inhibin and activin subunits in primary epithelial ovarian cancer.Gynecol Oncol. 1998 Apr;69(1):23-31. doi: 10.1006/gyno.1998.4958.
503 Mitochondrial transcription factor A regulates BCL2L1 gene expression and is a prognostic factor in serous ovarian cancer.Cancer Sci. 2012 Feb;103(2):239-444. doi: 10.1111/j.1349-7006.2011.02156.x. Epub 2011 Dec 23.
504 Molecular design of Stat3-derived peptide selectivity between BET proteins Brd2 and Brd4 in ovarian cancer.J Mol Recognit. 2018 Feb;31(2). doi: 10.1002/jmr.2679. Epub 2017 Oct 6.
505 Analysis of CC chemokine and chemokine receptor expression in solid ovarian tumours.Br J Cancer. 2001 Sep 14;85(6):891-7. doi: 10.1054/bjoc.2001.2020.
506 Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.Int J Mol Sci. 2019 Feb 3;20(3):660. doi: 10.3390/ijms20030660.
507 Prognostic impact of chondroitin-4-sulfotransferase CHST11 in ovarian cancer.Tumour Biol. 2015 Nov;36(11):9023-30. doi: 10.1007/s13277-015-3652-3. Epub 2015 Jun 18.
508 Intratumoral CRH modulates immuno-escape of ovarian cancer cells through FasL regulation.Br J Cancer. 2007 Sep 3;97(5):637-45. doi: 10.1038/sj.bjc.6603918. Epub 2007 Jul 31.
509 A rare population of tumor antigen-specific CD4(+)CD8(+) double-positive T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cells.J Immunother Cancer. 2019 Jan 9;7(1):7. doi: 10.1186/s40425-018-0467-y.
510 MiR-34c/SOX9 axis regulates the chemoresistance of ovarian cancer cell to cisplatin-based chemotherapy.J Cell Biochem. 2019 Mar;120(3):2940-2953. doi: 10.1002/jcb.26865. Epub 2018 Dec 9.
511 Bortezomib enhances cancer cell death by blocking the autophagic flux through stimulating ERK phosphorylation.Cell Death Dis. 2014 Nov 6;5(11):e1510. doi: 10.1038/cddis.2014.468.
512 Role of CYP1A2 1F polymorphism in cancer risk: evidence from a meta-analysis of 46 case-control studies.Gene. 2013 Jul 25;524(2):168-74. doi: 10.1016/j.gene.2013.04.038. Epub 2013 Apr 26.
513 Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis.Proc Natl Acad Sci U S A. 2014 Apr 8;111(14):5331-6. doi: 10.1073/pnas.1317242111. Epub 2014 Mar 24.
514 miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.Oncogene. 2019 Jan;38(4):564-580. doi: 10.1038/s41388-018-0459-x. Epub 2018 Aug 30.
515 Tissue factor-factor VIIa complex triggers protease activated receptor 2-dependent growth factor release and migration in ovarian cancer.Gynecol Oncol. 2017 Apr;145(1):167-175. doi: 10.1016/j.ygyno.2017.01.022. Epub 2017 Jan 29.
516 A novel duplication polymorphism in the FANCA promoter and its association with breast and ovarian cancer.BMC Cancer. 2005 Apr 29;5:43. doi: 10.1186/1471-2407-5-43.
517 Genetic and molecular analyses reveal G6PC as a key element connecting glucose metabolism and cell cycle control in ovarian cancer.Tumour Biol. 2015 Sep;36(10):7649-58. doi: 10.1007/s13277-015-3463-6. Epub 2015 Apr 30.
518 Targeting gonadotropin-releasing hormone receptor inhibits the early step of ovarian cancer metastasis by modulating tumor-mesothelial adhesion.Mol Ther. 2013 Jan;21(1):78-90. doi: 10.1038/mt.2012.187. Epub 2012 Nov 20.
519 Type 2 11beta-hydroxysteroid dehydrogenase activity in human ovarian cancer.Steroids. 2006 Nov;71(11-12):1019-23. doi: 10.1016/j.steroids.2006.09.001. Epub 2006 Oct 9.
520 Circulating GRP78 antibodies from ovarian cancer patients: a promising tool for cancer cell targeting drug delivery system?.Oncotarget. 2017 Nov 11;8(63):107176-107187. doi: 10.18632/oncotarget.22412. eCollection 2017 Dec 5.
521 Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.Cytokine. 2008 Apr;42(1):77-84. doi: 10.1016/j.cyto.2008.01.011. Epub 2008 Mar 7.
522 [Significantly increased interleukin-1A and interleukin-1 soluble type II receptor levels in women with ovarian cancer].Ginekol Pol. 2003 Sep;74(9):761-6.
523 PD-1 and CD103 Are Widely Coexpressed on Prognostically Favorable Intraepithelial CD8 T Cells in Human Ovarian Cancer.Cancer Immunol Res. 2015 Aug;3(8):926-35. doi: 10.1158/2326-6066.CIR-14-0239. Epub 2015 May 8.
524 Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis.Thromb Haemost. 2009 Mar;101(3):541-6.
525 Overexpression of MEKK3 confers resistance to apoptosis through activation of NFkappaB.J Biol Chem. 2004 Feb 27;279(9):7576-83. doi: 10.1074/jbc.M311659200. Epub 2003 Dec 8.
526 Matrix metalloproteinase-8 promoter gene polymorphisms in Mexican women with ovarian cancer.Med Oncol. 2014 Aug;31(8):132. doi: 10.1007/s12032-014-0132-3. Epub 2014 Jul 18.
527 Interobserver Agreement for Mismatch Repair Protein Immunohistochemistry in Endometrial and Nonserous, Nonmucinous Ovarian Carcinomas.Am J Surg Pathol. 2019 May;43(5):591-600. doi: 10.1097/PAS.0000000000001220.
528 The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness.Exp Cell Res. 2003 Aug 15;288(2):382-9. doi: 10.1016/s0014-4827(03)00250-7.
529 Chlamydia trachomatis and Anti-MUC1 Serology and Subsequent Risk of High-Grade Serous Ovarian Cancer: A Population-Based Case-Control Study in Northern Sweden.Transl Oncol. 2020 Jan;13(1):86-91. doi: 10.1016/j.tranon.2019.09.007. Epub 2019 Dec 2.
530 Notch3 Targeting: A Novel Weapon against Ovarian Cancer Stem Cells.Stem Cells Int. 2019 Jan 6;2019:6264931. doi: 10.1155/2019/6264931. eCollection 2019.
531 Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers.BMC Cancer. 2018 Mar 7;18(1):267. doi: 10.1186/s12885-018-4073-7.
532 Activation of ARK5/miR-1181/HOXA10 axis promotes epithelial-mesenchymal transition in ovarian cancer.Oncol Rep. 2015 Sep;34(3):1193-202. doi: 10.3892/or.2015.4113. Epub 2015 Jul 7.
533 Mifepristone mediates anti-proliferative effect on ovarian mesenchymal stem/stromal cells from female BRCA(1-/2-) carriers.Acta Obstet Gynecol Scand. 2019 Feb;98(2):250-261. doi: 10.1111/aogs.13485. Epub 2018 Nov 15.
534 Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer.Am J Cancer Res. 2019 Jan 1;9(1):145-159. eCollection 2019.
535 Aberrant expression of pim-3 promotes proliferation and migration of ovarian cancer cells.Asian Pac J Cancer Prev. 2015;16(8):3325-31. doi: 10.7314/apjcp.2015.16.8.3325.
536 Caspase-3-dependent activation of calcium-independent phospholipase A2 enhances cell migration in non-apoptotic ovarian cancer cells.J Biol Chem. 2006 Sep 29;281(39):29357-68. doi: 10.1074/jbc.M513105200. Epub 2006 Aug 1.
537 In vivo sensitization of ovarian tumors to chemotherapy by expression of E. coli purine nucleoside phosphorylase in a small fraction of cells.Gene Ther. 2000 Oct;7(20):1738-43. doi: 10.1038/sj.gt.3301286.
538 Autoantibody to thioredoxin reductase in an ovarian cancer patient.Biochem Biophys Res Commun. 1998 Jan 14;242(2):267-71. doi: 10.1006/bbrc.1997.7914.
539 Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells.J Biol Chem. 2005 Jul 15;280(28):26233-40. doi: 10.1074/jbc.M502003200. Epub 2005 May 19.
540 Activation of the PKC pathway stimulates ovarian cancer cell proliferation, migration, and expression of MMP7 and MMP10.Biol Reprod. 2013 Sep 27;89(3):73. doi: 10.1095/biolreprod.112.102327. Print 2013 Sep.
541 PKC regulates nuclear YAP1 localization and ovarian cancer tumorigenesis.Oncogene. 2017 Jan 26;36(4):534-545. doi: 10.1038/onc.2016.224. Epub 2016 Jun 20.
542 The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary.Cancer Biol Ther. 2006 Sep;5(9):1136-41. doi: 10.4161/cbt.5.9.2953. Epub 2006 Sep 28.
543 K-ras activation in neoplasms of the human female reproductive tract.Cancer Res. 1990 Oct 1;50(19):6139-45.
544 The role of the REG4 gene and its encoding product in ovarian epithelial carcinoma.BMC Cancer. 2015 Jun 16;15:471. doi: 10.1186/s12885-015-1435-2.
545 The 471delAAAG mutation and C353T polymorphism in the RNASEL gene in sporadic and inherited cancer in Israel.Fam Cancer. 2006;5(4):389-95. doi: 10.1007/s10689-006-0010-z. Epub 2006 Aug 31.
546 Maspin expression is characteristic for cisplatin-sensitive ovarian cancer cells and for ovarian cancer cases of longer survival rates.Int J Gynecol Pathol. 2006 Apr;25(2):131-9. doi: 10.1097/01.pgp.0000183050.30212.2f.
547 MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells.Oncol Rep. 2015 Jul;34(1):111-20. doi: 10.3892/or.2015.3952. Epub 2015 May 5.
548 Effects of shRNA-mediated knockdown of SPOCK1 on ovarian cancer growth and metastasis.Cell Mol Biol (Noisy-le-grand). 2015 Nov 30;61(7):102-9.
549 Decreasing the ratio of matriptase/HAI? by downregulation of matriptase as a potential adjuvant therapy in ovarian cancer.Mol Med Rep. 2016 Aug;14(2):1465-74. doi: 10.3892/mmr.2016.5435. Epub 2016 Jun 23.
550 4-Methylumbelliferone inhibits ovarian cancer growth by suppressing thymidine phosphorylase expression.J Ovarian Res. 2014 Oct 11;7:94. doi: 10.1186/s13048-014-0094-2.
551 MicroRNA-365 inhibits ovarian cancer progression by targeting Wnt5a.Am J Cancer Res. 2017 May 1;7(5):1096-1106. eCollection 2017.
552 Notch3 interactome analysis identified WWP2 as a negative regulator of Notch3 signaling in ovarian cancer.PLoS Genet. 2014 Oct 30;10(10):e1004751. doi: 10.1371/journal.pgen.1004751. eCollection 2014 Oct.
553 The impact of microRNA expression on cellular proliferation.Hum Genet. 2014 Jul;133(7):931-8. doi: 10.1007/s00439-014-1434-4. Epub 2014 Mar 8.
554 GLUT1 mRNA and protein expression in ovarian borderline tumors and cancer.Oncology. 2004;66(5):404-10. doi: 10.1159/000079489.
555 Theaflavin-3,3'-Digallate Enhances the Inhibitory Effect of Cisplatin by Regulating the Copper Transporter 1 and Glutathione in Human Ovarian Cancer Cells.Int J Mol Sci. 2018 Jan 2;19(1):117. doi: 10.3390/ijms19010117.
556 Genome-Wide Study of Response to Platinum, Taxane, and Combination Therapy in Ovarian Cancer: In vitro Phenotypes, Inherited Variation, and Disease Recurrence.Front Genet. 2016 Mar 22;7:37. doi: 10.3389/fgene.2016.00037. eCollection 2016.
557 Suppression of annexin A11 in ovarian cancer: implications in chemoresistance.Neoplasia. 2009 Jun;11(6):605-14, 1 p following 614. doi: 10.1593/neo.09286.
558 ATP-binding cassette transporter A7 accelerates epithelial-to-mesenchymal transition in ovarian cancer cells by upregulating the transforming growth factor- signaling pathway.Oncol Lett. 2018 Nov;16(5):5868-5874. doi: 10.3892/ol.2018.9366. Epub 2018 Aug 24.
559 ATP binding cassette subfamily B member 9 (ABCB9) is a prognostic indicator of overall survival in ovarian cancer.Medicine (Baltimore). 2019 May;98(19):e15698. doi: 10.1097/MD.0000000000015698.
560 Systematic analysis reveals a lncRNA-mRNA co-expression network associated with platinum resistance in high-grade serous ovarian cancer.Invest New Drugs. 2018 Apr;36(2):187-194. doi: 10.1007/s10637-017-0523-3. Epub 2017 Oct 30.
561 miR-139 Controls Viability Of Ovarian Cancer Cells Through Apoptosis Induction And Exosome Shedding Inhibition By Targeting ATP7A.Onco Targets Ther. 2019 Dec 6;12:10727-10737. doi: 10.2147/OTT.S221236. eCollection 2019.
562 A water-soluble polysaccharide from the roots of Polygala tenuifolia suppresses ovarian tumor growth and angiogenesis in vivo.Int J Biol Macromol. 2018 Feb;107(Pt A):713-718. doi: 10.1016/j.ijbiomac.2017.09.043. Epub 2017 Sep 15.
563 A systematic study on drug-response associated genes using baseline gene expressions of the Cancer Cell Line Encyclopedia.Sci Rep. 2016 Mar 10;6:22811. doi: 10.1038/srep22811.
564 SLC27A2 regulates miR-411 to affect chemo-resistance in ovarian cancer.Neoplasma. 2018 Nov 15;65(6):915-924. doi: 10.4149/neo_2018_180122N48. Epub 2018 Sep 4.
565 GLUT5 increases fructose utilization in ovarian cancer.Onco Targets Ther. 2019 Jul 8;12:5425-5436. doi: 10.2147/OTT.S205522. eCollection 2019.
566 MiRNA-8073 targets ZnT1 to inhibit malignant progression of ovarian cancer.Eur Rev Med Pharmacol Sci. 2019 Jul;23(14):6062-6069. doi: 10.26355/eurrev_201907_18419.
567 Universal BRCA1/BRCA2 Testing for Ovarian Cancer Patients is Welcomed, but with Care: How Women and Staff Contextualize Experiences of Expanded Access.J Genet Couns. 2017 Dec;26(6):1280-1291. doi: 10.1007/s10897-017-0108-5. Epub 2017 May 24.
568 The novel ZIP4 regulation and its role in ovarian cancer.Oncotarget. 2017 Sep 30;8(52):90090-90107. doi: 10.18632/oncotarget.21435. eCollection 2017 Oct 27.
569 High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer. PLoS One. 2017 Nov 1;12(11):e0187385.
570 Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.Nat Genet. 2017 May;49(5):680-691. doi: 10.1038/ng.3826. Epub 2017 Mar 27.
571 Overexpression of dihydrodiol dehydrogenase is associated with cisplatin-based chemotherapy resistance in ovarian cancer patients.Gynecol Oncol. 2005 Apr;97(1):110-7. doi: 10.1016/j.ygyno.2004.12.031.
572 Decreased expression of CYP27B1 correlates with the increased aggressiveness of ovarian carcinomas.Oncol Rep. 2015 Feb;33(2):599-606. doi: 10.3892/or.2014.3666. Epub 2014 Dec 11.
573 The ABO Blood Group is an Independent Prognostic Factor in Patients with Ovarian Cancer.J Cancer. 2019 Oct 22;10(26):6754-6760. doi: 10.7150/jca.36236. eCollection 2019.
574 ALDH1A2 Is a Candidate Tumor Suppressor Gene in Ovarian Cancer.Cancers (Basel). 2019 Oct 14;11(10):1553. doi: 10.3390/cancers11101553.
575 Asparagine Synthetase and Filamin A Have Different Roles in Ovarian Cancer.Front Oncol. 2019 Oct 18;9:1072. doi: 10.3389/fonc.2019.01072. eCollection 2019.
576 Association between EPHX1 polymorphism rs1051740 and the risk of ovarian cancer: a meta-analysis.Artif Cells Nanomed Biotechnol. 2019 Dec;47(1):2338-2342. doi: 10.1080/21691401.2019.1622551.
577 Glutamine-fructose-6-phosphate transaminase 2 (GFPT2) promotes the EMT of serous ovarian cancer by activating the hexosamine biosynthetic pathway to increase the nuclear location of -catenin.Pathol Res Pract. 2019 Dec;215(12):152681. doi: 10.1016/j.prp.2019.152681. Epub 2019 Oct 3.
578 -Glutamyl cyclotransferase contributes to tumor progression in high grade serous ovarian cancer by regulating epithelial-mesenchymal transition via activating PI3K/AKT/mTOR pathway.Gynecol Oncol. 2018 Apr;149(1):163-172. doi: 10.1016/j.ygyno.2018.01.023. Epub 2018 Feb 9.
579 FIH Is an Oxygen Sensor in Ovarian Cancer for G9a/GLP-Driven Epigenetic Regulation of Metastasis-Related Genes.Cancer Res. 2018 Mar 1;78(5):1184-1199. doi: 10.1158/0008-5472.CAN-17-2506. Epub 2017 Dec 19.
580 The Expression of HSD17B12 Is Associated with COX-2 Expression and Is Increased in High-Grade Epithelial Ovarian Cancer.Oncology. 2018;94(4):233-242. doi: 10.1159/000485624. Epub 2018 Jan 12.
581 Analysis of 17beta-hydroxysteroid dehydrogenase types 5, 7, and 12 genetic sequence variants in breast cancer cases from French Canadian Families with high risk of breast and ovarian cancer.J Steroid Biochem Mol Biol. 2009 Sep;116(3-5):134-53. doi: 10.1016/j.jsbmb.2009.05.005. Epub 2009 May 19.
582 MicroRNA-18a inhibits ovarian cancer growth via directly targeting TRIAP1 and IPMK.Oncol Lett. 2017 Jun;13(6):4039-4046. doi: 10.3892/ol.2017.5961. Epub 2017 Mar 31.
583 Value of [18F]FDG-PET/CT and CA125, serum levels and kinetic parameters, in early detection of ovarian cancer recurrence: Influence of histological subtypes and tumor stages.Medicine (Baltimore). 2018 Apr;97(17):e0098. doi: 10.1097/MD.0000000000010098.
584 Paraoxonase 2 overexpression inhibits tumor development in a mouse model of ovarian cancer.Cell Death Dis. 2018 Mar 12;9(3):392. doi: 10.1038/s41419-018-0395-2.
585 Overexpression of microRNA-195-5p reduces cisplatin resistance and angiogenesis in ovarian cancer by inhibiting the PSAT1-dependent GSK3/-catenin signaling pathway.J Transl Med. 2019 Jun 6;17(1):190. doi: 10.1186/s12967-019-1932-1.
586 Expression and biological role of the prostaglandin D synthase/SOX9 pathway in human ovarian cancer cells.Cancer Lett. 2007 Oct 8;255(2):182-93. doi: 10.1016/j.canlet.2007.04.007. Epub 2007 May 29.
587 Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia.Adv Exp Med Biol. 2008;617:359-66. doi: 10.1007/978-0-387-69080-3_34.
588 A novel p70 S6 kinase-microRNA biogenesis axis mediates multicellular spheroid formation in ovarian cancer progression.Oncotarget. 2016 Jun 21;7(25):38064-38077. doi: 10.18632/oncotarget.9345.
589 ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.J Pathol. 2020 Feb;250(2):159-169. doi: 10.1002/path.5356. Epub 2019 Dec 3.
590 Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer.Br J Cancer. 2001 Sep 28;85(7):1032-6. doi: 10.1054/bjoc.2001.2034.
591 Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Basic Clin Pharmacol Toxicol. 2012 Feb;110(2):199-204. doi: 10.1111/j.1742-7843.2011.00802.x. Epub 2011 Oct 25.
592 Role of decreased levels of lipid phosphate phosphatase-1 in accumulation of lysophosphatidic acid in ovarian cancer.Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3534-45.
593 Spermidine/spermine N1-acetyltransferase transient overexpression restores sensitivity of resistant human ovarian cancer cells to N1,N12-bis(ethyl)spermine and to cisplatin.Carcinogenesis. 2005 Oct;26(10):1677-86. doi: 10.1093/carcin/bgi129. Epub 2005 May 19.
594 Systematic Analysis of Gene Expression Alterations and Clinical Outcomes for Long-Chain Acyl-Coenzyme A Synthetase Family in Cancer.PLoS One. 2016 May 12;11(5):e0155660. doi: 10.1371/journal.pone.0155660. eCollection 2016.
595 Frequent translocations of 11q13.2 and 19p13.2 in ovarian cancer.Genes Chromosomes Cancer. 2014 Jun;53(6):447-53. doi: 10.1002/gcc.22152. Epub 2014 Feb 24.
596 Common variants at 19p13 are associated with susceptibility to ovarian cancer.Nat Genet. 2010 Oct;42(10):880-4. doi: 10.1038/ng.666. Epub 2010 Sep 19.
597 Secretion of annexin A3 from ovarian cancer cells and its association with platinum resistance in ovarian cancer patients.J Cell Mol Med. 2012 Feb;16(2):337-48. doi: 10.1111/j.1582-4934.2011.01316.x.
598 LncRNA CACS15 accelerates the malignant progression of ovarian cancer through stimulating EZH2-induced inhibition of APC.Am J Transl Res. 2019 Oct 15;11(10):6561-6568. eCollection 2019.
599 Down-regulated aquaporin 5 inhibits proliferation and migration of human epithelial ovarian cancer 3AO cells.J Ovarian Res. 2014 Aug 15;7:78. doi: 10.1186/s13048-014-0078-2.
600 ASPM and microcephalin expression in epithelial ovarian cancer correlates with tumour grade and survival.Br J Cancer. 2011 May 10;104(10):1602-10. doi: 10.1038/bjc.2011.117. Epub 2011 Apr 19.
601 ATP11B mediates platinum resistance in ovarian cancer.J Clin Invest. 2013 May;123(5):2119-30. doi: 10.1172/JCI65425. Epub 2013 Apr 15.
602 An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population.Mol Diagn Ther. 2014 Feb;18(1):85-91. doi: 10.1007/s40291-013-0059-y.
603 BAMBI is overexpressed in ovarian cancer and co-translocates with Smads into the nucleus upon TGF-beta treatment.Gynecol Oncol. 2010 May;117(2):189-97. doi: 10.1016/j.ygyno.2009.12.034. Epub 2010 Feb 26.
604 Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death.J Natl Cancer Inst. 2011 Nov 2;103(21):1596-612. doi: 10.1093/jnci/djr372. Epub 2011 Sep 28.
605 Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues.Int J Oncol. 2013 Dec;43(6):1925-34. doi: 10.3892/ijo.2013.2124. Epub 2013 Oct 3.
606 BMPR1B up-regulation via a miRNA binding site variation defines endometriosis susceptibility and CA125 levels.PLoS One. 2013 Dec 5;8(12):e80630. doi: 10.1371/journal.pone.0080630. eCollection 2013.
607 CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells.Oncotarget. 2010 Sep;1(5):329-38. doi: 10.18632/oncotarget.165.
608 CD164 regulates the tumorigenesis of ovarian surface epithelial cells through the SDF-1/CXCR4 axis.Mol Cancer. 2013 Oct 5;12(1):115. doi: 10.1186/1476-4598-12-115.
609 Human chorionic gonadotropin beta subunit genes CGB1 and CGB2 are transcriptionally active in ovarian cancer.Int J Mol Sci. 2013 Jun 17;14(6):12650-60. doi: 10.3390/ijms140612650.
610 Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients.Br J Cancer. 2012 Jan 3;106(1):189-98. doi: 10.1038/bjc.2011.510. Epub 2011 Nov 22.
611 CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis.Tumour Biol. 2012 Dec;33(6):2299-306. doi: 10.1007/s13277-012-0492-2. Epub 2012 Aug 25.
612 MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1.FEBS Lett. 2013 May 2;587(9):1434-9. doi: 10.1016/j.febslet.2013.03.023. Epub 2013 Mar 20.
613 CHM-1 induces apoptosis via p38-mediated upregulation of DR5 expression in human ovarian cancer SKOV3 cells.Eur J Pharmacol. 2011 Nov 16;670(1):96-104. doi: 10.1016/j.ejphar.2011.08.006. Epub 2011 Sep 3.
614 EZH2 regulates expression of p57 and contributes to progression of ovarian cancer in vitro and in vivo.Cancer Sci. 2011 Mar;102(3):530-9. doi: 10.1111/j.1349-7006.2010.01836.x. Epub 2011 Jan 18.
615 Flaxseed enriched diet-mediated reduction in ovarian cancer severity is correlated to the reduction of prostaglandin E(2) in laying hen ovaries.Prostaglandins Leukot Essent Fatty Acids. 2013 Sep;89(4):179-87. doi: 10.1016/j.plefa.2013.08.001. Epub 2013 Aug 14.
616 Expression and biological role of -catenin in human ovarian cancer.J Cancer Res Clin Oncol. 2012 Oct;138(10):1769-76. doi: 10.1007/s00432-012-1257-4. Epub 2012 Jun 15.
617 Upregulation of DLX5 promotes ovarian cancer cell proliferation by enhancing IRS-2-AKT signaling.Cancer Res. 2010 Nov 15;70(22):9197-206. doi: 10.1158/0008-5472.CAN-10-1568. Epub 2010 Nov 2.
618 Doc-2/hDab2 expression is up-regulated in primary pancreatic cancer but reduced in metastasis.Lab Invest. 2001 Jun;81(6):863-73. doi: 10.1038/labinvest.3780295.
619 Loss of DOK2 induces carboplatin resistance in ovarian cancer via suppression of apoptosis.Gynecol Oncol. 2013 Aug;130(2):369-76. doi: 10.1016/j.ygyno.2013.05.002. Epub 2013 May 14.
620 Systematic CpG islands methylation profiling of genes in the wnt pathway in epithelial ovarian cancer identifies biomarkers of progression-free survival.Clin Cancer Res. 2011 Jun 15;17(12):4052-62. doi: 10.1158/1078-0432.CCR-10-3021. Epub 2011 Apr 1.
621 Microcell-mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers.Neoplasia. 2010 Jul;12(7):579-89. doi: 10.1593/neo.10340.
622 Integrity of SOS1/EPS8/ABI1 tri-complex determines ovarian cancer metastasis.Cancer Res. 2010 Dec 1;70(23):9979-90. doi: 10.1158/0008-5472.CAN-10-2394. Epub 2010 Nov 30.
623 Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization.Oncogene. 2011 Jun 23;30(25):2874-87. doi: 10.1038/onc.2011.11. Epub 2011 Feb 21.
624 Ficolin-2 and ficolin-3 in women with malignant and benign ovarian tumours.Cancer Immunol Immunother. 2013 Aug;62(8):1411-9. doi: 10.1007/s00262-013-1445-3. Epub 2013 Jun 7.
625 C4orf7 contributes to ovarian cancer metastasis by promoting cancer cell migration and invasion.Oncol Rep. 2010 Oct;24(4):933-9.
626 The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.PLoS One. 2015 Sep 30;10(9):e0138692. doi: 10.1371/journal.pone.0138692. eCollection 2015.
627 Methylation analysis of tumour suppressor genes in ovarian cancer using MS-MLPA.Folia Biol (Praha). 2012;58(6):246-50.
628 Suppression of GNAI2 message in ovarian cancer.J Ovarian Res. 2014 Jan 14;7:6. doi: 10.1186/1757-2215-7-6.
629 Relations between GPR4 expression, microvascular density (MVD) and clinical pathological characteristics of patients with epithelial ovarian carcinoma (EOC).Curr Pharm Des. 2014;20(11):1904-16. doi: 10.2174/13816128113199990530.
630 Low penetrance alleles as risk modifiers in familial and sporadic breast cancer.Fam Cancer. 2012 Dec;11(4):629-36. doi: 10.1007/s10689-012-9563-1.
631 Genome-scale screen for DNA methylation-based detection markers for ovarian cancer.PLoS One. 2011;6(12):e28141. doi: 10.1371/journal.pone.0028141. Epub 2011 Dec 7.
632 Let-7 modulates acquired resistance of ovarian cancer to Taxanes via IMP-1-mediated stabilization of multidrug resistance 1.Int J Cancer. 2012 Apr 15;130(8):1787-97. doi: 10.1002/ijc.26190. Epub 2011 Aug 16.
633 Comparison of Inhibin Alpha Subunit and Antimllerian Hormone Immunoreactivity in Granulosa Cell and Mucinous Ovarian Tumors.Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):71-77. doi: 10.1097/PAI.0000000000000251.
634 Role of Jagged1/STAT3 signalling in platinum-resistant ovarian cancer.J Cell Mol Med. 2019 Jun;23(6):4005-4018. doi: 10.1111/jcmm.14286. Epub 2019 Apr 16.
635 Endothelial cell junctional adhesion molecule C plays a key role in the development of tumors in a murine model of ovarian cancer.FASEB J. 2013 Oct;27(10):4244-53. doi: 10.1096/fj.13-230441. Epub 2013 Jul 3.
636 KLK10 exon 3 unmethylated PCR product concentration: a new potential early diagnostic marker in ovarian cancer? - A pilot study.J Ovarian Res. 2018 Apr 24;11(1):32. doi: 10.1186/s13048-018-0407-y.
637 Epigenetic silencing of the LDOC1 tumor suppressor gene in ovarian cancer cells.Arch Gynecol Obstet. 2014 Jul;290(1):149-54. doi: 10.1007/s00404-014-3177-9. Epub 2014 Feb 21.
638 Nanoparticle-mediated delivery of siRNA targeting Parp1 extends survival of mice bearing tumors derived from Brca1-deficient ovarian cancer cells.Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):745-50. doi: 10.1073/pnas.1016538108. Epub 2010 Dec 27.
639 Identification of LMX1B as a novel oncogene in human ovarian cancer.Oncogene. 2014 Aug 14;33(33):4226-35. doi: 10.1038/onc.2013.375. Epub 2013 Sep 23.
640 Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer.Mol Cancer Ther. 2013 Jun;12(6):937-49. doi: 10.1158/1535-7163.MCT-12-1082. Epub 2013 Mar 27.
641 Knockdown of mediator complex subunit 19 inhibits the growth of ovarian cancer.Mol Med Rep. 2012 Nov;6(5):1050-6. doi: 10.3892/mmr.2012.1065. Epub 2012 Sep 5.
642 Correlation between germline mutations in MMR genes and microsatellite instability in ovarian cancer specimens.Fam Cancer. 2017 Jul;16(3):351-355. doi: 10.1007/s10689-017-9973-1.
643 Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma.Mod Pathol. 2012 Dec;25(12):1644-53. doi: 10.1038/modpathol.2012.118. Epub 2012 Jul 13.
644 Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel.Acta Pharmacol Sin. 2013 Apr;34(4):541-8. doi: 10.1038/aps.2012.197. Epub 2013 Mar 11.
645 NFATC1 promotes cell growth and tumorigenesis in ovarian cancer up-regulating c-Myc through ERK1/2/p38 MAPK signal pathway.Tumour Biol. 2016 Apr;37(4):4493-500. doi: 10.1007/s13277-015-4245-x. Epub 2015 Oct 26.
646 Common variation in Nemo-like kinase is associated with risk of ovarian cancer.Cancer Epidemiol Biomarkers Prev. 2012 Mar;21(3):523-8. doi: 10.1158/1055-9965.EPI-11-0797. Epub 2012 Jan 17.
647 MicroRNA-363 inhibits ovarian cancer progression by inhibiting NOB1.Oncotarget. 2017 Sep 30;8(60):101649-101658. doi: 10.18632/oncotarget.21417. eCollection 2017 Nov 24.
648 Expression and functional pathway analysis of nuclear receptor NR2F2 in ovarian cancer.J Clin Endocrinol Metab. 2013 Jul;98(7):E1152-62. doi: 10.1210/jc.2013-1081. Epub 2013 May 20.
649 Discovery of an orally active small-molecule irreversible inhibitor of protein disulfide isomerase for ovarian cancer treatment.Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16348-53. doi: 10.1073/pnas.1205226109. Epub 2012 Sep 17.
650 PES1 differentially regulates the expression of ER and ER in ovarian cancer.IUBMB Life. 2013 Dec;65(12):1017-25. doi: 10.1002/iub.1228. Epub 2013 Nov 24.
651 Plexin-B1 silencing inhibits ovarian cancer cell migration and invasion.BMC Cancer. 2010 Nov 8;10:611. doi: 10.1186/1471-2407-10-611.
652 PMS2 germline mutation c.943C>T (p.Arg315*)-induced Lynch syndrome-associated ovarian cancer.Mol Genet Genomic Med. 2019 Jun;7(6):e721. doi: 10.1002/mgg3.721. Epub 2019 May 5.
653 Myofibrillogenesis regulator 1 (MR-1) is a novel biomarker and potential therapeutic target for human ovarian cancer.BMC Cancer. 2011 Jun 25;11:270. doi: 10.1186/1471-2407-11-270.
654 iASPP and chemoresistance in ovarian cancers: effects on paclitaxel-mediated mitotic catastrophe.Clin Cancer Res. 2011 Nov 1;17(21):6924-33. doi: 10.1158/1078-0432.CCR-11-0588. Epub 2011 Sep 16.
655 Human ovarian cancer stroma contains luteinized theca cells harboring tumor suppressor gene GT198 mutations.J Biol Chem. 2013 Nov 15;288(46):33387-97. doi: 10.1074/jbc.M113.485581. Epub 2013 Oct 4.
656 Rab5a overexpression promoting ovarian cancer cell proliferation may be associated with APPL1-related epidermal growth factor signaling pathway.Cancer Sci. 2010 Jun;101(6):1454-62. doi: 10.1111/j.1349-7006.2010.01558.x. Epub 2010 Mar 10.
657 RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation.Mol Cancer Res. 2012 Sep;10(9):1169-77. doi: 10.1158/1541-7786.MCR-12-0331. Epub 2012 Jul 13.
658 Small ribosomal protein subunit S7 suppresses ovarian tumorigenesis through regulation of the PI3K/AKT and MAPK pathways.PLoS One. 2013 Nov 11;8(11):e79117. doi: 10.1371/journal.pone.0079117. eCollection 2013.
659 Mutation analysis of the SHFM1 gene in breast/ovarian cancer families.J Cancer Res Clin Oncol. 2013 Mar;139(3):529-32. doi: 10.1007/s00432-013-1385-5. Epub 2013 Feb 1.
660 Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer.Mol Cancer. 2018 Jun 21;17(1):96. doi: 10.1186/s12943-018-0844-7.
661 Cisplatin-induced downregulation of SOX1 increases drug resistance by activating autophagy in non-small cell lung cancer cell.Biochem Biophys Res Commun. 2013 Sep 20;439(2):187-90. doi: 10.1016/j.bbrc.2013.08.065. Epub 2013 Aug 29.
662 NSSR1 is regulated by testosterone in the mouse uterus and extensively expressed in endometrial carcinoma.Tumour Biol. 2011 Apr;32(2):359-66. doi: 10.1007/s13277-010-0128-3. Epub 2010 Nov 12.
663 Frequent hypermethylation and loss of heterozygosity of the testis derived transcript gene in ovarian cancer.Cancer Sci. 2010 May;101(5):1255-60. doi: 10.1111/j.1349-7006.2010.01497.x. Epub 2010 Jan 18.
664 Transcriptional regulation of hTREX84 in human cancer cells.PLoS One. 2012;7(8):e43610. doi: 10.1371/journal.pone.0043610. Epub 2012 Aug 27.
665 Inhibitory effect of soluble EP2 receptor on ovarian tumor growth in nude mice and utility of TMPRSS4 as a combinatorial molecular target.Int J Oncol. 2013 Aug;43(2):416-24. doi: 10.3892/ijo.2013.1957. Epub 2013 May 24.
666 DcR3 binds to ovarian cancer via heparan sulfate proteoglycans and modulates tumor cells response to platinum with corresponding alteration in the expression of BRCA1.BMC Cancer. 2012 May 14;12:176. doi: 10.1186/1471-2407-12-176.
667 STAMP alters the growth of transformed and ovarian cancer cells.BMC Cancer. 2010 Apr 7;10:128. doi: 10.1186/1471-2407-10-128.
668 Expression and function of HOXA genes in normal and neoplastic ovarian epithelial cells.Differentiation. 2009 Feb;77(2):162-71. doi: 10.1016/j.diff.2008.09.018. Epub 2008 Oct 25.
669 Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility.Tumour Biol. 2014 Apr;35(4):3385-9. doi: 10.1007/s13277-013-1446-z. Epub 2013 Nov 28.
670 The H3K9 methyltransferase G9a is a marker of aggressive ovarian cancer that promotes peritoneal metastasis.Mol Cancer. 2014 Aug 12;13:189. doi: 10.1186/1476-4598-13-189.
671 Unique pattern of component gene disruption in the NRF2 inhibitor KEAP1/CUL3/RBX1 E3-ubiquitin ligase complex in serous ovarian cancer.Biomed Res Int. 2014;2014:159459. doi: 10.1155/2014/159459. Epub 2014 Jul 9.
672 Threonyl-tRNA synthetase overexpression correlates with angiogenic markers and progression of human ovarian cancer.BMC Cancer. 2014 Aug 27;14:620. doi: 10.1186/1471-2407-14-620.
673 Cathepsin B and its interacting proteins, bikunin and TSRC1, correlate with TNF-induced apoptosis of ovarian cancer cells OV-90.FEBS Lett. 2006 Jan 9;580(1):245-50. doi: 10.1016/j.febslet.2005.12.005. Epub 2005 Dec 12.
674 Proteomic profiling identifies afamin as a potential biomarker for ovarian cancer.Clin Cancer Res. 2007 Dec 15;13(24):7370-9. doi: 10.1158/1078-0432.CCR-07-0747.
675 Frequent inactivation of a putative tumor suppressor, angiopoietin-like protein 2, in ovarian cancer.Cancer Res. 2008 Jul 1;68(13):5067-75. doi: 10.1158/0008-5472.CAN-08-0062.
676 Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.Int J Cancer. 2009 Sep 15;125(6):1454-63. doi: 10.1002/ijc.24546.
677 Phosphorylation of ATR-interacting protein on Ser239 mediates an interaction with breast-ovarian cancer susceptibility 1 and checkpoint function.Cancer Res. 2007 Jul 1;67(13):6100-5. doi: 10.1158/0008-5472.CAN-07-0369.
678 Five genes from chromosomal band 8p22 are significantly down-regulated in ovarian carcinoma: N33 and EFA6R have a potential impact on overall survival.Cancer. 2005 Dec 1;104(11):2417-29. doi: 10.1002/cncr.21538.
679 Epigenetic silencing of TCEAL7 (Bex4) in ovarian cancer.Oncogene. 2005 Jul 28;24(32):5089-100. doi: 10.1038/sj.onc.1208700.
680 Mechanisms of Cables 1 gene inactivation in human ovarian cancer development.Cancer Biol Ther. 2008 Feb;7(2):180-88. doi: 10.4161/cbt.7.2.5253. Epub 2007 Nov 15.
681 Distribution of microsatellite instability in Danish ovarian tumor patients and the prognostic value in ovarian cancer patients.Oncol Res. 2008;17(1):43-9. doi: 10.3727/096504008784046090.
682 Tumor-associated alterations in caspase-14 expression in epithelial malignancies.Clin Cancer Res. 2005 Aug 1;11(15):5462-71. doi: 10.1158/1078-0432.CCR-04-2527.
683 Regulators of mitotic arrest and ceramide metabolism are determinants of sensitivity to paclitaxel and other chemotherapeutic drugs.Cancer Cell. 2007 Jun;11(6):498-512. doi: 10.1016/j.ccr.2007.04.011.
684 Overexpression of CHP2 enhances tumor cell growth, invasion and metastasis in ovarian cancer.In Vivo. 2007 Jul-Aug;21(4):593-8.
685 Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer.Int J Gynecol Cancer. 2009 May;19(4):513-25. doi: 10.1111/IGC.0b013e3181a3cd38.
686 Cooperation between BRCA1 and p53 in repair of cyclobutane pyrimidine dimers.Cancer Biol Ther. 2005 Dec;4(12):1409-14. doi: 10.4161/cbt.4.12.2378. Epub 2005 Dec 5.
687 Characterization of a putative ovarian oncogene, elongation factor 1alpha, isolated by panning a synthetic phage display single-chain variable fragment library with cultured human ovarian cancer cells.Clin Cancer Res. 2007 Oct 1;13(19):5889-96. doi: 10.1158/1078-0432.CCR-07-0703.
688 Molecular pathogenesis of Fanconi anemia: recent progress.Blood. 2006 Jun 1;107(11):4223-33. doi: 10.1182/blood-2005-10-4240. Epub 2006 Feb 21.
689 Overexpression of FOXG1 contributes to TGF-beta resistance through inhibition of p21WAF1/CIP1 expression in ovarian cancer.Br J Cancer. 2009 Oct 20;101(8):1433-43. doi: 10.1038/sj.bjc.6605316. Epub 2009 Sep 15.
690 Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours.Br J Cancer. 2006 Mar 13;94(5):686-91. doi: 10.1038/sj.bjc.6602988.
691 Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation.Oncotarget. 2014 Jan 30;5(2):544-60. doi: 10.18632/oncotarget.1652.
692 Transcriptome analysis of serous ovarian cancers identifies differentially expressed chromosome 3 genes.Mol Carcinog. 2008 Jan;47(1):56-65. doi: 10.1002/mc.20361.
693 Induction of human tumor-associated differentially expressed gene-12 (TADG-12/TMPRSS3)-specific cytotoxic T lymphocytes in human lymphocyte antigen-A2.1-positive healthy donors and patients with advanced ovarian cancer.Cancer. 2009 Feb 15;115(4):800-11. doi: 10.1002/cncr.24048.
694 Epigenetic and genetic alterations of p33ING1b in ovarian cancer.Carcinogenesis. 2005 Apr;26(4):855-63. doi: 10.1093/carcin/bgi011. Epub 2005 Jan 27.
695 Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro.J Exp Clin Cancer Res. 2008 Nov 27;27(1):77. doi: 10.1186/1756-9966-27-77.
696 Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer.Int J Cancer. 2009 May 15;124(10):2353-60. doi: 10.1002/ijc.24214.
697 Mac-2 binding protein and galectin-3 expression in mucinous tumours of the ovary: an annealing control primer system and immunohistochemical study.Pathology. 2009;41(3):229-33. doi: 10.1080/00313020902756279.
698 ORCA-010, a novel potency-enhanced oncolytic adenovirus, exerts strong antitumor activity in preclinical models.Hum Gene Ther. 2014 Oct;25(10):897-904. doi: 10.1089/hum.2013.229. Epub 2014 Sep 17.
699 Mutation and expression analysis of LZTS1 in ovarian cancer.Cancer Lett. 2006 Feb 20;233(1):151-7. doi: 10.1016/j.canlet.2005.03.008.
700 A gene signature predictive for outcome in advanced ovarian cancer identifies a survival factor: microfibril-associated glycoprotein 2.Cancer Cell. 2009 Dec 8;16(6):521-32. doi: 10.1016/j.ccr.2009.10.018.
701 Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study.Hum Mol Genet. 2009 Jun 15;18(12):2297-304. doi: 10.1093/hmg/ddp138. Epub 2009 Mar 20.
702 The metastasis-associated gene MTA1 is upregulated in advanced ovarian cancer, represses ERbeta, and enhances expression of oncogenic cytokine GRO.Cancer Biol Ther. 2008 Sep;7(9):1460-7. doi: 10.4161/cbt.7.9.6427. Epub 2008 Sep 11.
703 Polymorphisms in NF-kappaB inhibitors and risk of epithelial ovarian cancer.BMC Cancer. 2009 Jun 6;9:170. doi: 10.1186/1471-2407-9-170.
704 Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer.Br J Cancer. 2009 Mar 24;100(6):993-1001. doi: 10.1038/sj.bjc.6604947. Epub 2009 Feb 24.
705 SPOC1, a novel PHD-finger protein: association with residual disease and survival in ovarian cancer.Int J Cancer. 2005 Sep 10;116(4):547-54. doi: 10.1002/ijc.20912.
706 Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis.Br J Cancer. 2009 Oct 20;101(8):1461-8. doi: 10.1038/sj.bjc.6605284. Epub 2009 Sep 8.
707 pRb2/p130 decreases sensitivity to apoptosis induced by camptothecin and doxorubicin but not by taxol. Clin Cancer Res. 2004 Dec 1;10(23):8085-93. doi: 10.1158/1078-0432.CCR-04-0996.
708 Alternative splicing of the multidrug resistance protein 1/ATP binding cassette transporter subfamily gene in ovarian cancer creates functional splice variants and is associated with increased expression of the splicing factors PTB and SRp20.Clin Cancer Res. 2004 Jul 15;10(14):4652-60. doi: 10.1158/1078-0432.CCR-03-0439.
709 RAD52 Y415X truncation polymorphism and epithelial ovarian cancer risk in Australian women.Cancer Lett. 2005 Feb 10;218(2):191-7. doi: 10.1016/j.canlet.2004.09.023.
710 Sohlh2 inhibits human ovarian cancer cell invasion and metastasis by transcriptional inactivation of MMP9.Mol Carcinog. 2016 Jul;55(7):1127-37. doi: 10.1002/mc.22355. Epub 2015 Jul 8.
711 Identification of a common polymorphism in the TopBP1 gene associated with hereditary susceptibility to breast and ovarian cancer.Eur J Cancer. 2006 Oct;42(15):2647-52. doi: 10.1016/j.ejca.2006.05.030. Epub 2006 Aug 23.
712 Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.Int J Cancer. 2005 Dec 20;117(6):1049-54. doi: 10.1002/ijc.21250.
713 The chemokine growth-regulated oncogene 1 (Gro-1) links RAS signaling to the senescence of stromal fibroblasts and ovarian tumorigenesis.Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16472-7. doi: 10.1073/pnas.0605752103. Epub 2006 Oct 23.
714 Suppression of ABHD2, identified through a functional genomics screen, causes anoikis resistance, chemoresistance and poor prognosis in ovarian cancer.Oncotarget. 2016 Jul 26;7(30):47620-47636. doi: 10.18632/oncotarget.9951.
715 Inhibitory short peptides targeting EPS8/ABI1/SOS1 tri-complex suppress invasion and metastasis of ovarian cancer cells.BMC Cancer. 2019 Sep 5;19(1):878. doi: 10.1186/s12885-019-6087-1.
716 Evaluation of the BRCA1 interacting genes RAP80 and CCDC98 in familial breast cancer susceptibility.Breast Cancer Res Treat. 2009 Jan;113(2):371-6. doi: 10.1007/s10549-008-9933-4. Epub 2008 Feb 13.
717 Breast and ovarian cancer referrals to the ACT Genetic Service: are we meeting guidelines?.Intern Med J. 2017 Mar;47(3):311-317. doi: 10.1111/imj.13357.
718 ACTL6A regulates follicle-stimulating hormone-driven glycolysis in ovarian cancer cells via PGK1.Cell Death Dis. 2019 Oct 24;10(11):811. doi: 10.1038/s41419-019-2050-y.
719 Actinin-4 gene amplification in ovarian cancer: a candidate oncogene associated with poor patient prognosis and tumor chemoresistance.Mod Pathol. 2009 Apr;22(4):499-507. doi: 10.1038/modpathol.2008.234. Epub 2009 Jan 16.
720 MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci. 2011 Feb 1;124(Pt 3):359-68. doi: 10.1242/jcs.072223. Epub 2011 Jan 11.
721 Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer.Lab Invest. 2010 Mar;90(3):414-25. doi: 10.1038/labinvest.2009.138. Epub 2010 Jan 11.
722 Genome-wide association study (GWAS) of ovarian cancer in Japanese predicted regulatory variants in 22q13.1.PLoS One. 2018 Dec 17;13(12):e0209096. doi: 10.1371/journal.pone.0209096. eCollection 2018.
723 Genome-wide association studies identify susceptibility loci for epithelial ovarian cancer in east Asian women.Gynecol Oncol. 2019 May;153(2):343-355. doi: 10.1016/j.ygyno.2019.02.023. Epub 2019 Mar 19.
724 MicroRNA-503-5p Inhibits the CD97-Mediated JAK2/STAT3 Pathway in Metastatic or Paclitaxel-Resistant Ovarian Cancer Cells.Neoplasia. 2019 Feb;21(2):206-215. doi: 10.1016/j.neo.2018.12.005. Epub 2019 Jan 9.
725 Expression of adiponectin and its receptors is altered in epithelial ovarian tumors and ascites-derived ovarian cancer cell lines.Int J Gynecol Cancer. 2015 Mar;25(3):399-406. doi: 10.1097/IGC.0000000000000369.
726 Integrative proteogenomic analyses of human tumours identifies ADNP as a novel oncogenic mediator of cell cycle progression in high-grade serous ovarian cancer with poor prognosis.EBioMedicine. 2019 Dec;50:191-202. doi: 10.1016/j.ebiom.2019.11.009. Epub 2019 Nov 22.
727 Early and consistent overexpression of ADRM1 in ovarian high-grade serous carcinoma.J Ovarian Res. 2017 Aug 7;10(1):53. doi: 10.1186/s13048-017-0347-y.
728 High expression of AGBL2 is a novel prognostic factor of adverse outcome in patients with ovarian carcinoma.Oncol Lett. 2019 Nov;18(5):4900-4906. doi: 10.3892/ol.2019.10829. Epub 2019 Sep 9.
729 Autophagic degradation of SQSTM1 inhibits ovarian cancer motility by decreasing DICER1 and AGO2 to induce MIRLET7A-3P.Autophagy. 2018;14(12):2065-2082. doi: 10.1080/15548627.2018.1501135. Epub 2018 Aug 17.
730 Elevated AKAP12 in paclitaxel-resistant serous ovarian cancer cells is prognostic and predictive of poor survival in patients.J Proteome Res. 2015 Apr 3;14(4):1900-10. doi: 10.1021/pr5012894. Epub 2015 Mar 19.
731 Identification of the cancer/testis antigens AKAP3 and CTp11 by SEREX in hepatocellular carcinoma.Oncol Rep. 2012 Nov;28(5):1792-8. doi: 10.3892/or.2012.2002. Epub 2012 Aug 30.
732 Ovarian cancer detection by DNA methylation in cervical scrapings.Clin Epigenetics. 2019 Nov 27;11(1):166. doi: 10.1186/s13148-019-0773-3.
733 Molecular cloning of differentially expressed genes in human epithelial ovarian cancer.Gynecol Oncol. 1994 Feb;52(2):247-52. doi: 10.1006/gyno.1994.1040.
734 Whole-exome sequencing of ovarian cancer families uncovers putative predisposition genes.Int J Cancer. 2020 Apr 15;146(8):2147-2155. doi: 10.1002/ijc.32545. Epub 2019 Jul 16.
735 The role of annexin A4 in cancer.Front Biosci (Landmark Ed). 2016 Jun 1;21(5):949-57. doi: 10.2741/4432.
736 Luteolin promotes the sensitivity of cisplatin in ovarian cancer by decreasing PRPA1-medicated autophagy.Cell Mol Biol (Noisy-le-grand). 2018 May 15;64(6):17-22.
737 APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.Gynecol Oncol. 2017 Dec;147(3):663-671. doi: 10.1016/j.ygyno.2017.10.016. Epub 2017 Oct 24.
738 APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma.Histol Histopathol. 2019 Apr;34(4):405-417. doi: 10.14670/HH-18-050. Epub 2018 Oct 5.
739 CXCL12 promotes human ovarian cancer cell invasion through suppressing ARHGAP10 expression.Biochem Biophys Res Commun. 2019 Oct 20;518(3):416-422. doi: 10.1016/j.bbrc.2019.07.098. Epub 2019 Aug 22.
740 Rgnef promotes ovarian tumor progression and confers protection from oxidative stress.Oncogene. 2019 Sep;38(36):6323-6337. doi: 10.1038/s41388-019-0881-8. Epub 2019 Jul 15.
741 ARID3B Directly Regulates Ovarian Cancer Promoting Genes.PLoS One. 2015 Jun 29;10(6):e0131961. doi: 10.1371/journal.pone.0131961. eCollection 2015.
742 Association of the ARLTS1 variants with familial ovarian cancer risk in China.Int J Gynecol Cancer. 2009 May;19(4):585-90. doi: 10.1111/IGC.0b013e3181a39d03.
743 Uterine and ovarian aryl hydrocarbon receptor (AHR) and aryl hydrocarbon receptor nuclear translocator (ARNT) mRNA expression in benign and malignant gynaecological conditions.Mol Hum Reprod. 2002 Jan;8(1):75-80. doi: 10.1093/molehr/8.1.75.
744 The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib.Cancer Biol Ther. 2018 Feb 1;19(2):132-137. doi: 10.1080/15384047.2017.1394556. Epub 2017 Dec 8.
745 Differentially androgen-modulated genes in ovarian epithelial cells from BRCA mutation carriers and control patients predict ovarian cancer survival and disease progression.Oncogene. 2007 Jan 11;26(2):198-214. doi: 10.1038/sj.onc.1209773. Epub 2006 Jul 10.
746 BAD phosphorylation determines ovarian cancer chemosensitivity and patient survival. Clin Cancer Res. 2011 Oct 1;17(19):6356-66. doi: 10.1158/1078-0432.CCR-11-0735. Epub 2011 Aug 17.
747 Silencing of BAG3 promotes the sensitivity of ovarian cancer cells to cisplatin via inhibition of autophagy.Oncol Rep. 2017 Jul;38(1):309-316. doi: 10.3892/or.2017.5706. Epub 2017 Jun 6.
748 The proto-oncogene Bcl3 induces immune checkpoint PD-L1 expression, mediating proliferation of ovarian cancer cells.J Biol Chem. 2018 Oct 5;293(40):15483-15496. doi: 10.1074/jbc.RA118.004084. Epub 2018 Aug 22.
749 Low BCL7A expression predicts poor prognosis in ovarian cancer.J Ovarian Res. 2019 May 10;12(1):41. doi: 10.1186/s13048-019-0518-0.
750 Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: predictive value of DNA-PK and phosphorylated ACC.Oncotarget. 2016 Nov 8;7(45):72654-72661. doi: 10.18632/oncotarget.12056.
751 Genome-wide investigation of regional blood-based DNA methylation adjusted for complete blood counts implicates BNC2 in ovarian cancer.Genet Epidemiol. 2014 Jul;38(5):457-66. doi: 10.1002/gepi.21815. Epub 2014 May 22.
752 Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.Br J Cancer. 2003 Jan 27;88(2):270-6. doi: 10.1038/sj.bjc.6600674.
753 Narrowing the field: cancer-specific promoters for mitochondrially-targeted p53-BH3 fusion gene therapy in ovarian cancer.J Ovarian Res. 2019 Apr 30;12(1):38. doi: 10.1186/s13048-019-0514-4.
754 Oncogene miR-934 promotes ovarian cancer cell proliferation and inhibits cell apoptosis through targeting BRMS1L.Eur Rev Med Pharmacol Sci. 2019 Jul;23(13):5595-5602. doi: 10.26355/eurrev_201907_18293.
755 BTN3A2 serves as a prognostic marker and favors immune infiltration in triple-negative breast cancer.J Cell Biochem. 2020 Mar;121(3):2643-2654. doi: 10.1002/jcb.29485. Epub 2019 Nov 6.
756 Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer.Cancer Res. 1999 Oct 15;59(20):5370-5.
757 The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.Oncogene. 2012 Apr 26;31(17):2175-86. doi: 10.1038/onc.2011.399. Epub 2011 Sep 19.
758 URI is an oncogene amplified in ovarian cancer cells and is required for their survival. Cancer Cell. 2011 Mar 8;19(3):317-32. doi: 10.1016/j.ccr.2011.01.019.
759 C1GALT1 Seems to Promote In Vitro Disease Progression in Ovarian Cancer.Int J Gynecol Cancer. 2017 Jun;27(5):863-871. doi: 10.1097/IGC.0000000000000965.
760 Knockdown of long non-coding RNA LINC00176 suppresses ovarian cancer progression by BCL3-mediated down-regulation of ceruloplasmin.J Cell Mol Med. 2020 Jan;24(1):202-213. doi: 10.1111/jcmm.14701. Epub 2019 Oct 30.
761 It is not all about BRCA: Cullin-Ring ubiquitin Ligases in ovarian cancer.Br J Cancer. 2015 Jan 6;112(1):9-13. doi: 10.1038/bjc.2014.594. Epub 2014 Dec 9.
762 CALB1 enhances the interaction between p53 and MDM2, and inhibits the senescence of ovarian cancer cells.Mol Med Rep. 2019 Jun;19(6):5097-5104. doi: 10.3892/mmr.2019.10212. Epub 2019 Apr 30.
763 Capn4 overexpression indicates poor prognosis of ovarian cancer patients.J Cancer. 2018 Jan 1;9(2):304-309. doi: 10.7150/jca.22004. eCollection 2018.
764 Protein kinase C alpha-CARMA3 signaling axis links Ras to NF-kappa B for lysophosphatidic acid-induced urokinase plasminogen activator expression in ovarian cancer cells.Oncogene. 2008 Feb 21;27(9):1273-80. doi: 10.1038/sj.onc.1210746. Epub 2007 Aug 27.
765 Small molecule inhibition of the CBF/RUNX interaction decreases ovarian cancer growth and migration through alterations in genes related to epithelial-to-mesenchymal transition.Gynecol Oncol. 2018 May;149(2):350-360. doi: 10.1016/j.ygyno.2018.03.005. Epub 2018 Mar 16.
766 CBX2 identified as driver of anoikis escape and dissemination in high grade serous ovarian cancer.Oncogenesis. 2018 Nov 26;7(11):92. doi: 10.1038/s41389-018-0103-1.
767 Coiled-Coil and C2 Domain-Containing Protein 1A (CC2D1A) Promotes Chemotherapy Resistance in Ovarian Cancer.Front Oncol. 2019 Oct 1;9:986. doi: 10.3389/fonc.2019.00986. eCollection 2019.
768 Development of a M cell-targeted microparticulate platform, BSK02? for oral immunization against the ovarian cancer antigen, sperm protein 17.J Biomed Mater Res B Appl Biomater. 2019 Jan;107(1):29-36. doi: 10.1002/jbm.b.34092. Epub 2018 Mar 4.
769 Evaluation of serum CCL18 as a potential biomarker for ovarian cancer.Cancer Biomark. 2017 Dec 12;21(1):97-104. doi: 10.3233/CBM-170305.
770 Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells.Eur J Cancer. 2016 Nov;67:152-163. doi: 10.1016/j.ejca.2016.08.007. Epub 2016 Sep 24.
771 LncRNA HOTAIR Regulates CCND1 and CCND2 Expression by Sponging miR-206 in Ovarian Cancer.Cell Physiol Biochem. 2018;49(4):1289-1303. doi: 10.1159/000493408. Epub 2018 Sep 11.
772 CCNG1 (Cyclin G1) regulation by mutant-P53 via induction of Notch3 expression promotes high-grade serous ovarian cancer (HGSOC) tumorigenesis and progression.Cancer Med. 2019 Jan;8(1):351-362. doi: 10.1002/cam4.1812. Epub 2018 Dec 18.
773 Cyclin G2 is degraded through the ubiquitin-proteasome pathway and mediates the antiproliferative effect of activin receptor-like kinase 7.Mol Biol Cell. 2008 Nov;19(11):4968-79. doi: 10.1091/mbc.e08-03-0259. Epub 2008 Sep 10.
774 APOBEC3B up-regulation independently predicts ovarian cancer prognosis: a cohort study.Cancer Cell Int. 2018 May 29;18:78. doi: 10.1186/s12935-018-0572-5. eCollection 2018.
775 Interrogation of Functional Cell-Surface Markers Identifies CD151 Dependency in High-Grade Serous Ovarian Cancer.Cell Rep. 2017 Mar 7;18(10):2343-2358. doi: 10.1016/j.celrep.2017.02.028.
776 Expression and significance of the protein and mRNA of metastasis suppressor gene ME491/CD63 and integrin alpha5 in ovarian cancer tissues.Eur J Gynaecol Oncol. 2007;28(3):179-83.
777 Alternative splicing of KAI1 abrogates its tumor-suppressive effects on integrin v3-mediated ovarian cancer biology.Cell Signal. 2015 Mar;27(3):652-62. doi: 10.1016/j.cellsig.2014.11.028. Epub 2014 Nov 27.
778 lncRNA UCA1-Mediated Cdc42 Signaling Promotes Oncolytic Vaccinia Virus Cell-to-Cell Spread in Ovarian Cancer.Mol Ther Oncolytics. 2019 Mar 26;13:35-48. doi: 10.1016/j.omto.2019.03.003. eCollection 2019 Jun 28.
779 Prediction of key genes in ovarian cancer treated with decitabine based on network strategy.Oncol Rep. 2016 Jun;35(6):3548-58. doi: 10.3892/or.2016.4697. Epub 2016 Mar 23.
780 MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways.Oncogene. 2019 Aug;38(32):6035-6050. doi: 10.1038/s41388-019-0860-0. Epub 2019 Jul 5.
781 Importance of Cadherins Methylation in Ovarian Cancer: a Next Generation Sequencing Approach.Pathol Oncol Res. 2019 Oct;25(4):1457-1465. doi: 10.1007/s12253-018-0500-y. Epub 2018 Oct 27.
782 MiR-542-3p, a microRNA targeting CDK14, suppresses cell proliferation, invasiveness, and tumorigenesis of epithelial ovarian cancer.Biomed Pharmacother. 2019 Feb;110:850-856. doi: 10.1016/j.biopha.2018.11.104. Epub 2018 Dec 14.
783 Hypermethylation of P15, P16, and E-cadherin genes in ovarian cancer.Toxicol Ind Health. 2015 Oct;31(10):924-30. doi: 10.1177/0748233713484657. Epub 2013 Apr 9.
784 Overexpression of WDFY2 inhibits prostate cancer cell growth and migration via inactivation of Akt pathway.Tumour Biol. 2017 Jun;39(6):1010428317704821. doi: 10.1177/1010428317704821.
785 CDKN3 knockdown reduces cell proliferation, invasion and promotes apoptosis in human ovarian cancer.Int J Clin Exp Pathol. 2015 May 1;8(5):4535-44. eCollection 2015.
786 Utility of paraneoplastic antigens as biomarkers for surveillance and prediction of recurrence in ovarian cancer.Cancer Biomark. 2017 Dec 6;20(4):369-387. doi: 10.3233/CBM-170652.
787 CEMIP promotes ovarian cancer development and progression via the PI3K/AKT signaling pathway.Biomed Pharmacother. 2019 Jun;114:108787. doi: 10.1016/j.biopha.2019.108787. Epub 2019 Mar 27.
788 CircRNA UBAP2 promotes the progression of ovarian cancer by sponging microRNA-144.Eur Rev Med Pharmacol Sci. 2019 Sep;23(17):7283-7294. doi: 10.26355/eurrev_201909_18833.
789 CHD5 Downregulation Associated with Poor Prognosis in Epithelial Ovarian Cancer.Gynecol Obstet Invest. 2011;72(3):203-7. doi: 10.1159/000323883. Epub 2011 Aug 23.
790 The inhibition of UBC13 expression and blockage of the DNMT1-CHFR-Aurora A pathway contribute to paclitaxel resistance in ovarian cancer.Cell Death Dis. 2018 Jan 24;9(2):93. doi: 10.1038/s41419-017-0137-x.
791 The novel, small-molecule DNA methylation inhibitor SGI-110 as an ovarian cancer chemosensitizer.Clin Cancer Res. 2014 Dec 15;20(24):6504-16. doi: 10.1158/1078-0432.CCR-14-1553. Epub 2014 Oct 14.
792 A transcriptome-wide association study of high-grade serous epithelial ovarian cancer identifies new susceptibility genes and splice variants.Nat Genet. 2019 May;51(5):815-823. doi: 10.1038/s41588-019-0395-x. Epub 2019 May 1.
793 The role of natural killer cells in combinatorial anti-cancer therapy using Sindbis viral vectors and irinotecan.Cancer Gene Ther. 2012 Aug;19(8):588-91. doi: 10.1038/cgt.2012.33. Epub 2012 Jun 8.
794 Chordin is underexpressed in ovarian tumors and reduces tumor cell motility.FASEB J. 2006 Feb;20(2):240-50. doi: 10.1096/fj.05-4126com.
795 CIB2 Negatively Regulates Oncogenic Signaling in Ovarian Cancer via Sphingosine Kinase 1.Cancer Res. 2017 Sep 15;77(18):4823-4834. doi: 10.1158/0008-5472.CAN-17-0025. Epub 2017 Jul 20.
796 MiR-1307 influences the chemotherapeutic sensitivity in ovarian cancer cells through the regulation of the CIC transcriptional repressor.Pathol Res Pract. 2019 Oct;215(10):152606. doi: 10.1016/j.prp.2019.152606. Epub 2019 Aug 19.
797 Cross-validation of genes potentially associated with overall survival and drug resistance in ovarian cancer.Oncol Rep. 2017 May;37(5):3084-3092. doi: 10.3892/or.2017.5534. Epub 2017 Mar 27.
798 Knockdown of creatine kinase B inhibits ovarian cancer progression by decreasing glycolysis.Int J Biochem Cell Biol. 2013 May;45(5):979-86. doi: 10.1016/j.biocel.2013.02.003. Epub 2013 Feb 14.
799 Ovarian epithelial cell lineage-specific gene expression using the promoter of a retrovirus-like element.Cancer Res. 2001 Feb 15;61(4):1291-5.
800 Folate-linked lipoplexes for short hairpin RNA targeting claudin-3 delivery in ovarian cancer xenografts.J Control Release. 2013 Dec 28;172(3):679-89. doi: 10.1016/j.jconrel.2013.10.015. Epub 2013 Oct 18.
801 Claudin-7 expression in human epithelial ovarian cancer.Int J Gynecol Cancer. 2008 Nov-Dec;18(6):1262-71. doi: 10.1111/j.1525-1438.2008.01194.x. Epub 2008 Feb 19.
802 An innovative immunotherapeutic strategy for ovarian cancer: CLEC10A and glycomimetic peptides.J Immunother Cancer. 2018 Apr 17;6(1):28. doi: 10.1186/s40425-018-0339-5.
803 Expression and action of kit ligand/stem cell factor in normal human and bovine ovarian surface epithelium and ovarian cancer.Biol Reprod. 2000 Jun;62(6):1600-9. doi: 10.1095/biolreprod62.6.1600.
804 Blockage of transdifferentiation from fibroblast to myofibroblast in experimental ovarian cancer models.Mol Cancer. 2009 Sep 27;8:78. doi: 10.1186/1476-4598-8-78.
805 CNDP2 Acts as an Activator for Human Ovarian Cancer Growth and Metastasis via the PI3K/AKT Pathway.Technol Cancer Res Treat. 2019 Jan 1;18:1533033819874773. doi: 10.1177/1533033819874773.
806 Inhibitor of apoptosis proteins (IAPs) mediate collagen type XI alpha 1-driven cisplatin resistance in ovarian cancer.Oncogene. 2018 Aug;37(35):4809-4820. doi: 10.1038/s41388-018-0297-x. Epub 2018 May 17.
807 Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.Oncol Rep. 2019 Jul;42(1):151-175. doi: 10.3892/or.2019.7147. Epub 2019 May 3.
808 Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.PLoS One. 2016 Oct 27;11(10):e0165385. doi: 10.1371/journal.pone.0165385. eCollection 2016.
809 Investigating key genes associated with ovarian cancer by integrating affinity propagation clustering and mutual information network analysis.Eur Rev Med Pharmacol Sci. 2016 Jun;20(12):2532-40.
810 Copine-III interacts with ErbB2 and promotes tumor cell migration.Oncogene. 2010 Mar 18;29(11):1598-610. doi: 10.1038/onc.2009.456. Epub 2009 Dec 14.
811 High-throughput assessment of the antibody profile in ovarian cancer ascitic fluids.Oncoimmunology. 2019 Jun 4;8(9):e1614856. doi: 10.1080/2162402X.2019.1614856. eCollection 2019.
812 The role of CT10 regulation of kinase-like in cancer.Future Oncol. 2014 Dec;10(16):2687-97. doi: 10.2217/fon.14.199.
813 circ-CSPP1 promotes proliferation, invasion and migration of ovarian cancer cells by acting as a miR-1236-3p sponge.Biomed Pharmacother. 2019 Jun;114:108832. doi: 10.1016/j.biopha.2019.108832. Epub 2019 Apr 11.
814 Transforming growth factor?miR?43?p/cystatin B axis is a therapeutic target in human ovarian cancer.Int J Oncol. 2019 Jul;55(1):267-276. doi: 10.3892/ijo.2019.4815. Epub 2019 May 28.
815 Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.Cell. 2018 Sep 20;175(1):159-170.e16. doi: 10.1016/j.cell.2018.08.065.
816 NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.Cancer Res. 2003 Sep 15;63(18):6076-83.
817 Active-Site Tryptophan, the Target of Antineoplastic C-Terminal Binding Protein Inhibitors, Mediates Inhibitor Disruption of CtBP Oligomerization and Transcription Coregulatory Activities.Mol Pharmacol. 2019 Jul;96(1):99-108. doi: 10.1124/mol.118.114363. Epub 2019 Apr 29.
818 BRCA1 expression is epigenetically repressed in sporadic ovarian cancer cells by overexpression of C-terminal binding protein 2.Neoplasia. 2013 Jun;15(6):600-8. doi: 10.1593/neo.121674.
819 CTCF promotes epithelial ovarian cancer metastasis by broadly controlling the expression of metastasis-associated genes.Oncotarget. 2017 Jul 10;8(37):62217-62230. doi: 10.18632/oncotarget.19216. eCollection 2017 Sep 22.
820 Correlation of Collagen Triple Helix Repeat Containing 1 Overexpression With Lymph Node and Peritoneal Metastasis in Epithelial Ovarian Cancer.Int J Gynecol Cancer. 2017 Jan;27(1):22-27. doi: 10.1097/IGC.0000000000000850.
821 Amazon Fruits Inhibit Growth and Promote Pro-apoptotic Effects on Human Ovarian Carcinoma Cell Lines.Biomolecules. 2019 Nov 6;9(11):707. doi: 10.3390/biom9110707.
822 Mllerian inhibiting substance inhibits an ovarian cancer cell line via -catenin interacting protein deregulation of the Wnt signal pathway.Int J Oncol. 2017 Mar;50(3):1022-1028. doi: 10.3892/ijo.2017.3874. Epub 2017 Feb 13.
823 Spliceosome-associated factor CTNNBL1 promotes proliferation and invasion in ovarian cancer.Exp Cell Res. 2017 Aug 1;357(1):124-134. doi: 10.1016/j.yexcr.2017.05.008. Epub 2017 May 10.
824 MUC16 impacts tumor proliferation and migration through cytoplasmic translocation of P120-catenin in epithelial ovarian cancer cells: an original research.BMC Cancer. 2019 Feb 22;19(1):171. doi: 10.1186/s12885-019-5371-4.
825 miR?77 targets CUL4A and regulates metastatic capability in ovarian cancer.Int J Mol Med. 2018 Jun;41(6):3147-3156. doi: 10.3892/ijmm.2018.3540. Epub 2018 Mar 7.
826 Expression and biological role of cytoglobin in human ovarian cancer.Tumour Biol. 2014 Jul;35(7):6933-9. doi: 10.1007/s13277-014-1941-x. Epub 2014 Apr 17.
827 Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers.Eur J Hum Genet. 2017 Apr;25(4):432-438. doi: 10.1038/ejhg.2016.203. Epub 2017 Feb 1.
828 DAAM1-mediated migration and invasion of ovarian cancer cells are suppressed by miR-208a-5p.Pathol Res Pract. 2019 Jul;215(7):152452. doi: 10.1016/j.prp.2019.152452. Epub 2019 May 14.
829 DACT1 Overexpression in type I ovarian cancer inhibits malignant expansion and cis-platinum resistance by modulating canonical Wnt signalling and autophagy.Sci Rep. 2017 Aug 24;7(1):9285. doi: 10.1038/s41598-017-08249-7.
830 DAXX promotes ovarian cancer ascites cell proliferation and migration by activating the ERK signaling pathway.J Ovarian Res. 2018 Oct 18;11(1):90. doi: 10.1186/s13048-018-0462-4.
831 Cell Cycle Regulator p27 Mediates Body Mass Index Effects in Ovarian Cancer in FIGO-stages I-II.Cancer Genomics Proteomics. 2019 Nov-Dec;16(6):443-450. doi: 10.21873/cgp.20148.
832 DDA1 is induced by NR2F6 in ovarian cancer and predicts poor survival outcome.Eur Rev Med Pharmacol Sci. 2017 Mar;21(6):1206-1213.
833 DDB2 represses ovarian cancer cell dedifferentiation by suppressing ALDH1A1.Cell Death Dis. 2018 May 1;9(5):561. doi: 10.1038/s41419-018-0585-y.
834 The RNA-binding protein DDX1 promotes primary microRNA maturation and inhibits ovarian tumor progression.Cell Rep. 2014 Sep 11;8(5):1447-60. doi: 10.1016/j.celrep.2014.07.058. Epub 2014 Aug 28.
835 Epigenetic down-regulated DDX10 promotes cell proliferation through Akt/NF-B pathway in ovarian cancer.Biochem Biophys Res Commun. 2016 Jan 22;469(4):1000-5. doi: 10.1016/j.bbrc.2015.12.069. Epub 2015 Dec 20.
836 Vitamin D and DDX4 regulate the proliferation and invasion of ovarian cancer cells.Oncol Lett. 2018 Jul;16(1):905-909. doi: 10.3892/ol.2018.8718. Epub 2018 May 16.
837 RGD delivery of truncated coagulase to tumor vasculature affords local thrombotic activity to induce infarction of tumors in mice.Sci Rep. 2017 Aug 15;7(1):8126. doi: 10.1038/s41598-017-05326-9.
838 Antitumor effects of PLGA nanoparticles encapsulating the human PNAS-4 gene combined with cisplatin in ovarian cancer.Oncol Rep. 2011 Sep;26(3):703-10. doi: 10.3892/or.2011.1337. Epub 2011 Jun 6.
839 Long noncoding RNA SNHG14 enhances migration and invasion of ovarian cancer by upregulating DGCR8.Eur Rev Med Pharmacol Sci. 2019 Dec;23(23):10226-10233. doi: 10.26355/eurrev_201912_19659.
840 Decreased DHRS2 expression is associated with HDACi resistance and poor prognosis in ovarian cancer.Epigenetics. 2020 Jan-Feb;15(1-2):122-133. doi: 10.1080/15592294.2019.1656155. Epub 2019 Sep 3.
841 The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3-induced dormant ovarian cancer xenografts.Cancer. 2019 Apr 15;125(8):1267-1280. doi: 10.1002/cncr.31935. Epub 2019 Jan 8.
842 MicroRNA-23a depletion promotes apoptosis of ovarian cancer stem cell and inhibits cell migration by targeting DLG2.Cancer Biol Ther. 2019;20(6):897-911. doi: 10.1080/15384047.2019.1579960. Epub 2019 Mar 12.
843 DLX1 acts as a crucial target of FOXM1 to promote ovarian cancer aggressiveness by enhancing TGF-/SMAD4 signaling.Oncogene. 2017 Mar;36(10):1404-1416. doi: 10.1038/onc.2016.307. Epub 2016 Sep 5.
844 Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers.Clin Cancer Res. 2004 Dec 15;10(24):8501-11. doi: 10.1158/1078-0432.CCR-04-1072.
845 Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.Mol Oncol. 2016 Jun;10(6):789-805. doi: 10.1016/j.molonc.2016.01.003. Epub 2016 Jan 29.
846 Erratum: Akt/mTOR-Mediated Autophagy Confers Resistance To BET Inhibitor JQ1 In Ovarian Cancer [Corrigendum].Onco Targets Ther. 2019 Nov 15;12:9793. doi: 10.2147/OTT.S236659. eCollection 2019.
847 Elmo1 helps dock180 to regulate Rac1 activity and cell migration of ovarian cancer.Int J Gynecol Cancer. 2014 Jun;24(5):844-50. doi: 10.1097/IGC.0000000000000137.
848 Characterization of DOK1, a candidate tumor suppressor gene, in epithelial ovarian cancer. Mol Oncol. 2011 Oct;5(5):438-53. doi: 10.1016/j.molonc.2011.07.003. Epub 2011 Jul 26.
849 OVCA1 expression and its correlation with the expression levels of cyclin D1 and p16 in cervical cancer and intraepithelial neoplasia.Oncol Lett. 2017 May;13(5):2929-2936. doi: 10.3892/ol.2017.5848. Epub 2017 Mar 13.
850 Dicer, Drosha, and outcomes in patients with ovarian cancer.N Engl J Med. 2008 Dec 18;359(25):2641-50. doi: 10.1056/NEJMoa0803785.
851 Desmocollin 3 mediates follicle stimulating hormone-induced ovarian epithelial cancer cell proliferation by activating the EGFR/Akt signaling pathway.Int J Clin Exp Pathol. 2015 Jun 1;8(6):6716-23. eCollection 2015.
852 Loss of MKP3 mediated by oxidative stress enhances tumorigenicity and chemoresistance of ovarian cancer cells.Carcinogenesis. 2008 Sep;29(9):1742-50. doi: 10.1093/carcin/bgn167. Epub 2008 Jul 16.
853 Effects of dynein light chain Tctex-type 3 on the biological behavior of ovarian cancer.Cancer Manag Res. 2019 Jul 1;11:5925-5938. doi: 10.2147/CMAR.S205158. eCollection 2019.
854 E2F6 functions as a competing endogenous RNA, and transcriptional repressor, to promote ovarian cancer stemness.Cancer Sci. 2019 Mar;110(3):1085-1095. doi: 10.1111/cas.13920. Epub 2019 Jan 25.
855 Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.Clin Cancer Res. 2007 Jan 1;13(1):144-51. doi: 10.1158/1078-0432.CCR-06-0780.
856 The RNF146 and ECHDC1 genes as candidates for inherited breast and ovarian cancer in Jewish Ashkenazi women.Fam Cancer. 2009;8(4):399-402. doi: 10.1007/s10689-009-9255-7. Epub 2009 Jun 11.
857 Fibulin-4 is associated with tumor progression and a poor prognosis in ovarian carcinomas.BMC Cancer. 2015 Mar 4;15:91. doi: 10.1186/s12885-015-1100-9.
858 Knockdown of EHF inhibited the proliferation, invasion and tumorigenesis of ovarian cancer cells.Mol Carcinog. 2016 Jun;55(6):1048-59. doi: 10.1002/mc.22349. Epub 2015 Aug 10.
859 eIF3a improve cisplatin sensitivity in ovarian cancer by regulating XPC and p27Kip1 translation.Oncotarget. 2015 Sep 22;6(28):25441-51. doi: 10.18632/oncotarget.4555.
860 Identifying Gene Network Rewiring by Integrating Gene Expression and Gene Network Data.IEEE/ACM Trans Comput Biol Bioinform. 2018 Nov-Dec;15(6):2079-2085. doi: 10.1109/TCBB.2018.2809603. Epub 2018 Feb 26.
861 ELF3 is a negative regulator of epithelial-mesenchymal transition in ovarian cancer cells.Oncotarget. 2017 Mar 7;8(10):16951-16963. doi: 10.18632/oncotarget.15208.
862 NF-B1, c-Rel, and ELK1 inhibit miR-134 expression leading to TAB1 upregulation in paclitaxel-resistant human ovarian cancer.Oncotarget. 2017 Apr 11;8(15):24853-24868. doi: 10.18632/oncotarget.15267.
863 TCEB2 confers resistance to VEGF-targeted therapy in ovarian cancer.Oncol Rep. 2016 Jan;35(1):359-65. doi: 10.3892/or.2015.4388. Epub 2015 Nov 3.
864 Engrailed-2 (EN2) - a novel biomarker in epithelial ovarian cancer.BMC Cancer. 2018 Oct 3;18(1):943. doi: 10.1186/s12885-018-4816-5.
865 circEPSTI1 regulates ovarian cancer progression via decoying miR-942.J Cell Mol Med. 2019 May;23(5):3597-3602. doi: 10.1111/jcmm.14260. Epub 2019 Mar 19.
866 Enhanced Recovery After Surgery for Suspected Ovarian Malignancy: A Survey of Perioperative Practice Among Gynecologic Oncologists in Australia and New Zealand to Inform a Clinical Trial.Int J Gynecol Cancer. 2017 Jun;27(5):1046-1050. doi: 10.1097/IGC.0000000000000982.
867 Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells.Mol Cancer. 2010 Sep 24;9:259. doi: 10.1186/1476-4598-9-259.
868 Expression of multiple human endogenous retrovirus surface envelope proteins in ovarian cancer.Int J Cancer. 2007 Jan 1;120(1):81-90. doi: 10.1002/ijc.22256.
869 ESRP1 is overexpressed in ovarian cancer and promotes switching from mesenchymal to epithelial phenotype in ovarian cancer cells.Oncogenesis. 2017 Oct 9;6(10):e389. doi: 10.1038/oncsis.2017.87.
870 Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13.
871 PEA3 is necessary for optimal epidermal growth factor receptor-stimulated matrix metalloproteinase expression and invasion of ovarian tumor cells.Mol Cancer Res. 2007 May;5(5):413-21. doi: 10.1158/1541-7786.MCR-07-0019. Epub 2007 May 2.
872 Analysis of gene expression regulated by the ETV5 transcription factor in OV90 ovarian cancer cells identifies FOXM1 overexpression in ovarian cancer.Mol Cancer Res. 2012 Jul;10(7):914-24. doi: 10.1158/1541-7786.MCR-11-0449. Epub 2012 May 15.
873 LFG-500, a newly synthesized flavonoid, induces apoptosis in human ovarian carcinoma SKOV3 cells with involvement of the reactive oxygen species-mitochondria pathway.Exp Ther Med. 2017 Jun;13(6):2819-2827. doi: 10.3892/etm.2017.4343. Epub 2017 Apr 18.
874 TCRP1 expression is associated with platinum sensitivity in human lung and ovarian cancer cells.Oncol Lett. 2017 Mar;13(3):1398-1405. doi: 10.3892/ol.2016.5534. Epub 2016 Dec 27.
875 Loss of the novel mitochondrial protein FAM210B promotes metastasis via PDK4-dependent metabolic reprogramming.Cell Death Dis. 2017 Jun 8;8(6):e2870. doi: 10.1038/cddis.2017.273.
876 Upregulation of circular RNA circFAM53B predicts adverse prognosis and accelerates the progression of ovarian cancer via the miR?46/VAMP2 and miR?47/MDM2 signaling pathways.Oncol Rep. 2019 Dec;42(6):2728-2737. doi: 10.3892/or.2019.7366. Epub 2019 Oct 10.
877 The identification of pathogenic variants in BRCA1/2 negative, high risk, hereditary breast and/or ovarian cancer patients: High frequency of FANCM pathogenic variants.Int J Cancer. 2019 Jun 1;144(11):2683-2694. doi: 10.1002/ijc.31992. Epub 2019 Jan 11.
878 FANCM and RECQL genetic variants and breast cancer susceptibility: relevance to South Poland and West Ukraine.BMC Med Genet. 2018 Jan 19;19(1):12. doi: 10.1186/s12881-018-0524-x.
879 Fibulin-5 is a tumour suppressor inhibiting cell migration and invasion in ovarian cancer.J Clin Pathol. 2016 Feb;69(2):109-16. doi: 10.1136/jclinpath-2015-203129. Epub 2015 Aug 6.
880 Icariin suppresses cell cycle transition and cell migration in ovarian cancer cells.Oncol Rep. 2019 Apr;41(4):2321-2328. doi: 10.3892/or.2019.6986. Epub 2019 Jan 28.
881 Emi1 protein accumulation implicates misregulation of the anaphase promoting complex/cyclosome pathway in ovarian clear cell carcinoma.Mod Pathol. 2008 Apr;21(4):445-54. doi: 10.1038/modpathol.3801022. Epub 2008 Jan 18.
882 Detection of c-erbB-2/neu and fibroblast growth factor-3/INT-2 but not epidermal growth factor receptor gene amplification in endometrial cancer by differential polymerase chain reaction.Cancer. 1995 Apr 15;75(8):2139-46. doi: 10.1002/1097-0142(19950415)75:8<2139::aid-cncr2820750817>3.0.co;2-6.
883 FGF9-induced ovarian cancer cell invasion involves VEGF-A/VEGFR2 augmentation by virtue of ETS1 upregulation and metabolic reprogramming.J Cell Biochem. 2018 Nov;119(10):8174-8189. doi: 10.1002/jcb.26820. Epub 2018 Jun 15.
884 miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer.Cell Death Dis. 2019 May 8;10(5):372. doi: 10.1038/s41419-019-1604-3.
885 Enhanced antitumor effect of biodegradable cationic heparin-polyethyleneimine nanogels delivering FILIP1LC103 gene combined with low-dose cisplatin on ovarian cancer.Oncotarget. 2017 Jul 22;8(44):76432-76442. doi: 10.18632/oncotarget.19464. eCollection 2017 Sep 29.
886 Flotillin 1 is differentially expressed in human epithelial ovarian tumors.Neoplasma. 2018;65(4):561-571. doi: 10.4149/neo_2018_170714N483.
887 Association of BRCA1/2 mutations with FMR1 genotypes: effects on menarcheal and menopausal age.Maturitas. 2013 Jun;75(2):148-51. doi: 10.1016/j.maturitas.2013.03.002. Epub 2013 Mar 23.
888 MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma.Cell Cycle. 2018;17(21-22):2474-2483. doi: 10.1080/15384101.2018.1542898. Epub 2018 Nov 18.
889 miR-590-3p Promotes Ovarian Cancer Growth and Metastasis via a Novel FOXA2-Versican Pathway.Cancer Res. 2018 Aug 1;78(15):4175-4190. doi: 10.1158/0008-5472.CAN-17-3014. Epub 2018 May 10.
890 FOXK1 facilitates cell proliferation through regulating the expression of p21, and promotes metastasis in ovarian cancer.Oncotarget. 2017 Jul 31;8(41):70441-70451. doi: 10.18632/oncotarget.19713. eCollection 2017 Sep 19.
891 The Tyrosine Kinase Adaptor Protein FRS2 Is Oncogenic and Amplified in High-Grade Serous Ovarian Cancer.Mol Cancer Res. 2015 Mar;13(3):502-9. doi: 10.1158/1541-7786.MCR-14-0407. Epub 2014 Nov 3.
892 MicroRNA-1 inhibits ovarian cancer cell proliferation and migration through c-Met pathway.Clin Chim Acta. 2017 Oct;473:237-244. doi: 10.1016/j.cca.2017.07.008. Epub 2017 Jul 8.
893 c-Fos mediates 1, 2-fucosyltransferase 1 and Lewisy expression in response to TGF-1 in ovarian cancer.Oncol Rep. 2017 Dec;38(6):3355-3366. doi: 10.3892/or.2017.6052. Epub 2017 Oct 23.
894 A FXYD5/TGF?SMAD positive feedback loop drives epithelialtomesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.Int J Oncol. 2020 Jan;56(1):301-314. doi: 10.3892/ijo.2019.4911. Epub 2019 Nov 13.
895 Canonical and noncanonical Wnt pathway: a comparison among normal ovary, benign ovarian tumor and ovarian cancer.Oncol Rep. 2009 Feb;21(2):313-20.
896 Elevated expression of Gab1 promotes breast cancer metastasis by dissociating the PAR complex.J Exp Clin Cancer Res. 2019 Jan 21;38(1):27. doi: 10.1186/s13046-019-1025-2.
897 MiR-125a regulates ovarian cancer proliferation and invasion by repressing GALNT14 expression.Biomed Pharmacother. 2016 May;80:381-387. doi: 10.1016/j.biopha.2015.12.027. Epub 2016 Apr 8.
898 GALNT6 expression enhances aggressive phenotypes of ovarian cancer cells by regulating EGFR activity.Oncotarget. 2017 Jun 27;8(26):42588-42601. doi: 10.18632/oncotarget.16585.
899 The role of glycosyltransferase enzyme GCNT3 in colon and ovarian cancer prognosis and chemoresistance.Sci Rep. 2018 May 31;8(1):8485. doi: 10.1038/s41598-018-26468-4.
900 MicroRNA-16 inhibits migration and invasion via regulation of the Wnt/-catenin signaling pathway in ovarian cancer.Oncol Lett. 2019 Mar;17(3):2631-2638. doi: 10.3892/ol.2019.9923. Epub 2019 Jan 14.
901 GEN-1 immunotherapy for the treatment of ovarian cancer.Future Oncol. 2019 Feb;15(4):421-438. doi: 10.2217/fon-2018-0423. Epub 2018 Oct 16.
902 ZFP403, a novel tumor suppressor, inhibits the proliferation and metastasis in ovarian cancer.Gynecol Oncol. 2017 Nov;147(2):418-425. doi: 10.1016/j.ygyno.2017.08.025. Epub 2017 Aug 31.
903 Growth hormone-releasing hormone antagonists inhibit growth of human ovarian cancer.Horm Metab Res. 2011 Oct;43(11):816-20. doi: 10.1055/s-0031-1287766. Epub 2011 Oct 18.
904 Therapeutic implications of GIPC1 silencing in cancer.PLoS One. 2010 Dec 30;5(12):e15581. doi: 10.1371/journal.pone.0015581.
905 The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer.Eur Rev Med Pharmacol Sci. 2017 Sep;21(18):4039-4044.
906 The oncogenic Golgi phosphoprotein 3 like overexpression is associated with cisplatin resistance in ovarian carcinoma and activating the NF-B signaling pathway.J Exp Clin Cancer Res. 2017 Oct 4;36(1):137. doi: 10.1186/s13046-017-0607-0.
907 Grb7 gene amplification and protein expression by FISH and IHC in ovarian cancer.Int J Clin Exp Pathol. 2015 Sep 1;8(9):11296-304. eCollection 2015.
908 GREB1 is an estrogen receptor-regulated tumour promoter that is frequently expressed in ovarian cancer.Oncogene. 2018 Nov;37(44):5873-5886. doi: 10.1038/s41388-018-0377-y. Epub 2018 Jul 4.
909 Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1.Cancer Lett. 2018 Oct 1;433:242-251. doi: 10.1016/j.canlet.2018.06.030. Epub 2018 Jun 28.
910 A natural entkaurane diterpenoid induces antiproliferation in ovarian cancer cells via ERK1/2 regulation and inhibition of cellular migration and invasion.Mol Med Rep. 2018 Oct;18(4):3898-3906. doi: 10.3892/mmr.2018.9377. Epub 2018 Aug 9.
911 HPIP Silencing Prevents Epithelial-Mesenchymal Transition Induced by TGF-1 in Human Ovarian Cancer Cells.Oncol Res. 2016;24(1):33-9. doi: 10.3727/096504016X14575597858654.
912 Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.Cancer Lett. 2017 Dec 28;411:65-73. doi: 10.1016/j.canlet.2017.09.048. Epub 2017 Oct 6.
913 Screening of HELQ in breast and ovarian cancer families.Fam Cancer. 2016 Jan;15(1):19-23. doi: 10.1007/s10689-015-9838-4.
914 LINC01342 promotes the progression of ovarian cancer by absorbing microRNA-30c-2-3p to upregulate HIF3A.J Cell Physiol. 2020 Apr;235(4):3939-3949. doi: 10.1002/jcp.29289. Epub 2019 Oct 9.
915 Increased HLA-DMB expression in the tumor epithelium is associated with increased CTL infiltration and improved prognosis in advanced-stage serous ovarian cancer.Clin Cancer Res. 2008 Dec 1;14(23):7667-73. doi: 10.1158/1078-0432.CCR-08-0479.
916 T-cell Responses to TP53 "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers.Clin Cancer Res. 2018 Nov 15;24(22):5562-5573. doi: 10.1158/1078-0432.CCR-18-0573. Epub 2018 May 31.
917 Human leukocyte antigen-E alleles and expression in patients with serous ovarian cancer.Cancer Sci. 2015 May;106(5):522-8. doi: 10.1111/cas.12641. Epub 2015 Apr 13.
918 Early expression of the Helicase-Like Transcription Factor (HLTF/SMARCA3) in an experimental model of estrogen-induced renal carcinogenesis.Mol Cancer. 2006 Jun 8;5:23. doi: 10.1186/1476-4598-5-23.
919 Humoral autoimmune responses to insulin-like growth factor II mRNA-binding proteins IMP1 and p62/IMP2 in ovarian cancer.J Immunol Res. 2014;2014:326593. doi: 10.1155/2014/326593. Epub 2014 Apr 27.
920 Low expression level of HMBOX1 in high-grade serous ovarian cancer accelerates cell proliferation by inhibiting cell apoptosis.Biochem Biophys Res Commun. 2018 Jun 22;501(2):380-386. doi: 10.1016/j.bbrc.2018.04.203. Epub 2018 May 10.
921 SRPX and HMCN1 regulate cancerassociated fibroblasts to promote the invasiveness of ovarian carcinoma.Oncol Rep. 2019 Dec;42(6):2706-2715. doi: 10.3892/or.2019.7379. Epub 2019 Oct 17.
922 Targeting the High-Mobility Group Box 3 Protein Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin.Cancer Res. 2019 Jul 1;79(13):3185-3191. doi: 10.1158/0008-5472.CAN-19-0542. Epub 2019 May 6.
923 Increased RHAMM expression relates to ovarian cancer progression.J Ovarian Res. 2017 Sep 27;10(1):66. doi: 10.1186/s13048-017-0360-1.
924 MiR-99a suppressed cell proliferation and invasion by directly targeting HOXA1 through regulation of the AKT/mTOR signaling pathway and EMT in ovarian cancer.Eur Rev Med Pharmacol Sci. 2019 Jun;23(11):4663-4672. doi: 10.26355/eurrev_201906_18046.
925 HOXA9 promotes homotypic and heterotypic cell interactions that facilitate ovarian cancer dissemination via its induction of P-cadherin.Mol Cancer. 2014 Jul 14;13:170. doi: 10.1186/1476-4598-13-170.
926 Endocrine disrupting chemical, bisphenol-A, induces breast cancer associated gene HOXB9 expression in vitro and in vivo. Gene. 2016 Sep 30;590(2):234-43. doi: 10.1016/j.gene.2016.05.009. Epub 2016 May 13.
927 Ovarian cancer variant rs2072590 is associated with HOXD1 and HOXD3 gene expression.Oncotarget. 2017 Oct 13;8(61):103410-103414. doi: 10.18632/oncotarget.21902. eCollection 2017 Nov 28.
928 Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia.Anticancer Drugs. 2019 Feb;30(2):117-127. doi: 10.1097/CAD.0000000000000696.
929 Role of Hydroxysteroid Dehydrogenase-Like 2 (HSDL2) in Human Ovarian Cancer.Med Sci Monit. 2018 Jun 12;24:3997-4008. doi: 10.12659/MSM.909418.
930 HSP60-regulated Mitochondrial Proteostasis and Protein Translation Promote Tumor Growth of Ovarian Cancer.Sci Rep. 2019 Sep 2;9(1):12628. doi: 10.1038/s41598-019-48992-7.
931 Secretion of cytokines and heat shock protein (HspA1A) by ovarian cancer cells depending on the tumor type and stage of disease.Cytokine. 2017 Jan;89:136-142. doi: 10.1016/j.cyto.2016.01.017. Epub 2016 Feb 8.
932 Heat shock protein 70-2 (HSP70-2) a novel cancer testis antigen that promotes growth of ovarian cancer.Am J Cancer Res. 2017 Jun 1;7(6):1252-1269. eCollection 2017.
933 High-temperature requirement factor A3 (Htra3): a novel serine protease and its potential role in ovarian function and ovarian cancers.Mol Cell Endocrinol. 2010 Oct 7;327(1-2):13-8. doi: 10.1016/j.mce.2010.06.001. Epub 2010 Jun 9.
934 Huwe1 Sustains Normal Ovarian Epithelial Cell Transformation and Tumor Growth through the Histone H1.3-H19 Cascade.Cancer Res. 2017 Sep 15;77(18):4773-4784. doi: 10.1158/0008-5472.CAN-16-2597. Epub 2017 Jul 7.
935 Isoprenylcysteine carboxylmethyltransferase regulates ovarian cancer cell response to chemotherapy and Ras activation.Biochem Biophys Res Commun. 2018 Jun 22;501(2):556-562. doi: 10.1016/j.bbrc.2018.05.038. Epub 2018 May 11.
936 Targeted tumor-penetrating siRNA nanocomplexes for credentialing the ovarian cancer oncogene ID4.Sci Transl Med. 2012 Aug 15;4(147):147ra112. doi: 10.1126/scitranslmed.3003778.
937 MiR-1307 promotes ovarian cancer cell chemoresistance by targeting the ING5 expression.J Ovarian Res. 2017 Jan 11;10(1):1. doi: 10.1186/s13048-016-0301-4.
938 Loss of INPP4B causes a DNA repair defect through loss of BRCA1, ATM and ATR and can be targeted with PARP inhibitor treatment.Oncotarget. 2015 Apr 30;6(12):10548-62. doi: 10.18632/oncotarget.3307.
939 Elevated plasma levels of the novel hormone INSL3 in a woman with metastatic ovarian cancer.Int J Biol Markers. 2007 Apr-Jun;22(2):159-60. doi: 10.1177/172460080702200210.
940 Epigenetic regulation of IQGAP2 promotes ovarian cancer progression via activating Wnt/-catenin signaling.Int J Oncol. 2016 Jan;48(1):153-60. doi: 10.3892/ijo.2015.3228. Epub 2015 Nov 4.
941 Upregulation of ITGBL1 predicts poor prognosis and promotes chemoresistance in ovarian cancer.Cancer Biomark. 2020;27(1):51-61. doi: 10.3233/CBM-190460.
942 Role of serum-derived hyaluronan-associated protein-hyaluronan complex in ovarian cancer.Oncol Rep. 2008 May;19(5):1245-51.
943 Loss of ITM2A, a novel tumor suppressor of ovarian cancer through G2/M cell cycle arrest, is a poor prognostic factor of epithelial ovarian cancer.Gynecol Oncol. 2016 Mar;140(3):545-53. doi: 10.1016/j.ygyno.2015.12.006. Epub 2015 Dec 12.
944 Knockdown of JARID2 inhibits the proliferation and invasion of ovarian cancer through the PI3K/Akt signaling pathway.Mol Med Rep. 2017 Sep;16(3):3600-3605. doi: 10.3892/mmr.2017.7024. Epub 2017 Jul 17.
945 Jumonji domain-containing 6 (JMJD6) identified as a potential therapeutic target in ovarian cancer.Signal Transduct Target Ther. 2019 Jul 26;4:24. doi: 10.1038/s41392-019-0055-8. eCollection 2019.
946 JRK is a positive regulator of -catenin transcriptional activity commonly overexpressed in colon, breast and ovarian cancer.Oncogene. 2016 Jun 2;35(22):2834-41. doi: 10.1038/onc.2015.347. Epub 2015 Oct 12.
947 GCN-5/PGC-1 signaling is activated and associated with metabolism in cyclin E1-driven ovarian cancer.Aging (Albany NY). 2019 Jul 17;11(14):4890-4899. doi: 10.18632/aging.102082.
948 HBO1 directs histone H4 specific acetylation, potentiating mechano-transduction pathways and membrane elasticity in ovarian cancer cells.Nanomedicine. 2019 Apr;17:254-265. doi: 10.1016/j.nano.2019.01.017. Epub 2019 Feb 10.
949 Expression of hMOF in different ovarian tissues and its effects on ovarian cancer prognosis.Oncol Rep. 2015 Feb;33(2):685-92. doi: 10.3892/or.2014.3649. Epub 2014 Dec 5.
950 Clinical relevance of cytoskeleton associated proteins for ovarian cancer.J Cancer Res Clin Oncol. 2018 Nov;144(11):2195-2205. doi: 10.1007/s00432-018-2710-9. Epub 2018 Aug 9.
951 The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-Myb.Oncogene. 2019 Feb;38(7):1080-1092. doi: 10.1038/s41388-018-0490-y. Epub 2018 Sep 11.
952 miR-146b promotes cell proliferation and increases chemosensitivity, but attenuates cell migration and invasion via FBXL10 in ovarian cancer.Cell Death Dis. 2018 Nov 8;9(11):1123. doi: 10.1038/s41419-018-1093-9.
953 The histone demethylase KDM4B regulates peritoneal seeding of ovarian cancer.Oncogene. 2017 May 4;36(18):2565-2576. doi: 10.1038/onc.2016.412. Epub 2016 Nov 21.
954 Inhibition of KIF20A by BKS0349 reduces endometriotic lesions in a xenograft mouse model.Mol Hum Reprod. 2019 Sep 1;25(9):562-571. doi: 10.1093/molehr/gaz044.
955 Methylation-mediated repression of MiR-424/503 cluster promotes proliferation and migration of ovarian cancer cells through targeting the hub gene KIF23.Cell Cycle. 2019 Jul;18(14):1601-1618. doi: 10.1080/15384101.2019.1624112. Epub 2019 Jun 9.
956 Overexpression of KIF2A is Suppressed by miR-206 and Associated with Poor Prognosis in Ovarian Cancer.Cell Physiol Biochem. 2018;50(3):810-822. doi: 10.1159/000494467. Epub 2018 Oct 23.
957 KIFCI, a novel putative prognostic biomarker for ovarian adenocarcinomas: delineating protein interaction networks and signaling circuitries.J Ovarian Res. 2014 May 12;7:53. doi: 10.1186/1757-2215-7-53. eCollection 2014.
958 LINC00702 accelerates the progression of ovarian cancer through interacting with EZH2 to inhibit the transcription of KLF2.Eur Rev Med Pharmacol Sci. 2019 Aug;23(3 Suppl):201-208. doi: 10.26355/eurrev_201908_18648.
959 Long non-coding RNA OR3A4 promotes metastasis of ovarian cancer via inhibiting KLF6.Eur Rev Med Pharmacol Sci. 2019 Mar;23(6):2360-2365. doi: 10.26355/eurrev_201903_17380.
960 Activation of KLF8 transcription by focal adhesion kinase in human ovarian epithelial and cancer cells.J Biol Chem. 2008 May 16;283(20):13934-42. doi: 10.1074/jbc.M709300200. Epub 2008 Mar 19.
961 Lentivirus-mediated knockdown of Krppel-like factor 9 inhibits the growth of ovarian cancer.Arch Gynecol Obstet. 2015 Feb;291(2):377-82. doi: 10.1007/s00404-014-3405-3. Epub 2014 Sep 13.
962 ARID1A ablation leads to multiple drug resistance in ovarian cancer via transcriptional activation of MRP2.Cancer Lett. 2018 Jul 28;427:9-17. doi: 10.1016/j.canlet.2018.04.013. Epub 2018 Apr 13.
963 Human kallikrein gene 11 (KLK11) mRNA overexpression is associated with poor prognosis in patients with epithelial ovarian cancer.Clin Cancer Res. 2004 Apr 15;10(8):2766-70. doi: 10.1158/1078-0432.ccr-03-0269.
964 A Kallikrein 15 (KLK15) single nucleotide polymorphism located close to a novel exon shows evidence of association with poor ovarian cancer survival.BMC Cancer. 2011 Apr 1;11:119. doi: 10.1186/1471-2407-11-119.
965 Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.PLoS One. 2017 Nov 2;12(11):e0186847. doi: 10.1371/journal.pone.0186847. eCollection 2017.
966 Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.Oncotarget. 2017 Mar 14;8(11):17819-17832. doi: 10.18632/oncotarget.14867.
967 Epidermolytic palmoplantar keratoderma cosegregates with a keratin 9 mutation in a pedigree with breast and ovarian cancer.Nat Genet. 1994 Jan;6(1):106-10. doi: 10.1038/ng0194-106.
968 Correlation of LAMA3 with onset and prognosis of ovarian cancer.Oncol Lett. 2019 Sep;18(3):2813-2818. doi: 10.3892/ol.2019.10600. Epub 2019 Jul 10.
969 LAMP3 expression correlated with poor clinical outcome in human ovarian cancer.Tumour Biol. 2017 Mar;39(3):1010428317695014. doi: 10.1177/1010428317695014.
970 La-Related Protein 4 as a Suppressor for Motility of Ovarian Cancer Cells.Tohoku J Exp Med. 2019 Jan;247(1):59-67. doi: 10.1620/tjem.247.59.
971 Recombinant adenoviral vector containing tumor-specific L-plastin promoter fused to cytosine deaminase gene as a transcription unit: generation and functional test.Arch Pharm Res. 2004 Jun;27(6):633-9. doi: 10.1007/BF02980163.
972 Silencing LGR6 Attenuates Stemness and Chemoresistance via Inhibiting Wnt/-Catenin Signaling in Ovarian Cancer.Mol Ther Oncolytics. 2019 Apr 19;14:94-106. doi: 10.1016/j.omto.2019.04.002. eCollection 2019 Sep 27.
973 Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling.Oncotarget. 2016 Jan 12;7(2):1408-20. doi: 10.18632/oncotarget.6368.
974 Overexpression of the RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with chemoresistance and poor disease outcome in ovarian cancer.Br J Cancer. 2015 Jul 28;113(3):414-24. doi: 10.1038/bjc.2015.254. Epub 2015 Jul 9.
975 Long noncoding RNA CASC9 promotes LIN7A expression via miR-758-3p to facilitate the malignancy of ovarian cancer.J Cell Physiol. 2019 Jul;234(7):10800-10808. doi: 10.1002/jcp.27903. Epub 2018 Dec 7.
976 LIM-homeobox transcription factor 1, alpha (LMX1A) inhibits tumourigenesis, epithelial-mesenchymal transition and stem-like properties of epithelial ovarian cancer.Gynecol Oncol. 2013 Mar;128(3):475-82. doi: 10.1016/j.ygyno.2012.12.018. Epub 2012 Dec 24.
977 Cancer-associated fibroblasts regulate endothelial adhesion protein LPP to promote ovarian cancer chemoresistance.J Clin Invest. 2018 Feb 1;128(2):589-606. doi: 10.1172/JCI95200. Epub 2017 Dec 18.
978 Immunohistochemical detection of the ras oncogene product p21 in advanced ovarian cancer. Lack of correlation with clinical outcome.Arch Pathol Lab Med. 1988 Feb;112(2):151-4.
979 A multiple mixed TiO(2) mesocrystal junction based PEC-colorimetric immunoassay for specific recognition of lipolysis stimulated lipoprotein receptor.Biosens Bioelectron. 2020 Jan 15;148:111809. doi: 10.1016/j.bios.2019.111809. Epub 2019 Oct 26.
980 Identification of key genes associated with the effect of estrogen on ovarian cancer using microarray analysis.Arch Gynecol Obstet. 2016 Feb;293(2):421-7. doi: 10.1007/s00404-015-3833-8. Epub 2015 Aug 12.
981 The significance of lumican expression in ovarian cancer drug-resistant cell lines.Oncotarget. 2017 Aug 10;8(43):74466-74478. doi: 10.18632/oncotarget.20169. eCollection 2017 Sep 26.
982 Cancer mortality in relatives of women with ovarian cancer: the OPCS Study. Office of Population Censuses and Surveys.Int J Cancer. 1996 Jan 26;65(3):284-94. doi: 10.1002/(SICI)1097-0215(19960126)65:3<284::AID-IJC2>3.0.CO;2-W.
983 Effects of metastasis-associated in colon cancer 1 inhibition by small hairpin RNA on ovarian carcinoma OVCAR-3 cells.J Exp Clin Cancer Res. 2011 Sep 16;30(1):83. doi: 10.1186/1756-9966-30-83.
984 The feasibility of detecting endometrial and ovarian cancer using DNA methylation biomarkers in cervical scrapings.J Gynecol Oncol. 2018 Jan;29(1):e17. doi: 10.3802/jgo.2018.29.e17.
985 Prognostic relevance of the Golgi mannosidase MAN1A1 in ovarian cancer: impact of N-glycosylation on tumour cell aggregation.Br J Cancer. 2019 Nov;121(11):944-953. doi: 10.1038/s41416-019-0607-2. Epub 2019 Oct 29.
986 Loss of HSulf-1: The Missing Link between Autophagy and Lipid Droplets in Ovarian Cancer.Sci Rep. 2017 Feb 7;7:41977. doi: 10.1038/srep41977.
987 MKK4 acts as a potential tumor suppressor in ovarian cancer.Tumour Biol. 2011 Aug;32(4):661-70. doi: 10.1007/s13277-011-0166-5. Epub 2011 Apr 14.
988 MAP2K6-FP Enhances the Sensitiveness of Paclitaxel for Ovarian Cancer via Inducing Autophagy.Int J Gynecol Cancer. 2017 Jul;27(6):1082-1087. doi: 10.1097/IGC.0000000000001003.
989 MARCH5 RNA promotes autophagy, migration, and invasion of ovarian cancer cells.Autophagy. 2017 Feb;13(2):333-344. doi: 10.1080/15548627.2016.1256520. Epub 2016 Nov 22.
990 Interaction of E3 Ubiquitin Ligase MARCH7 with Long Noncoding RNA MALAT1 and Autophagy-Related Protein ATG7 Promotes Autophagy and Invasion in Ovarian Cancer.Cell Physiol Biochem. 2018;47(2):654-666. doi: 10.1159/000490020. Epub 2018 May 22.
991 MDC1 promotes ovarian cancer metastasis by inducing epithelial-mesenchymal transition.Tumour Biol. 2015 Jun;36(6):4261-9. doi: 10.1007/s13277-015-3063-5. Epub 2015 Jan 16.
992 SUMO1 negatively regulates the transcriptional activity of EVI1 and significantly increases its co-localization with EVI1 after treatment with arsenic trioxide.Biochim Biophys Acta. 2013 Oct;1833(10):2357-68. doi: 10.1016/j.bbamcr.2013.06.003. Epub 2013 Jun 13.
993 Selenium-Binding Protein 1 (SBP1) autoantibodies in ovarian disorders and ovarian cancer.Reproduction. 2017 Mar;153(3):277-284. doi: 10.1530/REP-16-0265. Epub 2016 Dec 13.
994 METTL3 promotes ovarian carcinoma growth and invasion through the regulation of AXL translation and epithelial to mesenchymal transition.Gynecol Oncol. 2018 Nov;151(2):356-365. doi: 10.1016/j.ygyno.2018.09.015. Epub 2018 Sep 21.
995 The glycosyltransferase GnT-III activates Notch signaling and drives stem cell expansion to promote the growth and invasion of ovarian cancer.J Biol Chem. 2017 Sep 29;292(39):16351-16359. doi: 10.1074/jbc.M117.783936. Epub 2017 Aug 23.
996 Silencing of MICAL-L2 suppresses malignancy of ovarian cancer by inducing mesenchymal-epithelial transition.Cancer Lett. 2015 Jul 10;363(1):71-82. doi: 10.1016/j.canlet.2015.04.002. Epub 2015 Apr 9.
997 MICU1 drives glycolysis and chemoresistance in ovarian cancer.Nat Commun. 2017 May 22;8:14634. doi: 10.1038/ncomms14634.
998 Involvement of AF1q/MLLT11 in the progression of ovarian cancer.Oncotarget. 2017 Apr 4;8(14):23246-23264. doi: 10.18632/oncotarget.15574.
999 Matrix Metalloproteinase Expressions Play Important role in Prediction of Ovarian Cancer Outcome.Sci Rep. 2019 Aug 12;9(1):11677. doi: 10.1038/s41598-019-47871-5.
1000 Downregulation of the proapoptotic protein MOAP-1 by the UBR5 ubiquitin ligase and its role in ovarian cancer resistance to cisplatin.Oncogene. 2017 Mar 23;36(12):1698-1706. doi: 10.1038/onc.2016.336. Epub 2016 Oct 10.
1001 MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer.Oncol Rep. 2019 Aug;42(2):679-687. doi: 10.3892/or.2019.7199. Epub 2019 Jun 12.
1002 Epigenetic Regulation of the Homeobox Gene MSX1 Associates with Platinum-Resistant Disease in High-Grade Serous Epithelial Ovarian Cancer.Clin Cancer Res. 2016 Jun 15;22(12):3097-3104. doi: 10.1158/1078-0432.CCR-15-1669. Epub 2016 Jan 13.
1003 Angiotensin II type 2 receptor-interacting protein 3a inhibits ovarian carcinoma metastasis via the extracellular HMGA2-mediated ERK/EMT pathway.Tumour Biol. 2017 Jun;39(6):1010428317713389. doi: 10.1177/1010428317713389.
1004 Overexpression of mucin 13 due to promoter methylation promotes aggressive behavior in ovarian cancer cells.Yonsei Med J. 2014 Sep;55(5):1206-13. doi: 10.3349/ymj.2014.55.5.1206.
1005 MUS81 is associated with cell proliferation and cisplatin sensitivity in serous ovarian cancer.Biochem Biophys Res Commun. 2016 Aug 5;476(4):493-500. doi: 10.1016/j.bbrc.2016.05.152. Epub 2016 May 30.
1006 Diverse functions of myosin VI elucidated by an isoform-specific -helix domain.Nat Struct Mol Biol. 2016 Apr;23(4):300-308. doi: 10.1038/nsmb.3187. Epub 2016 Mar 7.
1007 Methylation of MYLK3 gene promoter region: a biomarker to stratify surgical care in ovarian cancer in a multicentre study.Br J Cancer. 2017 May 9;116(10):1287-1293. doi: 10.1038/bjc.2017.83. Epub 2017 Mar 28.
1008 Cloning and expression of functional cDNA genes of a mouse/human chimeric antibody rcM4.Tumori. 1994 Dec 31;80(6):473-9. doi: 10.1177/030089169408000613.
1009 [Corrigendum] miR-28-5p promotes the development and progression of ovarian cancer through inhibition of N4BP1.Int J Oncol. 2017 Jun;50(6):2236. doi: 10.3892/ijo.2017.3977. Epub 2017 Apr 27.
1010 New insight into NANOG: A novel therapeutic target for ovarian cancer (OC).Eur J Pharmacol. 2019 Jun 5;852:51-57. doi: 10.1016/j.ejphar.2019.03.003. Epub 2019 Mar 2.
1011 The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.Gynecol Oncol. 2015 Apr;137(1):143-51. doi: 10.1016/j.ygyno.2014.12.042. Epub 2015 Jan 8.
1012 Characterisation of a 161 kb deletion extending from the NBR1 to the BRCA1 genes in a French breast-ovarian cancer family.Hum Mutat. 2003 Jun;21(6):654. doi: 10.1002/humu.9148.
1013 High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.J Transl Med. 2019 May 20;17(1):166. doi: 10.1186/s12967-019-1904-5.
1014 NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms.Oncotarget. 2016 Jan 19;7(3):3018-32. doi: 10.18632/oncotarget.6576.
1015 Nectin-2 in ovarian cancer: How is it expressed and what might be its functional role?.Cancer Sci. 2019 Jun;110(6):1872-1882. doi: 10.1111/cas.13992. Epub 2019 May 2.
1016 Nectin-3 is a new biomarker that mediates the upregulation of MMP2 and MMP9 in ovarian cancer cells.Biomed Pharmacother. 2019 Feb;110:139-144. doi: 10.1016/j.biopha.2018.11.020. Epub 2018 Nov 20.
1017 Deregulation of sialidases in human normal and tumor tissues.Cancer Biomark. 2018 Feb 14;21(3):591-601. doi: 10.3233/CBM-170548.
1018 Nrf2 induces cisplatin resistance via suppressing the iron export related gene SLC40A1 in ovarian cancer cells.Oncotarget. 2017 Jul 25;8(55):93502-93515. doi: 10.18632/oncotarget.19548. eCollection 2017 Nov 7.
1019 Growth-suppressive effects of BPOZ and EGR2, two genes involved in the PTEN signaling pathway.Oncogene. 2001 Jul 27;20(33):4457-65. doi: 10.1038/sj.onc.1204608.
1020 NID1, a new regulator of EMT required for metastasis and chemoresistance of ovarian cancer cells.Oncotarget. 2017 May 16;8(20):33110-33121. doi: 10.18632/oncotarget.16145.
1021 Evaluation of Serum Nidogen-2 as a Screening and Diagnostic Tool for Ovarian Cancer.Gynecol Obstet Invest. 2018;83(5):461-465. doi: 10.1159/000481798. Epub 2017 Nov 7.
1022 Nucleoside Diphosphate Kinase-3 (NME3) Enhances TLR5-Induced NFB Activation.Mol Cancer Res. 2018 Jun;16(6):986-999. doi: 10.1158/1541-7786.MCR-17-0603. Epub 2018 Mar 9.
1023 Trabid, a new positive regulator of Wnt-induced transcription with preference for binding and cleaving K63-linked ubiquitin chains.Genes Dev. 2008 Feb 15;22(4):528-42. doi: 10.1101/gad.463208.
1024 Clinicopathological significance of steroidogenic factor-1 expression in ovarian cancer versus ovarian sex cord stromal tumor.Tumour Biol. 2015 Mar;36(3):1429-35. doi: 10.1007/s13277-014-2187-3. Epub 2015 Jan 22.
1025 Highly expressed NRSN2 is related to malignant phenotype in ovarian cancer.Biomed Pharmacother. 2017 Jan;85:248-255. doi: 10.1016/j.biopha.2016.11.012. Epub 2016 Nov 28.
1026 E2F2 induces MCM4, CCNE2 and WHSC1 upregulation in ovarian cancer and predicts poor overall survival.Eur Rev Med Pharmacol Sci. 2017 May;21(9):2150-2156.
1027 Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.PLoS Genet. 2013;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27.
1028 NUCKS nuclear elevated expression indicates progression and prognosis of ovarian cancer.Tumour Biol. 2017 Sep;39(9):1010428317714631. doi: 10.1177/1010428317714631.
1029 Tumor-associated autoantibodies as early detection markers for ovarian cancer? A prospective evaluation.Int J Cancer. 2018 Aug 1;143(3):515-526. doi: 10.1002/ijc.31335. Epub 2018 Mar 8.
1030 Single nucleotide variant in Nucleoporin 107 may be predictive of sensitivity to chemotherapy in patients with ovarian cancer.Pharmacogenet Genomics. 2017 Jul;27(7):264-269. doi: 10.1097/FPC.0000000000000288.
1031 Systematic review: Tumor-associated antigen autoantibodies and ovarian cancer early detection.Gynecol Oncol. 2017 Nov;147(2):465-480. doi: 10.1016/j.ygyno.2017.07.138. Epub 2017 Aug 8.
1032 Ovarian cancer immuno-reactive antigen domain containing 1 (OCIAD1), a key player in ovarian cancer cell adhesion.Gynecol Oncol. 2008 May;109(2):226-33. doi: 10.1016/j.ygyno.2007.12.024. Epub 2008 Mar 6.
1033 Methylation of OPCML promoter in ovarian cancer tissues predicts poor patient survival.Clin Chem Lab Med. 2014 May;52(5):735-42. doi: 10.1515/cclm-2013-0736.
1034 The human KLK8 (neuropsin/ovasin) gene: identification of two novel splice variants and its prognostic value in ovarian cancer. Clin Cancer Res. 2001 Apr;7(4):806-11.
1035 The non-coding RNA OTUB1-isoform2 promotes ovarian tumour progression and predicts poor prognosis.J Cell Mol Med. 2018 Oct;22(10):4794-4806. doi: 10.1111/jcmm.13733. Epub 2018 Jul 25.
1036 Ovarian tumor domain-containing protein 1 deubiquitinates and stabilizes p53.Cell Signal. 2017 May;33:22-29. doi: 10.1016/j.cellsig.2017.02.011. Epub 2017 Feb 13.
1037 Retro-inverso follicle-stimulating hormone peptide-mediated polyethylenimine complexes for targeted ovarian cancer gene therapy.Drug Deliv. 2018 Nov;25(1):995-1003. doi: 10.1080/10717544.2018.1461956.
1038 hPaf1/PD2 interacts with OCT3/4 to promote self-renewal of ovarian cancer stem cells.Oncotarget. 2017 Feb 28;8(9):14806-14820. doi: 10.18632/oncotarget.14775.
1039 miR-193b-3p possesses anti-tumor activity in ovarian carcinoma cells by targeting p21-activated kinase 3.Biomed Pharmacother. 2017 Dec;96:1275-1282. doi: 10.1016/j.biopha.2017.11.086. Epub 2017 Nov 21.
1040 PAK5 Induces EMT and Promotes Cell Migration and Invasion by Activating the PI3K/AKT Pathway in Ovarian Cancer.Anal Cell Pathol (Amst). 2018 Sep 2;2018:8073124. doi: 10.1155/2018/8073124. eCollection 2018.
1041 AKAP2 is upregulated in ovarian cancer, and promotes growth and migration of cancer cells.Mol Med Rep. 2017 Oct;16(4):5151-5156. doi: 10.3892/mmr.2017.7286. Epub 2017 Aug 18.
1042 Overcoming platinum resistance in ovarian cancer by targeting pregnancy-associated plasma protein-A.PLoS One. 2019 Nov 21;14(11):e0224564. doi: 10.1371/journal.pone.0224564. eCollection 2019.
1043 An epigenetic marker panel for screening and prognostic prediction of ovarian cancer.Int J Cancer. 2009 Jan 15;124(2):387-93. doi: 10.1002/ijc.23957.
1044 UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer.Cancers (Basel). 2018 Aug 8;10(8):262. doi: 10.3390/cancers10080262.
1045 PBOV1 correlates with progression of ovarian cancer and inhibits proliferation of ovarian cancer cells.Oncol Rep. 2016 Jan;35(1):488-96. doi: 10.3892/or.2015.4396. Epub 2015 Nov 4.
1046 Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1.Cancer Res. 2016 Nov 1;76(21):6351-6361. doi: 10.1158/0008-5472.CAN-16-0980. Epub 2016 Sep 2.
1047 HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.Cell Oncol (Dordr). 2017 Apr;40(2):133-144. doi: 10.1007/s13402-016-0308-2. Epub 2016 Dec 30.
1048 Low Expression of Protocadherin-8 Promotes the Progression of Ovarian Cancer.Int J Gynecol Cancer. 2018 Feb;28(2):346-354. doi: 10.1097/IGC.0000000000001169.
1049 MiR-200a-3p promoted the malignant behaviors of ovarian cancer cells through regulating PCDH9.Onco Targets Ther. 2019 Oct 8;12:8329-8338. doi: 10.2147/OTT.S220339. eCollection 2019.
1050 PCNA-associated factor P15(PAF) , targeted by FOXM1, predicts poor prognosis in high-grade serous ovarian cancer patients.Int J Cancer. 2018 Dec 1;143(11):2973-2984. doi: 10.1002/ijc.31800. Epub 2018 Oct 4.
1051 Targeted resequencing of the microRNAome and 3'UTRome reveals functional germline DNA variants with altered prevalence in epithelial ovarian cancer.Oncogene. 2015 Apr 16;34(16):2125-37. doi: 10.1038/onc.2014.117. Epub 2014 Jun 9.
1052 Multifunctional nanoparticles for co-delivery of paclitaxel and carboplatin against ovarian cancer by inactivating the JMJD3-HER2 axis.Nanoscale. 2017 Sep 14;9(35):13142-13152. doi: 10.1039/c7nr04473a.
1053 Berberine sensitizes ovarian cancer cells to cisplatin through miR-21/PDCD4 axis.Acta Biochim Biophys Sin (Shanghai). 2013 Sep;45(9):756-62. doi: 10.1093/abbs/gmt075. Epub 2013 Jul 3.
1054 ERp57small interfering RNA silencing can enhance the sensitivity of drugresistant human ovarian cancer cells to paclitaxel.Int J Oncol. 2019 Jan;54(1):249-260. doi: 10.3892/ijo.2018.4628. Epub 2018 Nov 7.
1055 Microarray-based identification of genes associated with prognosis and drug resistance in ovarian cancer.J Cell Biochem. 2019 Apr;120(4):6057-6070. doi: 10.1002/jcb.27892. Epub 2018 Oct 18.
1056 Overexpression of PDK4 is associated with cell proliferation, drug resistance and poor prognosis in ovarian cancer.Cancer Manag Res. 2018 Dec 24;11:251-262. doi: 10.2147/CMAR.S185015. eCollection 2019.
1057 PDZ and LIM domain protein 4 suppresses the growth and invasion of ovarian cancer cells via inactivation of STAT3 signaling.Life Sci. 2019 Sep 15;233:116715. doi: 10.1016/j.lfs.2019.116715. Epub 2019 Jul 31.
1058 PEA-15 induces autophagy in human ovarian cancer cells and is associated with prolonged overall survival.Cancer Res. 2008 Nov 15;68(22):9302-10. doi: 10.1158/0008-5472.CAN-08-2592.
1059 Imprinted tumor suppressor genes ARHI and PEG3 are the most frequently down-regulated in human ovarian cancers by loss of heterozygosity and promoter methylation.Cancer. 2008 Apr 1;112(7):1489-502. doi: 10.1002/cncr.23323.
1060 Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis.Clin Cancer Res. 2011 Apr 15;17(8):2250-9. doi: 10.1158/1078-0432.CCR-10-2718. Epub 2011 Mar 18.
1061 BRCA1 deficiency in ovarian cancer is associated with alteration in expression of several key regulators of cell motility - A proteomics study.Cell Cycle. 2015;14(12):1884-92. doi: 10.1080/15384101.2015.1036203.
1062 miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma.FASEB J. 2018 Jun 6:fj201800495RR. doi: 10.1096/fj.201800495RR. Online ahead of print.
1063 PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage.Cell Signal. 2013 Jan;25(1):74-84. doi: 10.1016/j.cellsig.2012.09.009. Epub 2012 Sep 11.
1064 Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.Neoplasia. 2010 Feb;12(2):161-72. doi: 10.1593/neo.91542.
1065 HOTAIR Promotes Proliferation, Migration, and Invasion of Ovarian Cancer SKOV3 Cells Through Regulating PIK3R3.Med Sci Monit. 2016 Jan 31;22:325-31. doi: 10.12659/msm.894913.
1066 Invasion of ovarian cancer cells is induced byPITX2-mediated activation of TGF- and Activin-A.Mol Cancer. 2015 Aug 23;14:162. doi: 10.1186/s12943-015-0433-y.
1067 Altered expression and loss of heterozygosity of the LOT1 gene in ovarian cancer.Gynecol Oncol. 2004 Dec;95(3):449-55. doi: 10.1016/j.ygyno.2004.08.051.
1068 Broad, ectopic expression of the sperm protein PLCZ1 induces parthenogenesis and ovarian tumours in mice.Development. 2007 Nov;134(21):3941-52. doi: 10.1242/dev.007930.
1069 MiR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2.Reprod Biol. 2018 Sep;18(3):218-224. doi: 10.1016/j.repbio.2018.07.005. Epub 2018 Jul 24.
1070 EGF- and cell-cycle-regulated STAG1/PMEPA1/ERG1.2 belongs to a conserved gene family and is overexpressed and amplified in breast and ovarian cancer.Mol Carcinog. 2003 Dec;38(4):188-200. doi: 10.1002/mc.10162.
1071 The reduction in pigment epithelium-derived factor is a sign of malignancy in ovarian cancer expressing low-level of vascular endothelial growth factor.Gynecol Endocrinol. 2009 Feb;25(2):104-9. doi: 10.1080/09513590802549841.
1072 Identification of potential prognostic TF-associated lncRNAs for predicting survival in ovarian cancer.J Cell Mol Med. 2019 Mar;23(3):1840-1851. doi: 10.1111/jcmm.14084. Epub 2018 Dec 13.
1073 Epigenetic activation of POTE genes in ovarian cancer.Epigenetics. 2019 Feb;14(2):185-197. doi: 10.1080/15592294.2019.1581590. Epub 2019 Mar 4.
1074 Expression of Inorganic Pyrophosphatase (PPA1) Correlates with Poor Prognosis of Epithelial Ovarian Cancer.Tohoku J Exp Med. 2017 Feb;241(2):165-173. doi: 10.1620/tjem.241.165.
1075 The BET bromodomain inhibitor i-BET151 impairs ovarian cancer metastasis and improves antitumor immunity.Cell Tissue Res. 2018 Dec;374(3):577-585. doi: 10.1007/s00441-018-2906-y. Epub 2018 Sep 4.
1076 Infrequent mutations of the PPP2R1A and PPP2R1B genes in patients with ovarian cancer.Mol Med Rep. 2013 Jun;7(6):1826-30. doi: 10.3892/mmr.2013.1416. Epub 2013 Apr 9.
1077 Upregulation of miR-614 promotes proliferation and inhibits apoptosis in ovarian cancer by suppressing PPP2R2A expression.Mol Med Rep. 2018 May;17(5):6285-6292. doi: 10.3892/mmr.2018.8714. Epub 2018 Mar 9.
1078 MiR-572 prompted cell proliferation of human ovarian cancer cells by suppressing PPP2R2C expression. Biomed Pharmacother. 2016 Feb;77:92-7.
1079 Age is associated with prognosis in serous ovarian carcinoma.J Ovarian Res. 2017 Jun 12;10(1):36. doi: 10.1186/s13048-017-0331-6.
1080 Peroxiredoxin-1 as a prognostic factor in patients with ovarian cancer.Ann Agric Environ Med. 2019 Sep 19;26(3):415-419. doi: 10.26444/aaem/105899. Epub 2019 Apr 1.
1081 Inhibition of mitochondrial translation as a therapeutic strategy for human ovarian cancer to overcome chemoresistance.Biochem Biophys Res Commun. 2019 Feb 5;509(2):373-378. doi: 10.1016/j.bbrc.2018.12.127. Epub 2018 Dec 25.
1082 PRKRA/PACT Expression Promotes Chemoresistance of Mucinous Ovarian Cancer.Mol Cancer Ther. 2019 Jan;18(1):162-172. doi: 10.1158/1535-7163.MCT-17-1050. Epub 2018 Oct 10.
1083 Long non-coding RNA RP11-552M11.4 favors tumorigenesis and development of cervical cancer via modulating miR-3941/ATF1 signaling.Int J Biol Macromol. 2019 Jun 1;130:24-33. doi: 10.1016/j.ijbiomac.2019.02.083. Epub 2019 Feb 18.
1084 PRR11 Overexpression Facilitates Ovarian Carcinoma Cell Proliferation, Migration, and Invasion Through Activation of the PI3K/AKT/-Catenin Pathway.Cell Physiol Biochem. 2018;49(2):696-705. doi: 10.1159/000493034. Epub 2018 Aug 30.
1085 PRSS21/testisin inhibits ovarian tumor metastasis and antagonizes proangiogenic angiopoietins ANG2 and ANGPTL4.J Mol Med (Berl). 2019 May;97(5):691-709. doi: 10.1007/s00109-019-01763-3. Epub 2019 Mar 25.
1086 PRSS3 expression is associated with tumor progression and poor prognosis in epithelial ovarian cancer.Gynecol Oncol. 2015 Jun;137(3):546-52. doi: 10.1016/j.ygyno.2015.02.022. Epub 2015 Feb 28.
1087 Specific MALDI imaging and profiling for biomarker hunting and validation: fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker.J Proteome Res. 2007 Nov;6(11):4127-34. doi: 10.1021/pr0702722. Epub 2007 Oct 16.
1088 PTTG1: a Unique Regulator of Stem/Cancer Stem Cells in the Ovary and Ovarian Cancer.Stem Cell Rev Rep. 2019 Dec;15(6):866-879. doi: 10.1007/s12015-019-09911-5.
1089 circPUM1 Promotes Tumorigenesis and Progression of Ovarian Cancer by Sponging miR-615-5p and miR-6753-5p.Mol Ther Nucleic Acids. 2019 Dec 6;18:882-892. doi: 10.1016/j.omtn.2019.09.032. Epub 2019 Oct 23.
1090 High expression of PXDN is associated with poor prognosis and promotes proliferation, invasion as well as migration in ovarian cancer.Ann Diagn Pathol. 2018 Jun;34:161-165. doi: 10.1016/j.anndiagpath.2018.03.002. Epub 2018 Mar 14.
1091 Activation of platelet-activating factor receptor and pleiotropic effects on tyrosine phospho-EGFR/Src/FAK/paxillin in ovarian cancer.Cancer Res. 2008 Jul 15;68(14):5839-48. doi: 10.1158/0008-5472.CAN-07-5771.
1092 Epigenetic inactivation of TMS1/ASC in ovarian cancer.Clin Cancer Res. 2004 Mar 15;10(6):2000-6. doi: 10.1158/1078-0432.ccr-0932-03.
1093 Tumor microenvironment-associated modifications of alternative splicing.RNA. 2014 Feb;20(2):189-201. doi: 10.1261/rna.042168.113. Epub 2013 Dec 11.
1094 Histone modifications silence the GATA transcription factor genes in ovarian cancer.Oncogene. 2006 Aug 31;25(39):5446-61. doi: 10.1038/sj.onc.1209533. Epub 2006 Apr 10.
1095 Rab23 promotes the cisplatin resistance of ovarian cancer via the Shh-Gli-ABCG2 signaling pathway.Oncol Lett. 2018 Apr;15(4):5155-5160. doi: 10.3892/ol.2018.7949. Epub 2018 Feb 5.
1096 Upregulation of Circular RNA VPS13C-has-circ-001567 Promotes Ovarian Cancer Cell Proliferation and Invasion.Cancer Biother Radiopharm. 2019 Mar;34(2):110-118. doi: 10.1089/cbr.2018.2641. Epub 2018 Oct 30.
1097 Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B.Nat Commun. 2015 Jan 8;6:5917. doi: 10.1038/ncomms6917.
1098 Polymorphisms of the Ras-Association Domain Family 1 Isoform A (RASSF1A) Gene are Associated with Ovarian Cancer, and with the Prognostic Factors of Grade and Stage, in Women in Southern China.Med Sci Monit. 2018 Apr 19;24:2360-2367. doi: 10.12659/msm.910058.
1099 The HRAS1 minisatellite locus and risk of ovarian cancer.Cancer Res. 2000 Jan 15;60(2):259-61.
1100 Suppression of FIP200 and autophagy by tumor-derived lactate promotes nave T cell apoptosis and affects tumor immunity.Sci Immunol. 2017 Nov 17;2(17):eaan4631. doi: 10.1126/sciimmunol.aan4631.
1101 The long non-coding RNA MALAT1 promotes ovarian cancer progression by regulating RBFOX2-mediated alternative splicing.Mol Carcinog. 2019 Feb;58(2):196-205. doi: 10.1002/mc.22919. Epub 2018 Oct 28.
1102 Rb2/p130 and protein phosphatase 2A: key mediators of ovarian carcinoma cell growth suppression by all-trans retinoic acid. Oncogene. 2006 Aug 28;25(38):5315-25. doi: 10.1038/sj.onc.1209679.
1103 High RNA-Binding Motif Protein 3 (RBM3) Expression is Independently Associated with Prolonged Overall Survival in Intestinal-Type Gastric Cancer.Med Sci Monit. 2017 Dec 21;23:6033-6041. doi: 10.12659/msm.905314.
1104 CRBP-1 over-expression is associated with poor prognosis in tongue squamous cell carcinoma.BMC Cancer. 2018 May 2;18(1):514. doi: 10.1186/s12885-018-4249-1.
1105 RCC2, a regulator of the RalA signaling pathway, is identified as a novel therapeutic target in cisplatin-resistant ovarian cancer.FASEB J. 2019 Apr;33(4):5350-5365. doi: 10.1096/fj.201801529RR. Epub 2019 Feb 15.
1106 Epigenetic regulation of interleukin-8 expression by class I HDAC and CBP in ovarian cancer cells.Oncotarget. 2017 Aug 7;8(41):70798-70810. doi: 10.18632/oncotarget.19990. eCollection 2017 Sep 19.
1107 Knockdown of NRSF inhibits cell proliferation of ovarian cancer via activating Hippo pathway.Life Sci. 2018 Dec 15;215:73-79. doi: 10.1016/j.lfs.2018.10.070. Epub 2018 Nov 2.
1108 Inhibition of HDAC1 and DNMT1 modulate RGS10 expression and decrease ovarian cancer chemoresistance.PLoS One. 2014 Jan 27;9(1):e87455. doi: 10.1371/journal.pone.0087455. eCollection 2014.
1109 RGS5 decreases the proliferation of human ovarian carcinomaderived primary endothelial cells through the MAPK/ERK signaling pathway in hypoxia.Oncol Rep. 2019 Jan;41(1):165-177. doi: 10.3892/or.2018.6811. Epub 2018 Oct 22.
1110 RIF1 promotes human epithelial ovarian cancer growth and progression via activating human telomerase reverse transcriptase expression.J Exp Clin Cancer Res. 2018 Aug 3;37(1):182. doi: 10.1186/s13046-018-0854-8.
1111 Risk of Ovarian Malignancy Algorithm versus Risk Malignancy Index-I for Preoperative Assessment of Adnexal Masses: A Systematic Review and Meta-Analysis.Gynecol Obstet Invest. 2019;84(6):591-598. doi: 10.1159/000501681. Epub 2019 Jul 16.
1112 Comparison of strategies targeting Raf-1 mRNA in ovarian cancer.Int J Cancer. 2006 Mar 15;118(6):1565-71. doi: 10.1002/ijc.21520.
1113 Downregulation of tumor suppressor gene ribonuclease T2 and gametogenetin binding protein 2 is associated with drug resistance in ovarian cancer.Oncol Rep. 2014 Jul;32(1):362-72. doi: 10.3892/or.2014.3175. Epub 2014 May 13.
1114 Reversal of cisplatin resistance by microRNA-139-5p-independent RNF2 downregulation and MAPK inhibition in ovarian cancer.Am J Physiol Cell Physiol. 2018 Aug 1;315(2):C225-C235. doi: 10.1152/ajpcell.00283.2017. Epub 2018 May 2.
1115 Early Loss of Histone H2B Monoubiquitylation Alters Chromatin Accessibility and Activates Key Immune Pathways That Facilitate Progression of Ovarian Cancer.Cancer Res. 2019 Feb 15;79(4):760-772. doi: 10.1158/0008-5472.CAN-18-2297. Epub 2018 Dec 18.
1116 Cloning of a human ortholog (RPH3AL) of (RNO)Rph3al from a candidate 17p13.3 medulloblastoma tumor suppressor locus.Genomics. 1999 Jul 1;59(1):97-101. doi: 10.1006/geno.1999.5864.
1117 Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition.PLoS One. 2015 Nov 30;10(11):e0143659. doi: 10.1371/journal.pone.0143659. eCollection 2015.
1118 A key anti-viral protein, RSAD2/VIPERIN, restricts the release of measles virus from infected cells.Virus Res. 2019 Apr 2;263:145-150. doi: 10.1016/j.virusres.2019.01.014. Epub 2019 Jan 23.
1119 Long non-coding RNA EPB41L4A-AS2 suppresses progression of ovarian cancer by sequestering microRNA-103a to upregulate transcription factor RUNX1T1.Exp Physiol. 2020 Jan;105(1):75-87. doi: 10.1113/EP087847. Epub 2019 Dec 9.
1120 Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.Int J Cancer. 2011 May 1;128(9):2063-74. doi: 10.1002/ijc.25554.
1121 H-RYK, an unusual receptor kinase: isolation and analysis of expression in ovarian cancer.Mol Med. 1996 Mar;2(2):189-203.
1122 Prognostic values of S100 family mRNA expression in ovarian cancer.Cancer Biomark. 2019;25(1):67-78. doi: 10.3233/CBM-182276.
1123 S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin.J Ovarian Res. 2019 Nov 18;12(1):113. doi: 10.1186/s13048-019-0592-3.
1124 Expression of S100A11 is a Prognostic Factor for Disease-free Survival and Overall Survival in Patients With High-grade Serous Ovarian Cancer.Appl Immunohistochem Mol Morphol. 2017 Feb;25(2):110-116. doi: 10.1097/PAI.0000000000000275.
1125 S100A7 Regulates Ovarian Cancer Cell Metastasis and Chemoresistance Through MAPK Signaling and Is Targeted by miR-330-5p.DNA Cell Biol. 2018 May;37(5):491-500. doi: 10.1089/dna.2017.3953. Epub 2018 Feb 27.
1126 Unfavourable prognostic significance of S100P expression in ovarian cancers.Histopathology. 2007 Jul;51(1):125-8. doi: 10.1111/j.1365-2559.2007.02714.x. Epub 2007 May 31.
1127 SALL2 represses cyclins D1 and E1 expression and restrains G1/S cell cycle transition and cancer-related phenotypes.Mol Oncol. 2018 Jun;12(7):1026-1046. doi: 10.1002/1878-0261.12308. Epub 2018 May 21.
1128 Functional and clinical significance of SALL4 in breast cancer.Tumour Biol. 2016 Sep;37(9):11701-11709. doi: 10.1007/s13277-016-5150-7. Epub 2016 Jul 21.
1129 Discovery and expression analysis of novel transcripts of the human SR-related CTD-associated factor 1 (SCAF1) gene in human cancer cells using Next-Generation Sequencing.Gene. 2018 Sep 5;670:155-165. doi: 10.1016/j.gene.2018.05.044. Epub 2018 May 19.
1130 Circular RNA Cdr1as Upregulates SCAI to Suppress Cisplatin Resistance in Ovarian Cancer via miR-1270 Suppression.Mol Ther Nucleic Acids. 2019 Dec 6;18:24-33. doi: 10.1016/j.omtn.2019.07.012. Epub 2019 Jul 29.
1131 Machine learning and bioinformatics models to identify gene expression patterns of ovarian cancer associated with disease progression and mortality.J Biomed Inform. 2019 Dec;100:103313. doi: 10.1016/j.jbi.2019.103313. Epub 2019 Oct 23.
1132 Genomic characterization of human SEC14L1 splice variants within a 17q25 candidate tumor suppressor gene region and identification of an unrelated embedded expressed sequence tag.Mamm Genome. 2001 Dec;12(12):925-9. doi: 10.1007/s00335-001-2073-3.
1133 Selenium-Binding Protein 1 expression in ovaries and ovarian tumors in the laying hen, a spontaneous model of human ovarian cancer.Gynecol Oncol. 2008 Apr;109(1):115-21. doi: 10.1016/j.ygyno.2007.12.030. Epub 2008 Feb 13.
1134 Altered patterns of transcription of the septin gene, SEPT9, in ovarian tumorigenesis.Int J Cancer. 2006 Mar 1;118(5):1325-9. doi: 10.1002/ijc.21486.
1135 Expression, Intracellular Localization, and Prognostic Value of Plasminogen Activator Inhibitor 1 and PAI-1 RNA-Binding Protein 1 in Primary and Recurrent Ovarian Cancer: A Study of the Tumor Bank Ovarian Cancer Network.Gynecol Obstet Invest. 2018;83(5):508-514. doi: 10.1159/000479027. Epub 2017 Jul 22.
1136 Treading the beaten path with old and new obstacles: a report from the Indian HIPEC registry.Int J Hyperthermia. 2018;35(1):361-369. doi: 10.1080/02656736.2018.1503345. Epub 2018 Oct 9.
1137 SEI1 induces genomic instability by inhibiting DNA damage response in ovarian cancer.Cancer Lett. 2017 Jan 28;385:271-279. doi: 10.1016/j.canlet.2016.09.032. Epub 2016 Oct 3.
1138 Serum circSETDB1 is a promising biomarker for predicting response to platinum-taxane-combined chemotherapy and relapse in high-grade serous ovarian cancer.Onco Targets Ther. 2019 Sep 11;12:7451-7457. doi: 10.2147/OTT.S220700. eCollection 2019.
1139 Genetic and epigenetic alterations of steroidogenic factor? in ovarian tumors.Int J Oncol. 2013 Feb;42(2):627-34. doi: 10.3892/ijo.2012.1758. Epub 2012 Dec 28.
1140 Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer.Biochem Biophys Res Commun. 2004 Apr 16;316(4):1156-62. doi: 10.1016/j.bbrc.2004.02.171.
1141 MiR-1180 from bone marrow-derived mesenchymal stem cells induces glycolysis and chemoresistance in ovarian cancer cells by upregulating the Wnt signaling pathway.J Zhejiang Univ Sci B. 2019 Mar.;20(3):219-237. doi: 10.1631/jzus.B1800190.
1142 SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway.Gynecol Oncol. 2009 Mar;112(3):646-53. doi: 10.1016/j.ygyno.2008.10.026. Epub 2008 Dec 18.
1143 Epigenetic silencing of SFRP5 is related to malignant phenotype and chemoresistance of ovarian cancer through Wnt signaling pathway.Int J Cancer. 2010 Aug 1;127(3):555-67. doi: 10.1002/ijc.25083.
1144 Elevation of SHARPIN Protein Levels in Prostate Adenocarcinomas Promotes Metastasis and Impairs Patient Survivals.Prostate. 2017 May;77(7):718-728. doi: 10.1002/pros.23302. Epub 2017 Feb 23.
1145 Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis.PLoS Med. 2019 Aug 7;16(8):e1002893. doi: 10.1371/journal.pmed.1002893. eCollection 2019 Aug.
1146 SHMT1 inhibits the metastasis of HCC by repressing NOX1-mediated ROS production.J Exp Clin Cancer Res. 2019 Feb 12;38(1):70. doi: 10.1186/s13046-019-1067-5.
1147 EZH2 blockade by RNA interference inhibits growth of ovarian cancer by facilitating re-expression of p21(waf1/cip1) and by inhibiting mutant p53.Cancer Lett. 2013 Aug 9;336(1):53-60. doi: 10.1016/j.canlet.2013.04.012. Epub 2013 Apr 18.
1148 Bioinformatics analysis to screen the key prognostic genes in ovarian cancer.J Ovarian Res. 2017 Apr 13;10(1):27. doi: 10.1186/s13048-017-0323-6.
1149 Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells.Gynecol Oncol. 2011 Sep;122(3):656-62. doi: 10.1016/j.ygyno.2011.04.052. Epub 2011 Jun 14.
1150 Overexpression of SMARCE1 is associated with CD8+ T-cell infiltration in early stage ovarian cancer.Int J Biochem Cell Biol. 2014 Aug;53:389-98. doi: 10.1016/j.biocel.2014.05.031. Epub 2014 May 29.
1151 Deletion of SMURF 1 represses ovarian cancer invasion and EMT by modulating the DAB2IP/AKT/Skp2 feedback loop.J Cell Biochem. 2019 Jun;120(6):10643-10651. doi: 10.1002/jcb.28354. Epub 2019 Jan 22.
1152 SNAP23 promotes the malignant process of ovarian cancer.J Ovarian Res. 2016 Nov 17;9(1):80. doi: 10.1186/s13048-016-0289-9.
1153 Down-regulation of OGT promotes cisplatin resistance by inducing autophagy in ovarian cancer.Theranostics. 2018 Oct 6;8(19):5200-5212. doi: 10.7150/thno.27806. eCollection 2018.
1154 The RNA binding protein SORBS2 suppresses metastatic colonization of ovarian cancer by stabilizing tumor-suppressive immunomodulatory transcripts.Genome Biol. 2018 Mar 16;19(1):35. doi: 10.1186/s13059-018-1412-6.
1155 MicroRNA-223-3p Regulates Ovarian Cancer Cell Proliferation and Invasion by Targeting SOX11 Expression.Int J Mol Sci. 2017 Jun 6;18(6):1208. doi: 10.3390/ijms18061208.
1156 SOX18 Affects Cell Viability, Migration, Invasiveness, and Apoptosis in Hepatocellular Carcinoma (HCC) Cells by Participating in Epithelial-to-Mesenchymal Transition (EMT) Progression and Adenosine Monophosphate Activated Protein Kinase (AMPK)/Mammalian Target of Rapamycin (mTOR).Med Sci Monit. 2019 Aug 20;25:6244-6254. doi: 10.12659/MSM.915729.
1157 Sex-determining region Y-box3 (SOX3) functions as an oncogene in promoting epithelial ovarian cancer by targeting Src kinase.Tumour Biol. 2016 Sep;37(9):12263-12271. doi: 10.1007/s13277-016-5095-x. Epub 2016 Jun 1.
1158 SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma.Gynecol Oncol. 2019 Jun;153(3):651-660. doi: 10.1016/j.ygyno.2019.03.099. Epub 2019 Mar 21.
1159 Sperm associated antigen 9 (SPAG9) a promising therapeutic target of ovarian carcinoma.Tumour Biol. 2018 May;40(5):1010428318773652. doi: 10.1177/1010428318773652.
1160 Tumor necrosis factor receptor modulator spermatogenesis-associated protein 2 is a novel predictor of outcome in ovarian cancer.Cancer Sci. 2019 Mar;110(3):1117-1126. doi: 10.1111/cas.13955. Epub 2019 Feb 16.
1161 Spy1 participates in the proliferation and apoptosis of epithelial ovarian cancer.J Mol Histol. 2016 Feb;47(1):47-57. doi: 10.1007/s10735-015-9646-z. Epub 2015 Dec 7.
1162 Emerging Roles of SPINK1 in Cancer.Clin Chem. 2016 Mar;62(3):449-57. doi: 10.1373/clinchem.2015.241513. Epub 2015 Dec 11.
1163 Downregulation of SPINK13 Promotes Metastasis by Regulating uPA in Ovarian Cancer Cells.Cell Physiol Biochem. 2018;45(3):1061-1071. doi: 10.1159/000487348. Epub 2018 Feb 7.
1164 Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer.Aging (Albany NY). 2019 Dec 3;11(23):11416-11439. doi: 10.18632/aging.102538. Epub 2019 Dec 3.
1165 SPOP Regulates The Biological Mechanism Of Ovarian Cancer Cells Through The Hh Signaling Pathway.Onco Targets Ther. 2019 Nov 6;12:9239-9248. doi: 10.2147/OTT.S215940. eCollection 2019.
1166 Knockdown of SPRY4 and SPRY4-IT1 inhibits cell growth and phosphorylation of Akt in human testicular germ cell tumours.Sci Rep. 2018 Feb 6;8(1):2462. doi: 10.1038/s41598-018-20846-8.
1167 SPSB1 enhances ovarian cancer cell survival by destabilizing p21.Biochem Biophys Res Commun. 2019 Mar 12;510(3):364-369. doi: 10.1016/j.bbrc.2019.01.088. Epub 2019 Jan 31.
1168 Expression analysis and prognostic significance of the SRA1 gene, in ovarian cancer.Biochem Biophys Res Commun. 2006 Jun 2;344(2):667-74. doi: 10.1016/j.bbrc.2006.03.184. Epub 2006 Apr 7.
1169 Serine/arginine-rich splicing factor 3 (SRSF3) regulates homologous recombination-mediated DNA repair.Mol Cancer. 2015 Aug 19;14:158. doi: 10.1186/s12943-015-0422-1.
1170 Transmembrane protein 88 (TMEM88) promoter hypomethylation is associated with platinum resistance in ovarian cancer.Gynecol Oncol. 2016 Sep;142(3):539-47. doi: 10.1016/j.ygyno.2016.06.017. Epub 2016 Jun 30.
1171 Sialyltransferase ST3GAL1 promotes cell migration, invasion, and TGF-1-induced EMT and confers paclitaxel resistance in ovarian cancer.Cell Death Dis. 2018 Oct 30;9(11):1102. doi: 10.1038/s41419-018-1101-0.
1172 Prognostic role of the sialyltransferase ST6GAL1 in ovarian cancer.Glycobiology. 2018 Nov 1;28(11):898-903. doi: 10.1093/glycob/cwy065.
1173 Stimulative role of ST6GALNAC1 in proliferation, migration and invasion of ovarian cancer stem cells via the Akt signaling pathway.Cancer Cell Int. 2019 Apr 5;19:86. doi: 10.1186/s12935-019-0780-7. eCollection 2019.
1174 Sequencing of a 'mouse azoospermia' gene panel in azoospermic men: identification of RNF212 and STAG3 mutations as novel genetic causes of meiotic arrest.Hum Reprod. 2019 Jun 4;34(6):978-988. doi: 10.1093/humrep/dez042.
1175 Targeting the centriolar replication factor STIL synergizes with DNA damaging agents for treatment of ovarian cancer.Oncotarget. 2017 Apr 18;8(16):27380-27392. doi: 10.18632/oncotarget.16068.
1176 PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer.Cell Rep. 2018 Dec 11;25(11):2972-2980.e5. doi: 10.1016/j.celrep.2018.11.054.
1177 Identification of cell membrane protein stress-induced phosphoprotein 1 as a potential ovarian cancer biomarker using aptamers selected by cell systematic evolution of ligands by exponential enrichment.Anal Chem. 2014 May 6;86(9):4521-7. doi: 10.1021/ac500466x. Epub 2014 Apr 9.
1178 Synergistic effects of eukaryotic co-expression plasmid-based STAT3-specific siRNA and LKB1 on ovarian cancer in vitro and in vivo.Oncol Rep. 2015 Feb;33(2):774-82. doi: 10.3892/or.2014.3623. Epub 2014 Nov 25.
1179 Evaluation of the potential of a new ribavirin analog impairing the dissemination of ovarian cancer cells.PLoS One. 2019 Dec 11;14(12):e0225860. doi: 10.1371/journal.pone.0225860. eCollection 2019.
1180 Sushi Domain Containing 2 (SUSD2) inhibits platelet activation and binding to high-grade serous ovarian carcinoma cells.Platelets. 2018 Dec;29(8):834-837. doi: 10.1080/09537104.2018.1530345. Epub 2018 Oct 18.
1181 Expression and mutations of BRCA in breast cancer and ovarian cancer: Evidence from bioinformatics analyses.Int J Mol Med. 2018 Dec;42(6):3542-3550. doi: 10.3892/ijmm.2018.3870. Epub 2018 Sep 11.
1182 Loss of TAB3 expression by shRNA exhibits suppressive bioactivity and increased chemical sensitivity of ovarian cancer cell lines via the NF-B pathway.Cell Prolif. 2016 Dec;49(6):657-668. doi: 10.1111/cpr.12293. Epub 2016 Sep 21.
1183 TBC1D8 Amplification Drives Tumorigenesis through Metabolism Reprogramming in Ovarian Cancer.Theranostics. 2019 Jan 24;9(3):676-690. doi: 10.7150/thno.30224. eCollection 2019.
1184 Role of APC-mediated MDR-1/CLCX-1 signaling pathway in ovarian tumors.J Biol Regul Homeost Agents. 2018 May-Jun;32(3):529-536.
1185 Downregulation of TCEAL7 expression induces CCND1 expression in non-small cell lung cancer.Mol Biol Rep. 2019 Oct;46(5):5251-5256. doi: 10.1007/s11033-019-04982-6. Epub 2019 Jul 18.
1186 TCF12 overexpression as a poor prognostic factor in ovarian cancer.Pathol Res Pract. 2019 Sep;215(9):152527. doi: 10.1016/j.prp.2019.152527. Epub 2019 Jul 7.
1187 Functional balance between Tcf21-Slug defines cellular plasticity and migratory modalities in high grade serous ovarian cancer cell lines.Carcinogenesis. 2020 Jun 17;41(4):515-526. doi: 10.1093/carcin/bgz119.
1188 Alterations in the expression of the apurinic/apyrimidinic endonuclease-1/redox factor-1 (APE1/Ref-1) in human ovarian cancer and indentification of the therapeutic potential of APE1/Ref-1 inhibitor.Int J Oncol. 2009 Nov;35(5):1069-79.
1189 Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.PLoS One. 2017 May 4;12(5):e0177244. doi: 10.1371/journal.pone.0177244. eCollection 2017.
1190 TET1 promotes cisplatin-resistance via demethylating the vimentin promoter in ovarian cancer.Cell Biol Int. 2017 Apr;41(4):405-414. doi: 10.1002/cbin.10734. Epub 2017 Feb 16.
1191 TET3 inhibits TGF-1-induced epithelial-mesenchymal transition by demethylating miR-30d precursor gene in ovarian cancer cells.J Exp Clin Cancer Res. 2016 May 4;35:72. doi: 10.1186/s13046-016-0350-y.
1192 TEX19 promotes ovarian carcinoma progression and is a potential target for epitope vaccine immunotherapy.Life Sci. 2020 Jan 15;241:117171. doi: 10.1016/j.lfs.2019.117171. Epub 2019 Dec 13.
1193 ERRATUM.Oncol Res. 2017 Jan 2;25(1):155. doi: 10.3727/096504017X14811155525280.
1194 Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.Jpn J Cancer Res. 2002 Oct;93(10):1114-22. doi: 10.1111/j.1349-7006.2002.tb01213.x.
1195 Microvessel density and CpG island methylation of the THBS2 gene in malignant ovarian tumors.J Physiol Pharmacol. 2008 Sep;59 Suppl 4:53-65.
1196 Icb-1 gene polymorphism rs1467465 is associated with susceptibility to ovarian cancer.J Ovarian Res. 2014 Apr 23;7:42. doi: 10.1186/1757-2215-7-42. eCollection 2014.
1197 Thy-1 predicts poor prognosis and is associated with self-renewal in ovarian cancer.J Ovarian Res. 2019 Nov 17;12(1):112. doi: 10.1186/s13048-019-0590-5.
1198 Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.Cancer Epidemiol Biomarkers Prev. 2018 Jun;27(6):680-688. doi: 10.1158/1055-9965.EPI-17-1101. Epub 2018 Mar 12.
1199 TM4SF1 is a potential target for anti-invasion and metastasis in ovarian cancer.BMC Cancer. 2019 Mar 15;19(1):237. doi: 10.1186/s12885-019-5417-7.
1200 TMED2 promotes epithelial ovarian cancer growth.Oncotarget. 2017 Oct 6;8(55):94151-94165. doi: 10.18632/oncotarget.21593. eCollection 2017 Nov 7.
1201 Knockdown of TMEM14A expression by RNAi inhibits the proliferation and invasion of human ovarian cancer cells.Biosci Rep. 2016 Feb 19;36(1):e00298. doi: 10.1042/BSR20150258. Print 2016.
1202 Overexpression of TMEM158 contributes to ovarian carcinogenesis.J Exp Clin Cancer Res. 2015 Aug 4;34(1):75. doi: 10.1186/s13046-015-0193-y.
1203 Inhibition of TMEM45A suppresses proliferation, induces cell cycle arrest and reduces cell invasion in human ovarian cancer cells.Oncol Rep. 2015 Jun;33(6):3124-30. doi: 10.3892/or.2015.3902. Epub 2015 Apr 7.
1204 A novel genome-based approach correlates TMPRSS3 overexpression in ovarian cancer with DNA hypomethylation.Gynecol Oncol. 2012 Jun;125(3):720-6. doi: 10.1016/j.ygyno.2012.03.026. Epub 2012 Mar 21.
1205 Thymosin 10 expression driven by the human TERT promoter induces ovarian cancer-specific apoptosis through ROS production.PLoS One. 2012;7(5):e35399. doi: 10.1371/journal.pone.0035399. Epub 2012 May 18.
1206 Tumor necrosis factor -induced protein 8 expression as a predictor of prognosis and resistance in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy.Hum Pathol. 2018 Dec;82:239-248. doi: 10.1016/j.humpath.2018.02.031. Epub 2018 Aug 11.
1207 TRAIL-R3-related apoptosis: epigenetic and expression analyses in women with ovarian neoplasia.Gynecol Oncol. 2012 Aug;126(2):268-73. doi: 10.1016/j.ygyno.2012.04.038. Epub 2012 Apr 30.
1208 Overexpression of salusin- is associated with poor prognosis in ovarian cancer.Oncol Rep. 2017 Mar;37(3):1826-1832. doi: 10.3892/or.2017.5429. Epub 2017 Feb 7.
1209 TPM4 promotes cell migration by modulating F-actin formation in lung cancer.Onco Targets Ther. 2019 May 31;12:4055-4063. doi: 10.2147/OTT.S198542. eCollection 2019.
1210 Tripartite Motif 16 Inhibits the Migration and Invasion in Ovarian Cancer Cells.Oncol Res. 2017 Apr 14;25(4):551-558. doi: 10.3727/096504016X14758370595285. Epub 2016 Oct 12.
1211 TRIM44 is indispensable for glioma cell proliferation and cell cycle progression through AKT/p21/p27 signaling pathway.J Neurooncol. 2019 Nov;145(2):211-222. doi: 10.1007/s11060-019-03301-0. Epub 2019 Oct 11.
1212 TRIM50 acts as a novel Src suppressor and inhibits ovarian cancer progression.Biochim Biophys Acta Mol Cell Res. 2019 Sep;1866(9):1412-1420. doi: 10.1016/j.bbamcr.2019.06.002. Epub 2019 Jun 6.
1213 Poly r(C) Binding Protein 1 Regulates Posttranscriptional Expression of the Ubiquitin Ligase TRIM56 in Ovarian Cancer.IUBMB Life. 2019 Feb;71(2):177-182. doi: 10.1002/iub.1948. Epub 2018 Oct 3.
1214 Ovarian cancer proliferation and apoptosis are regulated by human transfer RNA methyltransferase 9-likevia LIN9.Oncol Lett. 2017 Oct;14(4):4461-4466. doi: 10.3892/ol.2017.6750. Epub 2017 Aug 14.
1215 Trophinin is a potent prognostic marker of ovarian cancer involved in platinum sensitivity.Biochem Biophys Res Commun. 2007 Aug 24;360(2):363-9. doi: 10.1016/j.bbrc.2007.06.070. Epub 2007 Jun 19.
1216 TRRAP stimulates the tumorigenic potential of ovarian cancer stem cells.BMB Rep. 2018 Oct;51(10):514-519. doi: 10.5483/BMBRep.2018.51.10.042.
1217 Over-expression of the testis-specific gene TSGA10 in cancers and its immunogenicity.Microbiol Immunol. 2004;48(4):339-45. doi: 10.1111/j.1348-0421.2004.tb03515.x.
1218 TSPAN12 Precedes Tumor Proliferation by Cell Cycle Control in Ovarian Cancer.Mol Cells. 2019 Jul 31;42(7):557-567. doi: 10.14348/molcells.2019.0015.
1219 Knockdown of miR-629 Inhibits Ovarian Cancer Malignant Behaviors by Targeting Testis-Specific Y-Like Protein 5.DNA Cell Biol. 2017 Dec;36(12):1108-1116. doi: 10.1089/dna.2017.3904. Epub 2017 Oct 3.
1220 ADAM15 decreases integrin alphavbeta3/vitronectin-mediated ovarian cancer cell adhesion and motility in an RGD-dependent fashion.Int J Biochem Cell Biol. 2005 Mar;37(3):590-603. doi: 10.1016/j.biocel.2004.08.005.
1221 Expression and significance of ARID1A mRNA in endometriosis- associated ovarian cancer.J BUON. 2017 Sep-Oct;22(5):1314-1321.
1222 Sox9 and Hif-2 regulate TUBB3 gene expression and affect ovarian cancer aggressiveness.Gene. 2014 Jun 1;542(2):173-81. doi: 10.1016/j.gene.2014.03.037. Epub 2014 Mar 21.
1223 Ca(2+)/calmodulin-dependent protein kinase IV expression in epithelial ovarian cancer.Cancer Lett. 2002 Sep 26;183(2):185-93. doi: 10.1016/s0304-3835(02)00107-6.
1224 A polymerase-chain-reaction assay for the specific identification of transcripts encoded by individual carcinoembryonic antigen (CEA)-gene-family members.Int J Cancer. 1993 Sep 9;55(2):311-9. doi: 10.1002/ijc.2910550223.
1225 Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells.Oncogene. 2003 Jul 3;22(27):4243-56. doi: 10.1038/sj.onc.1206437.
1226 A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis.Biochem Biophys Res Commun. 2001 Feb 2;280(4):1148-54. doi: 10.1006/bbrc.2001.4250.
1227 Identification of the Critical Site of Calponin 1 for Suppression of Ovarian Cancer Properties.Anticancer Res. 2015 Nov;35(11):5993-9.
1228 Choosing wisely: Selecting PARP inhibitor combinations to promote anti-tumor immune responses beyond BRCA mutations.Gynecol Oncol. 2020 Feb;156(2):488-497. doi: 10.1016/j.ygyno.2019.09.021. Epub 2019 Oct 17.
1229 Suppression of chemotherapy-induced cytokine/lipid mediator surge and ovarian cancer by a dual COX-2/sEH inhibitor.Proc Natl Acad Sci U S A. 2019 Jan 29;116(5):1698-1703. doi: 10.1073/pnas.1803999116. Epub 2019 Jan 15.
1230 Thrombospondin-1 and -2 messenger RNA expression in epithelial ovarian tumor.Anticancer Res. 2001 Jul-Aug;21(4B):2983-7.
1231 Marked allelic imbalance on chromosome 5q31 does not explain alpha-catenin expression in epithelial ovarian cancer.Gynecol Oncol. 2004 Aug;94(2):416-21. doi: 10.1016/j.ygyno.2004.04.029.
1232 Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer.Neoplasia. 2006 Apr;8(4):268-78. doi: 10.1593/neo.05502.
1233 The homeoprotein DLX4 stimulates NF-B activation and CD44-mediated tumor-mesothelial cell interactions in ovarian cancer.Am J Pathol. 2015 Aug;185(8):2298-308. doi: 10.1016/j.ajpath.2015.04.004. Epub 2015 Jun 9.
1234 Cell type-specific methylation of an intronic CpG island controls expression of the MCJ gene.Carcinogenesis. 2004 May;25(5):693-701. doi: 10.1093/carcin/bgh066. Epub 2004 Jan 16.
1235 Differential gene expression in ovarian tumors reveals Dusp 4 and Serpina 5 as key regulators for benign behavior of serous borderline tumors.J Clin Oncol. 2005 Oct 10;23(29):7257-64. doi: 10.1200/JCO.2005.02.2541. Epub 2005 Aug 8.
1236 Expression of EBAG9/RCAS1 is associated with advanced disease in human epithelial ovarian cancer.Br J Cancer. 2004 Jun 1;90(11):2197-202. doi: 10.1038/sj.bjc.6601832.
1237 The eukaryotic translation elongation factor eEF1A2 induces neoplastic properties and mediates tumorigenic effects of ZNF217 in precursor cells of human ovarian carcinomas.Int J Cancer. 2008 Oct 15;123(8):1761-9. doi: 10.1002/ijc.23708.
1238 RECQL1 DNA repair helicase: a potential therapeutic target and a proliferative marker against ovarian cancer.PLoS One. 2013 Aug 9;8(8):e72820. doi: 10.1371/journal.pone.0072820. eCollection 2013.
1239 Genomic and protein expression analysis reveals flap endonuclease 1 (FEN1) as a key biomarker in breast and ovarian cancer.Mol Oncol. 2014 Oct;8(7):1326-38. doi: 10.1016/j.molonc.2014.04.009. Epub 2014 May 13.
1240 Aberrant expression of FGFRL1, a novel FGF receptor, in ovarian tumors.Int J Mol Med. 2005 Dec;16(6):1169-73.
1241 Expression of GBGT1 is epigenetically regulated by DNA methylation in ovarian cancer cells.BMC Mol Biol. 2014 Oct 7;15:24. doi: 10.1186/1471-2199-15-24.
1242 Gene expression profiles with cDNA microarray reveal RhoGDI as a predictive marker for paclitaxel resistance in ovarian cancers.Oncol Rep. 2006 May;15(5):1265-71.
1243 Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer.Clin Cancer Res. 2004 Aug 1;10(15):5178-86. doi: 10.1158/1078-0432.CCR-03-0103.
1244 GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy.Clin Exp Metastasis. 2002;19(4):291-9. doi: 10.1023/a:1015545407700.
1245 The presence of receptors for bombesin/GRP and mRNA for three receptor subtypes in human ovarian epithelial cancers.Regul Pept. 2000 Jun 30;90(1-3):77-84. doi: 10.1016/s0167-0115(00)00114-2.
1246 Association between glutathione S-transferase M 1 null genotype and risk of ovarian cancer: a meta-analysis.Tumour Biol. 2013 Dec;34(6):4059-63. doi: 10.1007/s13277-013-0995-5. Epub 2013 Jul 25.
1247 Downregulation of HOXC6 in Serous Ovarian Cancer.Cancer Invest. 2015;33(7):303-11. doi: 10.3109/07357907.2015.1041641. Epub 2015 Jun 5.
1248 Genome-wide significant risk associations for mucinous ovarian carcinoma.Nat Genet. 2015 Aug;47(8):888-97. doi: 10.1038/ng.3336. Epub 2015 Jun 15.
1249 Aberrant DNA methylation in the IFITM1 promoter enhances the metastatic phenotype in an intraperitoneal xenograft model of human ovarian cancer.Oncol Rep. 2014 May;31(5):2139-46. doi: 10.3892/or.2014.3110. Epub 2014 Mar 24.
1250 Recombinant adenovirus-mediated overexpression of PTEN and KRT10 improves cisplatin resistance of ovarian cancer in vitro and in vivo.Genet Mol Res. 2015 Jun 18;14(2):6591-7. doi: 10.4238/2015.June.18.1.
1251 miR-762 can negatively regulate menin in ovarian cancer.Onco Targets Ther. 2017 Apr 12;10:2127-2137. doi: 10.2147/OTT.S127872. eCollection 2017.
1252 Proteomic analysis of a preneoplastic phenotype in ovarian surface epithelial cells derived from prophylactic oophorectomies.Gynecol Oncol. 2005 Jul;98(1):68-76. doi: 10.1016/j.ygyno.2005.04.002.
1253 Downregulation of NEK11 is associated with drug resistance in ovarian cancer.Int J Oncol. 2014 Sep;45(3):1266-74. doi: 10.3892/ijo.2014.2503. Epub 2014 Jun 18.
1254 OVA66 increases cell growth, invasion and survival via regulation of IGF-1R-MAPK signaling in human cancer cells.Carcinogenesis. 2014 Jul;35(7):1573-81. doi: 10.1093/carcin/bgu070. Epub 2014 Mar 25.
1255 Anti-apoptotic hPEBP4 silencing promotes TRAIL-induced apoptosis of human ovarian cancer cells by activating ERK and JNK pathways.Int J Mol Med. 2006 Sep;18(3):505-10.
1256 Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines.Mol Cell Proteomics. 2014 Nov;13(11):3138-51. doi: 10.1074/mcp.M113.033217. Epub 2014 Aug 5.
1257 Nac1 interacts with the POZ-domain transcription factor, Miz1.Biosci Rep. 2014 Jun 5;34(3):e00110. doi: 10.1042/BSR20140049.
1258 Gonadotropin-releasing hormone retards doxorubicin-induced apoptosis and serine/threonine phosphatase inhibition in ovarian cancer cells.Oncol Rep. 2005 May;13(5):813-7.
1259 Antisense suppression of pygopus2 results in growth arrest of epithelial ovarian cancer.Clin Cancer Res. 2006 Apr 1;12(7 Pt 1):2216-23. doi: 10.1158/1078-0432.CCR-05-2433.
1260 Rab25 is responsible for phosphoinositide 3-kinase/AKTmediated cisplatin resistance in human epithelial ovarian cancer cells.Mol Med Rep. 2015 Mar;11(3):2173-8. doi: 10.3892/mmr.2014.2963. Epub 2014 Nov 17.
1261 RASAL2 down-regulation in ovarian cancer promotes epithelial-mesenchymal transition and metastasis.Oncotarget. 2014 Aug 30;5(16):6734-45. doi: 10.18632/oncotarget.2244.
1262 Epigenetic regulation of the ras effector/tumour suppressor RASSF2 in breast and lung cancer.Oncogene. 2008 Mar 13;27(12):1805-11. doi: 10.1038/sj.onc.1210805. Epub 2007 Sep 24.
1263 Role of microsatellite instability in borderline ovarian tumors.Anticancer Res. 2003 Nov-Dec;23(6D):5139-41.
1264 Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine.Clin Cancer Res. 2006 Jan 15;12(2):432-41. doi: 10.1158/1078-0432.CCR-05-0461.
1265 The role of S100A14 in epithelial ovarian tumors.Oncotarget. 2014 Jun 15;5(11):3482-96. doi: 10.18632/oncotarget.1947.
1266 Associations of genewide SNPs in SNAI1 and TWIST1 with breast cancer and ovarian cancer susceptibility among Chinese Han women.Oncol Rep. 2018 Dec;40(6):3573-3584. doi: 10.3892/or.2018.6725. Epub 2018 Sep 21.
1267 Reduced expression of SOX7 in ovarian cancer: a novel tumor suppressor through the Wnt/-catenin signaling pathway.J Ovarian Res. 2014 Sep 5;7:87. doi: 10.1186/s13048-014-0087-1.
1268 Increased expression of cSHMT, Tbx3 and utrophin in plasma of ovarian and breast cancer patients.Int J Cancer. 2006 Jan 15;118(2):412-21. doi: 10.1002/ijc.21332.
1269 Expression of betaglycan, an inhibin coreceptor, in normal human ovaries and ovarian sex cord-stromal tumors and its regulation in cultured human granulosa-luteal cells.J Clin Endocrinol Metab. 2003 Oct;88(10):5002-8. doi: 10.1210/jc.2003-030704.